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Cardiovascular risk in inflammatory joint diseases, the role of systemic in-
flammation
Inflammatory joint diseases (IJD), including rheumatoid arthritis (RA), ankylosing 
spondylitis (AS) and systemic lupus erythematosus (SLE), are chronic (auto)immune 
disease systemically affecting joints and related tissue and present with extra-articular 
manifestations induced by systemic and progressive inflammation. RA is the most 
common type of IJD affecting up to 1 percent of the population and characterized 
by symmetrical inflammation of the joints, mainly hands and feet [1]. Differently, 
in AS the inflammatory target point of inflammation are the entheses and the spine 
[2], while SLE is a complex and heterogeneous autoimmune disease characterized by 
inflammatory response and immune complex deposits in organs, including joints, skin, 
kidney’s and brain [3]. Importantly, patients with IJD have an increased mortality [4, 
5] mainly of cardiovascular origin [6, 7]. The increased mortality is partly explained by 
the increased prevalence of cardiovascular comorbidities identified in this population. 
Nowadays, persistent inflammation is known to be a key mechanism in the development 
of cardiovascular disease [8, 9].
Models describing the role of systemic inflammation in the development of 
cardiovascular disease indicate an important role for circulating cytokines and oxidative 
stress. In the development of atherosclerosis, it is hypothesized that circulating 
cytokines and increased oxidative stress induce endothelial dysfunction and accelerate 
the development of atherosclerosis. Endothelial dysfunction is a maladaptive state 
with disruption of vascular homeostasis resulting from a pro-inflammatory state. By 
expressing adhesion molecules and inflammatory cytokines, endothelial cells amplify an 
inflammatory cascade facilitating monocyte infiltration in the subendothelial layer. LDL 
cholesterol accumulates in the subendothelial space and is oxidized, which is essential 
for the development of atherosclerotic plaques [10]. Furthermore, reactive oxygen species 
(ROS) are a group of small reactive species that play crucial roles in the regulation of 
biocellular processes. The balance between ROS and antioxidant species is essential 
to maintain cellular homoeostasis. Hence, an imbalance in oxidant and antioxidant 
mechanisms leads to a state of oxidative stress. In several chronic diseases, including 
RA, there is abundant oxidative stress [11]. Although essential for vascular homeostasis, 
an excess of ROS might lead to vascular injury. The latter being the result of a complex 
cascade, including oxidative modification of lipoproteins, endothelial activation, and 
leucocyte migration and differentiation resulting in acceleration of atherogenesis [10].
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Cardiac disease and systemic inflammation
Both, RA and AS, are associated with cardiac dysfunction and, in severe cases, congestive 
heart failure (CHF) [12-14]. CHF is a cardiac disease where functional or structural 
disorders of the myocardium impair the ability of the cardiac ventricles to fill (diastolic 
dysfunction) and/or eject blood (systolic dysfunction). Two different forms of CHF are 
distinguished, heart failure with preserved ejection fraction (HFpEF) and heart failure 
with reduced ejection fraction (HFrEF). HFpEF presents with high filling pressures due 
to diastolic left ventricular dysfunction (LV) leading to impaired relaxation of the left 
ventricle [15]. HFrEF presents with a failing cardiac pump function due to systolic LV 
dysfunction. Depending on the severity, clinical presentation of CHF includes dyspnea, 
fatigue, swollen ankles and exercise intolerance. CHF is one of the most prevalent 
causes of death in RA patients [13, 14]. Initially, cardiac dysfunction in RA patients 
was assumed to be secondary to ischaemic heart disease. However, the incidence of 
congestive heart failure (HFpEF and HFrEF) cannot be explained by atherosclerotic 
disease alone [16-19]. This also holds for AS patients, where an increased prevalence of 
LV diastolic dysfunction is found [12].
Accordingly, Paulus and Tschöpe proposed a hypothesis describing the role of 
systemic inflammation in cardiac dysfunction [20]. According to this hypothesis, 
systemic inflammation with elevated concentrations of circulating cytokines, such 
as interleukin 6 (IL-6) and tumor necrosis factor alfa (TNF), can induce oxidative 
stress and endothelial activation. Consequently, presentation of adhesion molecules 
(VCAM-1 and E-selectin) by activated endothelial cells leads to monocyte infiltration 
in the myocardium. These monocytes produce transforming growth factor-β (TGF-
β), resulting in the differentiation of fibroblasts into myofibroblasts, with subsequent 
deposition of collagen in the interstitial space. In addition, oxidative stress results in 
disrupted crosstalk between endothelial cells and cardiomyocytes, leading to stiffness 
and hypertrophy of cardiomyocytes and a decreased ability to relax. These processes 
ultimately lead to preclinical diastolic ventricular dysfunction, which might evolve into 
(clinical) heart failure with preserved ejection fraction (figure 1).
1
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Figure 1: Shared mechanisms in the development of heart failure with preserved or reduced 
ejection fraction in patients with rheumatoid arthritis and gout Systemic inflammation with ele-
vated concentrations of circulating cytokines, such as IL-6 and TNF, induce oxidative stress and 
endothelial activation. Consequently, presentation of adhesion molecules (VCAM-1 and E-se-
lectin) by endothelial cells leads to monocyte infiltration in the myocardium. These monocytes 
produce TGF-β, resulting in the differentiation of fibroblasts into myofibroblasts, with subsequent 
deposition of collagen in the interstitial space. In addition, intracellular oxidative stress results 
in disrupted crosstalk between endothelial cells and cardiomyocytes, leading to stiffness and 
hypertrophy of cardiomyocytes with a subsequent decreased ability to contract and relax. These 
processes ultimately lead to preclinical diastolic ventricular dysfunction, which might evolve into 
heart failure with preserved ejection fraction. Ischaemia, mostly secondary to atherosclerosis, 
leads to autophagy, apoptosis, and necrosis of cardiomyocytes, and deposition of collagen in the 
interstitial space. This condition can give rise to systolic ventricular dysfunction, which in severe 
cases can lead to heart failure with reduced ejection fraction [20]. ROS=reactive oxygen species.
Specific cardiac diseases in ankylosing spondylitis
AS is also associated with other cardiac manifestations, i.e. aortic valve regurgitation 
(AVR) and conduction disorders, which are assumed to be due to systemic inflammation. 
The current hypothesis on valve involvement in AS is that collagen tissue and more 
specifically entheses, are the structures where inflammatory processes in AS mainly 
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take place [21]. Pro-inflammatory cytokines, such as interleukins 23 and 17, have an 
important role in this inflammatory process and IL-23 stimulates IL-17 production by 
Th17-cells that further amplifies this inflammation [22-24]. The relevance for cardiac 
involvement in AS, is that entheses and the part of the aortic valve that inserts into 
the aortic root are histologically similar [24]. Sherlock et al. demonstrated in mice that 
both, entheses and this part of the aortic root, contain IL-23 receptor positive T-cells 
that can induce local inflammation after systemic exposure to Il-23 [24]. In the aortic 
root, inflammation may cause root dilatation and the inflammation may extend to 
the annulus, resulting in basal thickening and downward retraction of the cusps, also 
resulting in AVR [25-27]. The thickening of the annulus itself could also disturb the 
laminar blood flow resulting in deterioration of valve function.
Important electrical conduction elements, such as the atrial-ventricular (AV) node and 
the bundle branches are located in very close proximity to the heart valves. In addition 
to the aortic root and the cusps of the aortic valve, in AS the inflammatory process 
therefore may extend to the atrial ventricular node (AV-node) and interventricular 
septum, leading to AV-blocks and bundle branch blocks (BBB’s) [27].
Beyond the heart
Beyond the heart, IJD are associated with well-established cardiovascular risk factors 
such as hypertension, dyslipidemia, less favorable body composition and increased 
insulin resistance. In part this is related to decreased mobility due to pain and physical 
restraints and in part to use of non-steroidal anti-inflammatory drugs (NSAIDs). 
However, it has been shown that systemic inflammation also plays an important role 
in the development and sustainment of these CV risk factors. For example, systemic 
inflammation is associated with a more atherogenic lipid profile. A phenomenon where 
lower levels of total cholesterol are associated with increased CVD risk, also known as 
the lipid paradox [28-31]. Furthermore, studies demonstrated that RA and AS patients 
have increased insulin resistance that is correlated with disease activity [32-35]. In 
addition, systemic inflammation has been linked to less favorable body composition in 
IJD, whereas increased disease activity leads to increased (visceral) adipose tissue and/
or decreased muscle mass [36-38].
Anti-inflammatory therapy and cardiovascular prevention
The key role of systemic and progressive inflammation in development of cardiac 
disease offers possibilities in CVD prevention and treatment strategies in IJD with 
1
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anti-inflammatory therapy. Mounting evidence shows anti-inflammatory therapy in 
IJD has an ameliorating effects on incident CVD including cardiac diseases [39-41]. 
Unfortunately, adequate guidelines in this field are still lacking. This is partly due 
to poorly designed studies and conflicting results, including studies which were not 
designed to answer this research question. Therefore, a knowledge gap in this field 
remains where yet unanswered questions should be investigated. Firstly, the question 
arises about the current prevalence of these cardiac diseases in Dutch RA and AS 
patients with the current treatment strategies. In the past decennia treatment of IJD 
has significantly improved by early treatment and the introduction of biologic DMARD’s. 
Biologics, mainly available for patients in wealthy countries, revolutionized treatment 
and prognosis of IJD patients. The prevalence of CVD including cardiac manifestations 
in this group might differ in relation to past populations or socio-economic status of the 
countries distorting the impact of the problem in current clinical practice. Secondly, the 
effect of anti-inflammatory therapy on the cardiac function should be further elucidated. 
Thirdly, specific subgroups of IJD patients at high risk for cardiac disease should be 
identified where additional prevention or treatment are needed. Finally, future studies 
should assess the cost-effectiveness of implementation of preventive measures in order 
to establish sustainable guidelines for clinical practice.
Outline and aims of the thesis
This thesis aims to improve knowledge about the role of systemic inflammation in 
the development of cardiovascular disease and particularly cardiac dysfunction. 
Furthermore, to elucidate the added value of cardiac screening in this population. 
In Part I of this thesis including chapters 2-5, we focus on the role of inflammation 
in the development of CVD in IJD patients. Chapter 2 describes the prevalence, 
pathophysiology, and guidelines for CVD in IJD, i.e. RA and gout. In chapter 3 we 
reviewed the current literature on the effect of anti-inflammatory treatment, i.e. 
anti-TNF, on the cardiac function and the prevalence and incidence of CHF in RA. We 
performed echocardiography to assess the effect of anti-TNF on the cardiac function in 
RA patients with active disease in chapter 4. Part I finishes with chapter 5 describing 
a case report of a SLE patient with SLE induced heart failure with preserved ejection 
fraction (HFpEF) where the heart failure was treated with anti-inflammatory therapy. 
In part II, we focus on the role of systemic inflammation and cardiac diseases in AS 
patients. In this light, in chapter 6, we performed a large cross-sectional study in AS 
patients and osteoarthritis (OA) controls, the CARDAS study, to assess the prevalence 
of cardiac valve disease, conduction disturbances and cardiac dysfunction in AS. In our 
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aim to identify a subgroup of AS patients at risk for aortic valve disease, in chapter 7, 
we performed a sub study of the CARDAS study to assess the association between HLA-
B27 genotype and aortic root dilatation and aortic valve regurgitation. Finally, part 
III reports on clinical trials focusing on relation between systemic inflammation and 
cardiovascular disease beyond the heart. In chapter 8, we conducted a cross-sectional 
controlled study in AS patients and healthy controls to assess the difference in retinal 
vasculature and to assess the value of retinal screening for cardiovascular disease. 
Furthermore, we assessed the effect of anti-inflammatory therapy on insulin resistance 
and body composition in RA patients in chapter 9.
Table 1. Research questions
Chapter 1  General introduction
Part I
Chapter 2 What is the role of systemic inflammation on the cardiovascular disease in 
inflammatory joint disease?
Chapter 3 What is the effect of anti-inflammatory treatment, i.e. biologic DMARD’s, on the 
cardiac function and the incidence and prevalence of congestive heart failure in 
RA patients described in the literature?
Chapter 4 What is the effect of anti-TNF on the systolic and diastolic cardiac function in 
RA patients?
Chapter 5 What is the effect of anti-inflammatory treatment in SLE induced HFpEF?
Part II
Chapter 6 What is the burden for cardiac disease in AS patients and is screening indicated? 
What is the prevalence of cardiac valve disease, conduction disturbances and 
cardiac dysfunction in AS?
Chapter 7 Is the HLA-B27 genotype associated with the aortic root dilatation in AS patients?
Part III
Chapter 8 Does retinal screening in AS patients reveal patients at risk for cardiovascular 
disease? Do retinal microvascular abnormalities differ between AS patients and 
healthy volunteers?
Chapter 9 What is the mechanism of anti-inflammatory therapy, i.e. anti-TNF, on reducing 
risk for cardiovascular disease? Does anti-TNF improve insulin resistance and 
body composition in RA patients?
Chapter 10 Summary, general discussion and future perspectives
1
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Abstract
The increased risk of cardiovascular morbidity and mortality in rheumatoid arthritis 
and gout has been increasingly acknowledged in past decades, with accumulating 
evidence that gout, just as with rheumatoid arthritis, is an independent cardiovascular 
risk factor. Although both diseases have a completely different pathogenesis, the 
underlying pathophysiological mechanisms in systemic inflammation overlap to 
some extent. Following the recognition that systemic inflammation has an important 
causative role in cardiovascular disease, anti-inflammatory therapy in both conditions 
and urate-lowering therapies in gout are expected to lower the cardiovascular burden of 
patients. Unfortunately, much of the existing data showing that urate-lowering therapy 
has consistent beneficial effects on cardiovascular outcomes in patients with gout are 
of low quality and contradictory. We will discuss the latest evidence in this respect. 
Cardiovascular disease risk management for patients with rheumatoid arthritis and gout 
is essential. Clinical guidelines and implementation of cardiovascular risk management 
in daily clinical practice, as well as unmet needs and areas for further investigation, 
will be discussed.
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Introduction
Cardiovascular disease is the most frequent cause of death worldwide. The 2017 Global 
Burden of Disease Study showed that 17·8 million people died of cardiovascular disease 
globally, accounting for 21% of all deaths [1]. Well established, traditional risk factors 
for cardiovascular disease comprise age, sex, race, hypertension, diabetes, smoking, and 
hyperlipidaemia, all of which are included in various prediction models. However, over 
the past 20 years several non-traditional risk factors, such as chronic inflammation, 
have emerged as amplifiers of cardiovascular disease risk [2].
Rheumatoid arthritis is the most common autoimmune arthritis, with a prevalence 
of up to 1%, [2] and is characterised by a symmetrical polyarthritis with possible 
systemic manifestations. Rheumatoid arthritis is an accepted independent risk factor 
for cardiovascular disease, driven by the underlying chronic inflammatory process. 
However, traditional cardiovascular risk factors remain important [3].
Gout is the most common crystal-induced, autoinflammatory joint disease with a 
prevalence of between 0·1% and 10·0% [4]. Gout occurs when monosodium urate 
crystals are deposited in joints and soft tissues. Hyperuricaemia—defined by a serum 
urate concentration above the saturation point (ie, ≥0·41 mmol/L [≥6·8 mg/dL])—results 
predominantly from reduced renal excretion of uric acid, which is a consequence 
of genetics, comorbidities, and therapies. A continuum has been suggested, from 
asymptomatic hyperuricaemia to asymptomatic subclinical crystal deposition detectable 
only by ultrasound or dual-energy CT, to the clinical inflammatory state of gout flares, to 
chronic gouty arthritis with tophi and gouty bone erosions [5]. If not treated adequately, 
gout is a debilitating disease with systemic manifestations, such as monosodium urate 
crystal deposition in organs and worsening of cardiorenal function [6,7]. In addition 
to gout flares, patients with gout frequently have a high burden of cardiovascular 
comorbidities, which might explain, in part, the high cardiovascular mortality when 
compared with the general population [8]. During the past 20 years, gout has been shown 
to be an independent cardiovascular risk factor, with higher cardiovascular mortality 
than in the general population [9].
In this Review, we will discuss epidemiological data on cardiovascular disease in 
rheumatoid arthritis and gout, not only for atherosclerotic disease but also for venous 
thrombotic disease and heart failure, as clinical and subclinical prevalence of the two 
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diseases is higher than previously thought. The underlying pathophysiology of increased 
cardiovascular risk relevant to inflammatory arthritis, as well as the observed effect of 
anti-inflammatory and disease modifying treatments such as urate-lowering therapies 
in gout, will be reviewed and discussed. Increased cardiovascular risk in patients 
with inflammatory arthritis necessitates cardiovascular risk assessment and current 
management guidelines and their practical implications will be discussed. Finally, we 




Patients with rheumatoid arthritis have up to a two-times higher risk of developing 
atherosclerotic cardiovascular disease than the general population, similar to patients 
with diabetes [10]. The risk of ischaemic heart disease is increased in patients with early 
rheumatoid arthritis and symptom duration of less than 1 year, and probably even in 
the subclinical stage [11]. The risk of cerebrovascular incidents is increased by about 
50% (relative risk 1·48, 95% CI 0·70-3·12), whereas the risk of myocardial infarction is 
doubled (relative risk 2·00, 1·23-3·29) [11]. Moreover, patients with rheumatoid arthritis 
have almost twice the risk of developing congestive heart failure (rate ratio 1·7, 95% CI 
1·3-2·1), including both heart failure with preserved ejection fraction and heart failure 
with reduced ejection fraction [12].
Several factors contribute to increased cardiovascular risk, including comorbidities 
such as diabetes, dyslipidaemia, and hypertension; [13] albeit the data for hypertension 
are somewhat conflicting [14]. Lipids seem to have paradoxical associations with 
cardiovascular risk in rheumatoid arthritis. During active disease, low total cholesterol 
and LDL cholesterol are associated with increased cardiovascular risk (the so-called lipid 
paradox) [15]. Effective antirheumatic therapies resulting in reduced disease activity of 
rheumatoid arthritis reverse the cholesterol reduction, thus leading to increased lipid 
concentrations, [16] and lipid concentrations in well controlled rheumatoid arthritis are 
generally stable and similar to those in the general population [11,15,17]. Furthermore, 
patients with rheumatoid arthritis also have more than a two-times increased risk of 
venous thrombotic disease compared with the general population (cumulative incidence 
of 6·7% [SE 1·7] vs 2·8% [1·1], p=0·005) [18].
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Studies show that all-cause mortality among patients with rheumatoid arthritis was 
54% higher than in the general population, primarily because of cardiovascular disease 
(32%), [19] with a median shortened life expectancy of 6–7 years [20]. In one study, 
the estimated standardised cardiovascular-mortality ratio was 1·2 (95% CI 1·05-1·43), 
[21] which is substantially less than reported in earlier studies. The improvement in 
cardiovascular mortality in patients with rheumatoid arthritis over the past 20 years 
could be attributed to the early initiation of more effective antirheumatic treatments 
(conventional synthetic and biological disease-modifying antirheumatic drugs 
[DMARDs]) [22]. Decreased disease activity following effective therapy is associated 
with a lower cardiovascular risk, and vice versa, whereas cardiovascular risk remains 
unchanged in patients who do not respond to biological DMARDs [23]. However, it 
should be noted that about 50% of increased cardiovascular disease risk in patients 
with rheumatoid arthritis is associated with traditional cardiovascular risk factors [24].
Gout
A large retrospective database study in the UK (8386 patients with gout vs 39 766 
without gout) showed that the prevalence of hypertension in patients with gout at 
baseline was twice as high compared with the control group (36% vs 17%). Patients 
were also more often obese (60% vs 44%) and hyperlipidaemic (6% vs 3%) with more 
prevalent use of statins (34% vs 26%) [25]. A high prevalence of these traditional risk 
factors was also seen in the large National Health and Nutrition Examination Survey 
2007–08, including 7·7 million US patients with gout. Moreover, the National Health 
and Nutrition Examination Survey showed that 26% of patients with gout had diabetes 
compared with almost 8% in the non-gout population (OR 2·36, 95% CI 1·5-3·7) [26].
In a large retrospective Dutch cohort of primary care patients with gout, 796 (30%) of 
2655 patients already had established cardiovascular disease at cohort entry compared 
with 1557 (20%) of 7891 in the non-gout control group. After 3 years of follow-up, 
154 (8%) of 1859 patients with gout had developed cardiovascular disease, compared 
with 318 (5%) of 6334 in the non-gout control group [13]. There was an even higher 
incidence of cardiovascular disease (47%) in patients managed by rheumatologists, 
possibly explained by a higher portion of severe gout seen in this setting [8].
Gout is an independent risk factor for cardiovascular disease; however, the strength 
of the association of hyperuricaemia and gout with other traditional cardiovascular 
risk factors makes distinguishing the isolated influence of gout on that risk difficult 
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[27]. Although atherosclerotic disease, hypertension, and chronic kidney disease are 
associated with elevated serum urate concentrations, the causal relationship and 
direction of association between urate and these disorders is still under debate [28]. 
An increase in serum urate concentration leads to an increased risk of hypertension 
(odds ratio [OR] 1·16 per 0·06 mmol/L increase [1 mg/dL increase], 95% CI 1·07-1·24) and 
increased LDL cholesterol (men: OR 1·16 per 0·06 mmol/L increase [1 mg/dL increase], 
1·01-1·33; women: OR 1·22 per 0·06 mmol/L increase [1 mg/dL increase], 1·06-1·39) [29,30].
In the past decade, several observational studies have suggested an association between 
hyperuricaemia, gout, and congestive heart failure. A cross-sectional study of 15 722 
patients in the USA found the prevalence of congestive heart failure to be 10% in 
patients with gout versus 2% in patients without gout [31]. Another study in patients 
with coronary artery disease showed that patients with gout had a higher prevalence 
of congestive heart failure (500 [36%] of 1406) than those without gout (3847 [25%] of 
15 795) [32]. Furthermore, individuals with asymptomatic hyperuricaemia already have 
an increased risk of congestive heart failure, [33,34] and there appears to be a linear 
relationship with serum urate concentrations.
Gout increases the risk of mortality from cardiovascular disease (hazard ratio [HR] 1·29, 
95% CI 1·14-1·44) [35]. During a mean follow-up of 4 years among 706 patients with gout, 
[38] (59%) of 64 deaths had a cardiovascular attribution [36]. Looking for trends and 
possible improvement of cardiovascular mortality in gout, analysis of a medical record 
database representative of the UK compared cumulative mortality rates of individuals 
with gout versus non-gout between 1999–2006 and 2007–2014. The investigators found 
that the high mortality in patients with gout remained unchanged, whereas mortality 
rates for rheumatoid arthritis have improved over the same time period. This mortality 
gap might be related to suboptimal gout care (insufficient allocation of medication, 
insufficient treatment, and low drug adherence), as well as insufficient management 
of cardiovascular comorbidities. Gout specific characteristics that are associated with 
high cardiovascular risk are elevated serum urate concentrations (>0·55 mmol/L [>9·1 
mg/dL]), longer disease duration (≥2 years), oligoarticular or polyarticular disease, and 
joint damage and tophi, which all reflect a more severe disease state [8].
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Pathophysiology
Although rheumatoid arthritis and gout have different pathogenic stimuli (not known for 
rheumatoid arthritis; monosodium urate crystal deposition for gout), different immune 
pathways (eg, antibody-mediated in rheumatoid arthritis; interleukin [IL]-1 driven in 
gout flares), and in most cases different clinical presentation (more chronic symmetric 
synovitis in rheumatoid arthritis; mostly monoarthritic gout flares with asymptomatic 
periods), imaging studies have shown that in gout, subclinical inflammation and 
synovitis are present, even during asymptomatic periods [37]. Importantly, persistent 
inflammation is known to be a key mechanism in the development of cardiovascular 
disease [38,39]. Cardiovascular disease in patients with gout and rheumatoid arthritis 
can be divided into three main categories: atherosclerosis, thromboembolism, and 
cardiac dysfunction (figure 1 ). The pathophysiological mechanisms of these diseases 
are different. However, the inflammatory processes of gout and rheumatoid arthritis in 
the development of cardiovascular diseases partly overlap.
Figure 1. Rheumatoid arthritis, gout, and their shared pathophysiological mechanisms 
behind cardiovascular comorbidities
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The histological image (left) shows synovitis in rheumatoid arthritis. The polarisation 
microscopy image (right) illustrates monosodium urate crystals in synovial fluid during 
a gout flare.
Atherosclerosis
Postulated shared mechanisms of rheumatoid arthritis and gout are systemic 
inflammation, reactive oxygen species (ROS)-induced oxidative stress, and endothelial 
dysfunction, all of which lead to atherosclerosis (figure 2 ).
Figure 2. Summary of shared mechanisms in the development of cardiovascular disease 
in patients with rheumatoid arthritis and gout
The left column describes gout and rheumatoid arthritis-related mechanisms inducing atherosclerosis. 
NET=neutrophil extracellular trap.
The pathways of inflammation in rheumatoid arthritis and gout share some components 
of the innate and adaptive immune system, including activated neutrophils. Exaggerated 
neutrophil activation has been linked to autoimmunity and autoinflammation in 
rheumatoid arthritis and gout. One of the supposed links is the formation of neutrophil 
extracellular traps (NETs). NETosis involves a neutrophil cell death process in which 
DNA is extruded, together with cytoplasmic and granular contents, to trap and eliminate 
extracellular pathogens and neutralise inflammatory cytokines. This process, which was 
first described in gout by Schauer and colleagues, [40] could explain the self-limiting 
character of gout flares. Extracellular DNA exerts cytotoxic and prothrombotic effects 
and might be a causal link between inflammation and coagulation. Moreover, complexes 
of presumably NET-borne DNA stimulate vascular plasmacytoid dendritic cells, with 
a strong interferon type 1 response, promoting atherogenesis [41]. NETs might also 
directly cause endothelial dysfunction by activation and induction of damage to 
endothelial cells, illustrated by the establishment of NETs in atherosclerotic lesions 
and arterial thrombi in humans [42].
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In addition to neutrophils, different proinflammatory cytokines play a central role 
in the pathogenesis of rheumatoid arthritis and gout. In rheumatoid arthritis, the 
reason for immune system activation has not been completely elucidated. However, 
proinflammatory cytokines, such as tumour necrosis factor (TNF), IL-6, and IL-1, are 
important in the inflammatory process. In gout, the central inflammatory pathogenic 
process is assumed to be hyperuricaemia, leading to monosodium urate crystal 
deposition [43]. These crystals provoke a host response, resulting in recurrent gout 
flares by acting as a danger signal for the innate immune system through activation 
of the NLRP3 inflammasome with the immediate release of mature IL-1β by resident 
macrophages, as well the release of other cytokines [44]. The NLRP3 inflammasome 
has an important role in the initiation of a gout flare. Inflammasome activity causes 
oxidative stress, mitochondrial dysfunction, endoplasmic reticulum stress, and 
lysosome rupture, which are all important events in atherogenesis and could lead to 
atherosclerotic plaque instability and ultimately rupture [42].
ROS are a group of small reactive species that play crucial roles in the regulation of 
biocellular processes. The balance between ROS and antioxidant species is essential 
to maintain cellular homoeostasis. Hence, an imbalance in oxidant and antioxidant 
mechanisms leads to a state of oxidative stress. In several chronic diseases, including 
rheumatoid arthritis, there is abundant oxidative stress [45]. Although essential 
for vascular homoeostasis, an excess of ROS might lead to vascular injury. Vascular 
injury being the result of a complex cascade, including oxidative modification of 
lipoproteins, endothelial activation, and leucocyte migration and differentiation 
resulting in acceleration of atherogenesis [46] Oxidative stress might also link gout 
with cardiovascular disease. Although soluble urate has antioxidant properties, during 
urate generation the catalytic enzyme xanthine oxidase produces substantial amounts 
of ROS that affect biocellular mechanisms. There is some experimental evidence that in 
patients with gout, higher activity of xanthine oxidoreductase (XO) is associated with 
larger amounts of ROS. Indirectly, it was shown that inhibiting endothelium-bound XO 
resulted in reduced ROS with favourable effects on vascular function [47,48].
Endothelial dysfunction is a maladaptive state with disruption of vascular homoeostasis 
resulting from a proinflammatory state. By expressing adhesion molecules and 
inflammatory cytokines, endothelial cells amplify an inflammatory cascade facilitating 
monocyte infiltration in the subendothelial layer. LDL cholesterol accumulates in 
the subendothelial space and is oxidised, which is essential for the development of 
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atherosclerotic plaques [46]. Endothelial dysfunction is the earliest phenomenon in 
the development of atherosclerosis and was first described in rheumatoid arthritis in 
2002; [49] it has been observed in patients with early rheumatoid arthritis without 
traditional risk factors and in those with long-standing disease. In rheumatoid arthritis, 
systemic inflammation with proinflammatory mediators, such as IL-1β and TNF, is 
assumed to play a role in the development of endothelial dysfunction, as shown in 
rodent models [50]. Impaired endothelium-dependent arterial responsiveness has been 
observed in patients with untreated gout, compared with individuals without gout, with 
the degree of impairment related to both serum urate and high sensitive C-reactive 
protein concentrations [51].
There are published case series and case reports of urate crystal deposition in the spine 
and solid organs in histological samples fixed with alcohol (no dissolution of crystals) 
[52]. A current observational study investigated alcohol-fixed specimens of coronary 
arteries from explanted hearts with polarisation microscopy and detected strongly 
birefringent urate crystals in about 10% of coronary arteries [53]. Whether or not crystal 
deposition in the vessels with subsequent local inflammation contributes to a higher 
cardiovascular risk in these patients is not known.
Venous thromboembolism
The immune system and coagulation system are linked to increased activity of the 
fibrinolytic system in patients with inflammatory joint diseases. Tissue factor initiates 
the extrinsic coagulation cascade and is found on extravascular cells, such as monocytes 
and neutrophils. C-reactive protein, TNF, IL-6, and complement activation might amplify 
tissue factor synthesis in monocytes and endothelial cells, and high concentrations of 
tissue factor have been found in patients with rheumatoid arthritis, particularly in those 
with a high disease activity [54]. Consequently, increased concentrations of coagulation 
factors were shown in patients with rheumatoid arthritis [54]. The role for TNF seems 
plausible, as in the general population this cytokine might induce an imbalance between 
clotting and fibrinolysis, resulting in a hypercoagulable state. Furthermore, a role for IL-6 
was suggested by a randomised trial in patients with rheumatoid arthritis that showed 
that IL-6 receptor blockade reduced coagulation activation parameters by more than 40% 
compared with placebo [55]. To date, data on the role of cytokines in the development 
of thromboembolism in gout are not available and observational data suggests that 
gout is an independent risk factor for the development of deep vein thrombosis and 
pulmonary embolism [56]. In addition to extensive neutrophil activation in gout, increased 
147647_BaniaamamMilad-BNW_v6.indd   30 03/08/2021   15:52
CV risk in RA & gout | 31
platelet reactivity has been detected. This finding might serve as one explanation for a 
prothrombotic state and association with thromboembolism in gout [57].
Cardiac dysfunction
Initially, cardiac dysfunction in patients with rheumatoid arthritis was assumed to 
be secondary to ischaemic heart disease. However, the incidence of congestive heart 
failure (heart failure with preserved ejection fraction and heart failure with reduced 
ejection fraction) cannot be explained by atherosclerotic disease alone. A case-control 
study showed that patients with rheumatoid arthritis had a rapidly increasing risk of 
developing non-ischaemic congestive heart failure after clinical onset [58]. Congestive 
heart failure was seen more frequently in patients with rheumatoid arthritis compared 
with patients with osteoarthritis (adjusted risk 3·9% [95% CI 3·4-4·3] for rheumatoid 
arthritis vs 2·3% [1·6-3·3] for osteoarthritis) [59]. Patients with rheumatoid arthritis 
treated with TNF-blocking agents had significantly less congestive heart failure than 
those who were not receiving anti-TNF treatment [59]. Another study found an increased 
prevalence of heart failure with preserved ejection fraction in patients with rheumatoid 
arthritis, which correlated primarily with disease activity and with anti-inflammatory 
treatments (ie, conventional synthetic DMARDs and biological DMARDs) [60]. In 
addition, patients with rheumatoid arthritis are susceptible to more rapid subclinical 
changes in diastolic function than are the general population [61]. Altogether, these 
studies suggest that systemic inflammatory activity and cardiac dysfunction cannot 
be attributed to atherosclerosis alone.
Chronic systemic inflammation has two distinct pathways in the development 
of cardiac dysfunction (figure 3 ). First, chronic systemic inflammation leads to 
myocardial remodelling, and, specifically, to diastolic dysfunction. This process starts 
with inflammation-induced microvascular dysfunction, [63] leading to deposition of 
collagen with subsequent stiffness and hypertrophy of cardiomyocytes and a decreased 
ability of the myocardium to contract and relax, which might evolve into heart failure 
with preserved ejection fraction [64]. Second, systemic inflammation and traditional 
cardiovascular risk factor-induced coronary microvascular dysfunction and activation 
lead to atherosclerosis with ischaemic heart disease. This ischaemia leads to autophagy, 
apoptosis and necrosis of cardiomyocytes, and collagen deposition in the interstitial 
space giving rise to systolic ventricular dysfunction. In severe cases, heart failure with 
reduced ejection fraction might develop [62]. Several studies have assessed the effect of 
anti-inflammatory therapy on cardiac function in rheumatoid arthritis, and a systematic 
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review revealed that biological DMARD therapy probably has favourable effects on 
cardiac dysfunction in rheumatoid arthritis [65].
Figure 3. Shared mechanisms in the development of heart failure with preserved or 
reduced ejection fraction in patients with rheumatoid arthritis and gout
Systemic inflammation with elevated concentrations of circulating cytokines, such as IL-6 and 
TNF, induce oxidative stress and endothelial activation. Consequently, presentation of adhesion 
molecules (VCAM-1 and E-selectin) by endothelial cells leads to monocyte infiltration in the 
myocardium. These monocytes produce TGF-β, resulting in the differentiation of fibroblasts 
into myofibroblasts, with subsequent deposition of collagen in the interstitial space. In addition, 
intracellular oxidative stress results in disrupted crosstalk between endothelial cells and 
cardiomyocytes, leading to stiffness and hypertrophy of cardiomyocytes with a subsequent 
decreased ability to contract and relax. These processes ultimately lead to preclinical diastolic 
ventricular dysfunction, which might evolve into heart failure with preserved ejection fraction. 
Ischaemia, mostly secondary to atherosclerosis, leads to autophagy, apoptosis, and necrosis of 
cardiomyocytes, and deposition of collagen in the interstitial space. This condition can give rise 
to systolic ventricular dysfunction, which in severe cases can lead to heart failure with reduced 
ejection fraction. Adapted from Paulus and Tschöpe, [62] by permission of Elsevier. ROS=reactive 
oxygen species.
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Remarkably, the pathogenesis of cardiac dysfunction in hyperuricaemia and gout has 
not been adequately investigated to date [66]. Previous studies showed an association 
between serum urate concentration and inflammation, thus suggesting a comparable 
pathogenesis with rheumatoid arthritis [67]. Furthermore, increased serum urate 
concentration and higher activity of ROS-generating XO in gout might lead to endothelial 
dysfunction with decreased nitric oxide production [68]. Hypertension might also have a 
causal role because gout and hyperuricaemia are independent predictors of developing 
hypertension. One interventional study assessing urate-lowering therapy in patients 
with heart failure did not find significant beneficial effects of allopurinol, probably 
because there was already advanced structural myocardial damage and multimorbidity 
in the patient population [69]. Studies with early urate-lowering interventions are 
needed to answer the question of whether, and to what extent, urate concentration 
and the associated inflammation in gout constitutes an independent risk factor for 
cardiac dysfunction [70].
Cardiovascular effects of drug treatment
Rheumatoid arthritis
Most non-steroidal anti-inflammatory drugs (NSAIDs), including the cyclooxygenase 
inhibitors, are associated with about a two-times increased cardiovascular risk [71]. 
The exception is probably naproxen, although the published literature is conflicting in 
this respect [72]. Cardiovascular risk is associated with COX-2 selectivity, and the lower 
COX-2 selectivity of naproxen than of other NSAIDs (eg, cyclooxygenase inhibitors) 
is assumed to translate into a lower cardiovascular risk [73]. In clinical practice, 
weighing the benefits of these drugs against cardiovascular risk is often difficult. The 
first risk model that could aid in clinical decision making regarding the use of these 
drugs was published in 2019 [74]. This model was based on the Precision trial, [75] a 
large randomised controlled trial in which patients with osteoarthritis or rheumatoid 
arthritis were randomised to naproxen, ibuprofen, or celecoxib [75]. A major toxicity 
risk calculator was developed from easily accessible cardiovascular risk factors (ie, age, 
gender, diabetes, cardiovascular disease, hypertension, current smoking, statin use, 
serum creatinine, rheumatoid arthritis, and haematocrit) to calculate a 1-year risk 
score yielding three risk categories: low (<1%), intermediate (1–4%), or high risk (>4%). 
However, external validation is necessary before such a calculator can be implemented 
in daily clinical practice.
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There has been a long-standing debate on whether steroids (eg, low dose of prednisolone, 
<10 mg daily) have unfavourable cardiovascular effects in an inflammatory situation. 
This effect is suggested by observational studies, but these data are confounded by 
indication because of high disease activity and should therefore be interpreted with 
caution [76]. Hopefully this debate can be settled by the Gloria trial (NCT02585258), 
a multicentre, 2-year trial assessing the safety and effectiveness of a daily 5 mg dose 
of prednisolone versus a matching placebo added to standard of care in older patients 
(aged ≥65 years) with rheumatoid arthritis.
One of the first studies suggesting that cardiovascular mortality risk in rheumatoid 
arthritis could be reduced by methotrexate was published in 2002 [77]. Of 1240 patients 
with rheumatoid arthritis with a mean follow-up of 6 years, 191 (15%) patients had died, 
84 (44%) of which were cardiovascular deaths. Methotrexate use was associated with 
a 70% reduction in cardiovascular mortality (HR 0·3, 95% CI 0·2-0·7). Methotrexate 
also has favourable effects on non-fatal cardiovascular events, with meta-analysis 
showing a risk reduction of 28% in comparison with treatment without methotrexate 
[78]. Other conventional synthetic DMARDs, such as sulfasalazine, might also have 
favourable cardiovascular effects [79]. In addition to beneficial effects on the lipid 
profile, hydroxychloroquine has been associated with a reduction in cardiovascular 
events in patients with rheumatoid arthritis [80]. The recent association of high-
dose hydroxychloroquine with QT prolongation in patients with COVID-19 has raised 
questions about the use of hydroxychloroquine in patients with rheumatoid arthritis 
[81]. As such, it is important to note that disease activity of rheumatoid arthritis itself is 
associated with QT prolongation [82]. Furthermore, there have been no published reports 
indicating that the use of hydroxychloquine in patients with rheumatoid arthritis is 
associated with an increased risk for QT prolongation. Hence, there is no indication to 
restrict the use of hydroxychloroquine in people with rheumatoid arthritis to require 
baseline electrocardiograms.
The first large-scale investigation that compared the effect of anti-TNF agents 
versus conventional synthetic DMARDs on cardiovascular mortality in patients with 
rheumatoid arthritis found an adjusted HR for death of 0·65 (95% CI 0·46–0·93) [83]. The 
risk of acute coronary syndrome in rheumatoid arthritis was studied in 7704 patients 
from a Swedish registry (32 621 patient-years) compared with the general population; 
[84] the HR for acute coronary syndrome was 2·0 (95% CI 1·8–2·3) for patients who were 
previously untreated with biologics and 1·6 (1·4–1·9) for patients using TNF inhibitors.
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A meta-analysis of 28 studies with 236 525 patients with rheumatoid arthritis 
investigated the reduction in cardiovascular events with methotrexate and TNF 
inhibitors in comparison with patients previously untreated with these agents [85]. 5410 
Cardiovascular events were observed and the relative risk was 0·72 (95% CI 0·57-0·91) for 
methotrexate and 0·70 (0·54-0·90) for TNF inhibitors. Hence, favourable cardiovascular 
effects might be mediated through an overall reduction in inflammation and are not 
drug specific.
In 2017, Janus kinase (JAK) inhibitors were suggested to be associated with an increased 
risk of thromboembolic disease [86] and concerns have been reported by the US Food 
and Drug Administration (FDA) about the safety of tofacitinib. These concerns emerged 
from a postmarketing trial evaluating the safety of tofacitinib at two doses (5 mg twice 
daily and 10 mg dose twice daily) versus a control group given a TNF inhibitor [87]. 
There was an increased incidence of pulmonary embolism and an increased overall 
mortality in patients taking 10 mg tofacitinib twice daily [88]. Subsequently, a warning 
was issued indicating that tofacitinib 10 mg twice daily is contraindicated in patients 
who have an increased thromboembolic risk. In view of these events, it is important that 
the prescribed dose for the treatment of rheumatoid arthritis is restricted to 5 mg twice 
daily. The trial programme for baricitinib, the other JAK inhibitor currently licensed 
for rheumatoid arthritis, identified more thromboembolic events in the 4 mg group in 
comparison with the placebo group, [89] and as a result the 4 mg dose was not approved 
in the USA. By contrast, a warning was issued in Europe, indicating that the 4 mg 
dose should not be used in patients with rheumatoid arthritis with an increased risk of 
venous thromboembolism. Further studies are needed to investigate and to differentiate 
between the potential adverse effect of JAK inhibitors and the hypercoagulable character 
of rheumatoid arthritis.
Gout
First-line treatment of gout flares is usually with an NSAID or cyclooxygenase 
inhibitor. The duration of treatment, in general, is short, as gout flares in the early 
stages of disease are often limited to a few days. Whether or not this treatment 
increases cardiovascular risk is not known. Furthermore, there are no data on the 
cumulative yearly dose of NSAID or cyclooxygenase inhibitor intake for patients 
with recurrent gout flares, as these drugs are often available without prescription. In 
advanced gout in particular, chronic use of these drugs might be relevant with respect 
to adverse cardiovascular effects.
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Colchicine is frequently used for treatment of acute gout flares and is also given as a 
low-dose regimen to prevent gout flares during initiation of urate-lowering therapy. 
Colchicine was first used as an anti-inflammatory treatment in cardiovascular disease. 
A 2018 narrative review showed that colchicine has beneficial effects on atherosclerosis 
with plaque stabilisation, reduction of cardiovascular damage, and reduction in 
recurrence of acute coronary syndromes [90]. Colchicine might also have protective 
effects in stable coronary artery disease [91]. Two retrospective cohort studies in patients 
with gout showed a lower incidence of combined cardiovascular outcomes in patients 
treated with colchicine [92,93]. By contrast, a trial showed that short-term low-dose 
colchicine does not improve endothelial function in patients with coronary artery 
disease [94]. However, an exploratory analysis indicated that endothelial function was 
significantly improved in the subgroup of patients with leucocyte activation, further 
indicating the important role of inflammation in atherosclerosis [94]. Ongoing trials, 
such as the COLCOT trial (NCT02551094), will hopefully settle the debate about the 
efficacy of low-dose colchicine for secondary prevention in patients with coronary 
disease. In patients with gout, more research is needed to establish the effects of 
colchicine on cardiovascular risk.
Gout flares that do not respond to NSAIDs, cyclooxygenase inhibitors, or colchicine are 
frequently treated with steroids, either systemically or by intra-articular injection. As 
data on patients with gout are scarce, one can only speculate as to whether the typically 
short treatment duration has any unfavourable cardiovascular effects.
In 2013, the anti-IL-1β antibody canakinumab was approved by the FDA and the 
European Medicines Agency for gout inflammation refractory to conventional anti-
inflammatory treatment [95]. A 2019 trial of the IL-1 receptor antagonist, anakinra, 
showed efficacy in controlling inflammation during gout flare without cardiovascular 
safety issues [96]. The CANTOS trial, [97] which investigated anti-inflammatory therapy 
with canakinumab for secondary cardiovascular prevention in patients with myocardial 
infarction, showed only a modest decrease in recurrent cardiovascular events (about 
15%) compared with placebo, and this result was independent of lipid-lowering effects. 
Whether patients with gout had a cardiovascular benefit from IL-1β-blocking therapy 
was not answered by this trial.
In patients with diagnosed gout, urate-lowering therapy with a treat-to-target strategy to 
reduce serum urate below 0·36 mmol/L (6 mg/dL) is an essential therapeutic intervention 
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recommended by current gout guidelines [98]. The efficacy of a treat-to-target approach 
on regression of tophi, frequency of gout flares, and MRI-detected synovitis has been 
shown [99]. To reach the serum urate target, patients could be treated with urate-
lowering drugs such as XO inhibitors (eg, allopurinol), uricosurics (and combination 
with XO inhibitors—eg, benzbromaron), or a recombinant uricase (eg, rasburicase). 
Urate-lowering therapy should, in theory, reduce the risk of cardiovascular disease in 
gout. This therapy could decrease the risk by directly lowering urate concentration or 
indirectly through XO inhibition, with a subsequent reduction in oxidative stress and 
improvements in endothelial function.
A systematic review and meta-analysis of randomised controlled trials [100] revealed that 
urate-lowering therapy with allopurinol, a purine XO inhibitor, lowered the incidence 
of major cardiovascular events (OR 0·65, 95% CI 0·41-1·05), total cardiovascular events 
(OR 0·57, 0·46-0·72), myocardial infarction or the need of urgent revascularisation (OR 
0·38, 0·17-0·83), and new or worsening hypertension (OR 0·32, 0·18-0·58) in patients with 
various cardiovascular conditions versus the control group, but did not affect overall 
or cardiovascular mortality. These effects were not observed with non-purine-like XO 
inhibitors, such as febuxostat [100]. However, febuxostat lowered the composite event 
rate (cerebral, cardiovascular, and renal events, as well as all deaths) in patients with 
hyperuricaemia who were at risk of cerebral, cardiovascular, or renal disease compared 
with a non-febuxostat group (HR 0·75, 95% CI 0·59-0·95) [101].
In a systematic review and meta-analysis in patients with gout urate-lowering therapy 
with an XO inhibitor was not shown to reduce cardiovascular events compared with 
placebo [102]. In addition, another systematic review and meta-analysis showed that 
there was no significant association between all-cause mortality and allopurinol use 
in patients with gout, albeit the number of studies was small [103]. Finally, a trial of 
nurse-led gout care in a primary care setting consisting of extensive patient education 
and involvement, as well as a treat-to-target strategy, was shown to be superior in 
reaching a serum urate concentration of less than 0·36 mmol/L (6 mg/dL) compared 
with standard care (95% vs 30%, risk ratio 3·18, 95% CI 2·42-4·18, p<0·0001) [104]. Fewer 
deaths were observed in the nurse-led care group, but numbers were too small to draw 
firm conclusions. To date, data regarding the effect of uricosurics or uricase treatment 
on cardiovascular risk in gout are absent. In general, available evidence is not sufficient 
to draw definite conclusions and further studies are needed.
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In 2019, the FDA issued a public safety alert with a warning of increased risk of death 
with febuxostat compared with allopurinol [105]. This warning was based on results from 
the CARES trial. Although febuxostat was shown to be non-inferior to allopurinol for 
the primary outcome (a composite of death and major cardiovascular events; HR 1·03, 
upper limit of the one-sided 98·5% CI 1·23, p=0·002 for non-inferiority), the incidence of 
secondary outcome measures, including death from any cause (HR 1·22, 95% CI 1·01-1·47) 
and cardiovascular death (HR 1·34, 1·03-1·73), was significantly higher with febuxostat 
than with allopurinol [106]. Definite conclusions from this trial are difficult to draw: 
first, no significant difference was observed in the primary outcome of the trial, second, 
there was a very high rate of discontinuation of therapy, with the majority of deaths 
occurring after stopping the drug, and finally, a control group without a XO inhibitor 
was absent [106]. The FDA therefore first mandated febuxostat not to be used in patients 
with cardiovascular disease but thereafter restricted the approved use to patients who 
could not be treated effectively or had severe side-effects with allopurinol. Important 
data will come from the FAST trial, comparing the cardiovascular safety of allopurinol 
and febuxostat in the management of symptomatic hyperuricaemia (EUDRACT number: 
2011–001883–23, ISRCTN72443728).
Management of cardiovascular risk
The recognition of an increased cardiovascular disease risk in arthritis prompted 
the European League Against Rheumatism (EULAR) to set out evidence-based 
recommendations for the management of cardiovascular disease risk in inflammatory 
arthritis, and these guidelines were updated in 2017 [107]. Rheumatoid arthritis is also 
now accepted as an independent cardiovascular disease risk factor by the European 
Society of Cardiology guidelines [108]. To reduce the risk of cardiovascular disease 
in patients with rheumatoid arthritis, optimal disease control is necessary, and 
cardiovascular disease management should be the responsibility of the rheumatologist. 
Risk assessment should be done at least once every 5 years, and should be reassessed 
following major changes in DMARD therapy. Cardiovascular risk management is 
also important for patients with gout, since gout is associated with a high rate of 
traditional cardiovascular risk factors and is also considered an independent risk factor 
for cardiovascular disease and associated mortality. In the 2016 update of EULAR’s 
evidence-based recommendations for the management of gout, two overarching 
principles were that every patient with gout should receive advice regarding lifestyle 
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and that they should be screened for cardiovascular comorbidities and cardiovascular 
risk factors. However, no specific recommendations for cardiovascular risk management 
were given [109]. This omission was one of the main reasons for the assembly of a 
EULAR taskforce to develop recommendations for the management of atherosclerotic 
cardiovascular risk in rheumatic and musculoskeletal diseases, including systemic lupus 
erythematosus, antiphospholipid syndrome, vasculitis, and gout [110].
Cardiovascular risk prediction models
In Europe, the Systematic Coronary Risk Evaluation calculator is used for cardiovascular 
disease risk prediction. This model estimates the 10-year risk of cardiovascular mortality 
and includes age, gender, smoking status, total cholesterol to HDL cholesterol ratio, and 
systolic blood pressure. However, Systematic Coronary Risk Evaluation was developed 
solely for the general population and therefore underestimates the cardiovascular risk 
in patients with rheumatoid arthritis. To correct for this underestimation, EULAR 
recommends use of a multiplication factor of 1·5 [107]. Importantly, EULAR advises 
screening for cardiovascular disease risk in all patients with inflammatory arthritis 
and states that the rheumatologist is responsible for its initiation. Subsequently, several 
prediction models for cardiovascular disease risk, such as QRISK3, have incorporated 
rheumatoid arthritis in their risk model [111]. The Expanded Risk Score in rheumatoid 
arthritis is derived from the CORRONA registry and includes rheumatoid arthritis 
specific features (laboratory data are not needed) [74]. This risk score appears to perform 
as well as QRISK3 [112]. The The table shows the characteristics of these algorithms. 
Thus far, no gout-specific cardiovascular risk scores have been developed, probably 
because of an absence of consistent data on cardiovascular outcomes.
2
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Table
Characteristics of different cardiovascular prediction models
Age
(years)






40–70 10-year risk for 
cardiovascular 
mortality
Age, gender, smoking 
habits, total cholesterol 
to HDL cholesterol ratio, 
systolic blood pressure
Multiplication by 
1·5 to correct for 
underestimation
QRISK3 24–80 10-year risk for 
cardiovascular 
morbidity
Established risk factors and 
additional factors, such 
as the stage of chronic 
kidney disease (assessed 
in 5 grades), a measure 





severe mental illness, 








Risk Score in 
rheumatoid 
arthritis




specific factors: disease 
duration, disease activity, 
disability, and use of 
corticosteroids
Laboratory data 




registry; [74] not 
yet externally 
validated
Antihypertensive agents and statins in rheumatoid arthritis and gout
Statins reduce cholesterol concentrations and cardiovascular disease in patients with 
rheumatoid arthritis to a similar extent as in the general population. Furthermore, 
statins are not associated with more adverse events in comparison to the general 
population. The TRACE RA study compared the effect of 40 mg atorvastatin with 
placebo in patients with rheumatoid arthritis and found a significant reduction in LDL 
cholesterol in the atorvastatin group [113]. In this group, LDL concentrations were 
similar to those observed in the general population. A risk reduction of 34% in major 
cardiovascular events compared with placebo was observed, although this difference 
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did not reach statistical significance possibly due to a lower than expected event 
rate. Furthermore, statins have anti-inflammatory properties that might translate 
into further reductions in cardiovascular disease risk as well as a modest reduction 
in rheumatic disease. A meta-analysis has shown the pleiotropic effects of statins, 
with a decline in inflammation markers (oestrogen receptor, C-reactive protein), pro-
inflammatory cytokines (TNF, IL-1, and IL-6), and fewer tender and swollen joints [114].
The EULAR recommendations for gout advise systematic screening and care in terms 
of cardiovascular diseases and risk factors [98]. This strategy can be complicated 
because many drugs targeting comorbidities can aggravate hyperuricaemia and gout 
by lowering renal excretion of uric acid—eg, antihypertensive drugs such as β blockers, 
non-losartan angiotensin 2 receptor blockers, thiazides, and loop diuretics [115]. This is 
also true for low-dose aspirin, but as the effect is very modest, use of low-dose aspirin 
for cardioprotective reasons should not be precluded in high-risk patients with gout 
[116]. Statins (atorvastatin and simvastatin), and also fenofibrate, have urate-lowering 
effects by increasing renal-urate excretion [117, 118]. Importantly, initiation of statins 
lowers the risk of all-cause mortality in gout, and might have greater benefits amongst 
those without previous circulatory disease [119].
Lifestyle
The effects of dietary measures in rheumatoid arthritis are still uncertain because 
of an absence of adequately powered studies. Observational studies show that diet, 
exercise, and stress are associated with outcomes such as inflammation or disease 
activity. Therefore, EULAR recommends a general healthy lifestyle for all patients 
with rheumatoid arthritis, defined as a healthy diet (Mediterranean), regular exercise, 
and smoking cessation. Exercise improves cardiorespiratory fitness and decreases 
cardiovascular risk in patients with rheumatoid arthritis [120].
There is low-to-moderate quality evidence for beneficial effects of weight loss with 
respect to lowering serum uric acid, achieving serum uric acid targets, and preventing 
flares in patients with gout [121]. The EULAR guideline recommends that patients with 
gout receive advice regarding lifestyle that includes avoidance of alcohol and sugar 
sweetened drinks, and discourages excessive intake of meat and seafood (purine-low 
diet). In addition to purines, the intake of fructose is also associated with an increase 
in uric acid production and should be avoided.
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Guidance on smoking cessation is similar to the general population as smoking has 
multiple adverse effects, such as increasing the risk of cardiovascular disease, respiratory 
disease, and cancer. Smoking also seems to have a pathogenic role in rheumatoid 
arthritis, promoting disease activity and reducing response to antirheumatic therapy. In 
contrast to rheumatoid arthritis, a relationship between smoking and the development 
of gout has not been found [122].
Cardiovascular risk management in daily clinical practice
Many studies have indicated poor adherence to cardiovascular disease risk, management 
in rheumatoid arthritis. For example, in a cross-sectional study 282 (71%) of 400 patients 
with rheumatoid arthritis had hypertension, of which 171 (61%) were treated with 
antihypertensive medications. Moreover, despite treatment, many of these patients 
had suboptimal blood pressure [123]. Also, hypercholesterolaemia is underdiagnosed 
and undertreated in patients with rheumatoid arthritis [124].
Notwithstanding guidelines for the implementation of cardiovascular risk, management 
in clinical practice is often difficult [125]. Nevertheless, successful implementation 
of cardiovascular disease risk management was shown in a Dutch programme for 
cardiovascular disease care [126]. This programme included a collaboration between 
primary care and secondary care professionals with a shared laboratory system 
for primary care physicians and rheumatologists, in which primary care physicians 
received reimbursement for additional costs from health-care insurance companies. 
Lipid screening (as a proxy for cardiovascular disease risk management) was done in 
454 (72%) of 600 patients with rheumatoid arthritis and increased to almost 90% after 
primary care physicians were sent reminder letters. Implementation of cardiovascular 
risk management for patients with gout has not been systematically studied and to what 
extent it has been applied in either primary or secondary care is unknown.
Research agenda
Unfortunately, despite several guidelines for cardiovascular disease risk management, 
implementation in daily clinical practice is still poor. A study in the UK confirmed 
this in a group of 673 patients with gout in primary care. Monitoring of lipids (34 
[5%]), blood pressure (178 [26%]), and glucose (43 [6%]) within 1 month after their first 
gout consultation was infrequently recorded [127]. This finding indicates the urgent 
unmet need for optimisation of cardiovascular risk management in these patients. 
At the same time, we should not forget that patients often also have other comorbid 
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conditions. Optimal preventive treatment requires attention to these comorbidities, 
which are commonly seen in inflammatory arthritis and include osteoporosis, fatigue, 
and depression. The rationale is that the underlying mechanisms of these common 
comorbidities, particularly in rheumatoid arthritis, overlap. In our view, such a 
multimorbidity, holistic approach is the optimal way to achieve substantial improvement 
in the quality of life of these patients. Lastly, further randomised controlled trials 
with cardiovascular endpoints are needed, especially in gout, to ascertain optimal 
serum urate concentrations to improve the cardiovascular-risk profile. Another 
relevant question is whether early urate-lowering therapy—in case of asymptomatic 
hyperuricaemia and evidence of crystal deposition by ultrasound or dual-energy CT—has 
favourable cardiovascular effects, as shown for early treatment intervention in patients 
with rheumatoid arthritis.
Conclusions and future research
Rheumatoid arthritis and gout—two inflammatory joint diseases with different 
underlying causes—are associated with about a 50–70% increased risk of cardiovascular 
disease compared with the general population. These patients not only have 
inflammation of joints but also experience systemic effects, including cardiovascular and 
haematological manifestations. Different underlying pathophysiological mechanisms, 
such as systemic inflammation, elevated oxidative stress, endothelial dysfunction, and 
changes in lipid profiles, might contribute to a substantially higher cardiovascular risk 
in these patients. The increased cardiovascular risk includes not only a higher rate of 
ischaemic cardiovascular disease but also subclinical heart failure, which seems far 
more prevalent than previously thought. Early therapeutic intervention with current 
antirheumatic treatment in rheumatoid arthritis has shown favourable effects on 
cardiovascular disease risk. Unfortunately, in gout, evidence that urate-lowering therapy 
has consistent beneficial effects on cardiovascular outcomes is still scarce. Following the 
recognition that inflammation has an important causative role for cardiovascular risk 
in gout, anti-inflammatory therapy and urate-lowering therapies are expected to reduce 
the cardiovascular burden of these patients. Therefore, optimal anti-inflammatory 
control of patients with rheumatoid arthritis and effective urate-lowering therapy in 
patients with gout are the main treatment goals to date. In addition to adequate control 
of disease activity, attention of the treating physician should be given to the treatment 
of concomitant cardiovascular diseases and management of risk factors—eg, adequate 
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control of hypertension and dislipidaemia. For individual cardiovascular risk estimation 
in patients with rheumatoid arthritis and gout, the use of established cardiovascular 
risk scores (eg, Systematic Coronary Risk Evaluation) could be implemented in daily 
assessments. The inclusion of a multiplication factor for gout in cardiovascular risk 
scores, as already accepted for rheumatoid arthritis, should be considered.
Search strategy and selection criteria
We followed the main steps in writing a narrative review, and MTN formulated 
cardiovascular research questions addressing epidemiological and pathophysiological 
aspects of rheumatoid arthritis and gout, cardiovascular effects of drug treatment, and 
management of cardiovascular risk. References for this Review were identified through 
searches of PubMed with the terms “rheumatoid arthritis”, “gout”, “hyperuricemia”, 
“gouty”, “arthritis, “gouty”, “atherosclerosis”, “cardiovascular disease”, “cardiovascular 
event”, “myocardial ischemia”, “cerebrovascular disease”, “stroke”, “angina pectoris”, 
“coronary disease”, “coronary artery disease”, “coronary arterial disease”, “peripheral 
artery disease”, “peripheral arterial disease”, “congestive heart failure”, “cardiac 
dysfunction”, and “cardiovascular risk management” from Jan 1, 1998, to April 1, 2019. 
Articles were also identified through searches of the authors’ own files. Only papers 
published in English were reviewed. The final reference list was generated on the basis 
of originality and relevance to the broad scope of this Review.
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Abstract
Introduction
A common cardiovascular manifestation in rheumatoid arthritis (RA) is congestive 
heart failure (CHF) in which inflammation is considered to play a pivotal role. Although 
anti-inflammatory therapy such as biological disease-modifying anti-rheumatic drugs 
(bDMARDs) have the potential of improving the cardiac function and reducing the 
risk of CHF, the published studies showed contrasting results. This review aims to 
systematically summarize and analyze literature regarding the effect of bDMARDs on 
the cardiac function and on the risk of CHF in RA.
Areas covered
Observational cohort, randomized controlled trials and case-controlled studies were 
included. The systematic literature search was conducted in PubMed, Wiley/Embase, 
Cochrane, Web of Science and clinicaltrials.gov (up to 2017). Two authors assessed 
abstracts for inclusion and methodological quality was assessed by one reviewer.
Expert opinion
RA patients have a clinically relevant increased risk of developing CHF needing further 
attention. However, we found a lack of high quality studies. Future studies should focus 
on distinguishing the effect of myocardial inflammation reduction versus antibody-
specific myocardial cellular effects of bDMARDs to improve the understanding of the 
effects of bDMARDs in RA patients and the relation with the development of CHF.
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1. Introduction
Rheumatoid arthritis (RA) is a chronic inflammatory joint disease affecting 
approximately 1% of the adult population1. Cardiovascular disease (CVD) is the main 
cause of premature mortality and the most observed comorbidity in RA 2, 3. Therefore, 
RA is recognized as an independent risk factor for the development of CVD in addition to 
the “classic” risk factors indicated by the Framingham study 2. One of the most common 
cardiovascular manifestation is congestive heart failure (CHF), with a relative risk of 
twofold compared to the normal population which is not solely explained by traditional 
cardiovascular risk factors and/or clinical ischemic heart disease 4, 5. Though the exact 
pathophysiology is not yet known, systemic inflammation is considered to play a pivotal 
role in the development of CHF as well as atherosclerotic disease 6, 7. Anti-inflammatory 
therapy such as biological disease-modifying anti-rheumatic drugs (bDMARDs) or may 
have the potential of reducing the risk of developing CHF secondary to suppression of 
systemic inflammation. However, prior studies showed contrasting results in respect to 
the effect of bDMARDs on cardiac function. Therefore, this review aims to systematically 
summarize and analyze literature on the effect of bDMARDs on the cardiac function 
and on the risk of developing CHF in RA patients.
2. Objective
To determine the effect of bDMARDs on the risk of developing congestive heart failure 
in patients with rheumatoid arthritis.
3
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3. Methods
3.1. Criteria for considering studies for this review
3.1.1. Types of studies
We included RCTs, retrospective cohorts, prospective cohorts and case-control studies.
Inclusion criteria
· Studies including adults over the age of 18 years.
· Patients diagnosed with rheumatoid arthritis.




· Guidelines and updates




3.1.2. Type of participants
Adults diagnosed with rheumatoid arthritis
3.1.2. Type of interventions
Interventions




· Certolizumab pegol (anti-TNF)
· Golimumab (anti-TNF)
· Tocilizumab (anti-interleukin-6)
· Abatacept (T-cell co-stimulation blocker)
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· Conventional synthetic disease-modifying anti-rheumatic drugs (csDMARD)
· Placebo
· Healthy volunteers
3.1.3. Type of outcome measures
a) Incidence/prevalence of congestive heart failure.
b) Cardiac function assessed by echocardiography, MRI or cardiac serum biomarkers.
3.2. Search methods for identification of studies
The systematic review is based on Preferred Reporting Items for Systematic Reviews and 
Meta-Analyses method (PRISMA) 8, 9. With support of a search specialist* we searched 
the following databases:
· Wiley/Embase library database up to 20 March 2017;
· the PubMed database up to 6 April 2017;
· the Cochrane database up to 2 May 2017;
· the Web of Science database up to 2 May 2017;
· Clinicaltrials.gov up to 2 May 2017 (no results).
3.3. Data collection and analysis
3.3.1. Selection studies
Two authors (MB, AB) independently assessed and selected studies eligible for this 
systematic review. Disagreement was resolved by consensus. One author (MB) reviewed 
the methodology criteria and methods.
3.3.2. Data extraction and management
One author (MB) extracted data items from the selected studies with the use of 
a standardized excel data form 10. The items included: author, title, year, journal, 
country, date of data abstraction, study design, objective of study, single/multi center, 
region, method of selection, enrollment start date, enrollment end date, methods 
3
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used to prevent and control for confounding, selection bias, and information bias for 
observational studies, funding, author’s financial relationship and other potential 
conflicts of interest, inclusion criteria, exclusion criteria, subjects included, length of 
follow up, mean/median age, % female subjects, mean/median age RA onset, mean/
median RA duration, bDMARD and dose , description of co-medication, disease activity 
baseline, disease activity follow up, outcome, measurement method, outcome baseline, 
outcome follow up, measure of effect or association used, between group summary, 
statistical method, limitations.
The same author assessed the quality of the evidence by the following quality assessment 
tools:
· The Newcastle-Ottawa Scale 11 for retrospective cohorts and case control studies.
· A Modified Newcastle-Ottawa scale for prospective cohorts. To make the quality 
assessment applicable for prospective cohorts we removed question 3 and 4 of part 
Selection from the original Newcastle-Ottawa scale and added a question regarding 
whether the study had a control group or not.
· QUADAS-2 12 for cross-sectional studies.
4. Results
The search resulted in 1177 potential articles from Medline/PubMed (n=155), Wiley/
Cochrane library (n=13), Web of Science (n=211), EMBASE (n=798) and clinicaltrials.
gov (no results). Subsequently, 1124 articles were excluded based on double-blind 
screening of title and abstract including 238 duplicates. The remaining 52 full text 
articles were assessed and 21 articles were eligible for this systematic review. See 
Figure 1 for the flowchart of the search and selection process. All the included studies 
comprised RA patients for whom bDMARD therapy was necessary. Due to the small 
number of published articles we included a broad spectrum of type of studies including: 
RCT’s, retrospective cohorts, prospective cohorts and case-control studies. Included 
articles were divided in three main categories: cardiac function imaging studies, 
CHF prevalence/incidence studies and cardiac function biomarker studies. Cardiac 
function imaging studies consisted of studies assessing the change of cardiac function 
by magnetic resonance imaging (MRI) or echocardiography. Echocardiographic 
assessment techniques included speckle tracking echocardiography, Doppler tissue 
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echocardiography and/or conventional echocardiography. Prevalence and/or incidence 
of CHF studies included retrospective and prospective studies, cross-sectional studies 
and a nested case-control study. NT-proBNP was the main biomarker used to assess the 
cardiac function. Cardiac hemodynamic assessment was performed with the use of the 
Portapres system, a non-invasive hemodynamic beat to beat monitoring system. All 
included articles are summarized in table 1.
Figure 1. Flow chart of the search and selection process.
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4.1. Cardiac function imaging studies
The following 3 studies investigated the cardiac function with the use of cardiac MRI 
(cMRI)13. Kobayashi H. et al. found a significant higher left ventricle mass index and 
lower EF in RA patients at baseline. After one year of tocilizumab treatment (anti-
interleukin-6) they observed a significant increase of the ejection fraction (EF), decrease 
of the left ventricle mass index (LVMI) and normalization of several left ventricle (LV) 
morphological features compared with the control group 13. In addition, these findings 
were positively correlated with amelioration of the disease activity. However, in a cross-
sectional study Giles et al. observed a significant lower LV mass in RA patients compared 
with their control group 14.
Furthermore, Kobayashi Y. et al. demonstrated in a pilot study a significant improvement 
of regional left ventricular (LV) function by cMRI strain analysis after 52 weeks 
tocilizumab treatment 15. This systematic review includes 6 studies in which cardiac 
function was assessed by echocardiography. Vizzardi et al. assessed the cardiac function 
by speckle tracking echocardiography in a longitudinal 2, 3 and 4 chamber view in which 
RA patients underwent echocardiography before starting anti-tumor necrosis factor 
(TNF) (etanercept, adalimumab or infliximab) and after 1 year therapy. Their results 
exhibited no modification of the LV function after 1 year anti-TNF therapy 16.
In a prospective controlled observational cohort Ikonomidis 2009 et al. showed 
improvement of myocardial deformation parameters in RA patients after 30 days 
treatment with anakinra (anti-interleukin-1) assessed by speckle echocardiography 
17. Anakinra treatment was more effective in improving LV deformation parameters 
than corticosteroid treatment in the control group. In another study Ikonomidis et al. 
investigated the effect of anakinra on cardiac function in 60 RA patients without coronary 
artery disease (CAD) compared to 20 RA patients with CAD. To serve as control, the same 
groups were administrated placebo after a 48-hours wash out period and repeated the 
assessment. The results demonstrated significant improvement of the cardiac function 3 
hours after administration investigated by tissue Doppler and speckle tracking parameters 
of myocardial deformation and LV twisting. In addition, the echocardiographic parameters 
showed more improvement of the cardiac function in RA patients with known CAD 
compared to RA patients without CAD 18. Two studies investigated the effect of anti-TNF 
on the cardiac function. Kotyla et al. showed an 8% improvement (p<0.05) of the EF in 23 
RA patients after 1 year infliximab administration 19.
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In contrast, Cetin et al. prospectively investigated the effect of infliximab in RA patients 
on the LV function controlled by prednisolone therapy after 3 months administration. 
An improvement of only one diastolic function parameter (E/E’) was found in the 
infliximab-treated compared to the prednisolone-treated patients 20. Ikonomidis et 
al.21 conducted an observational trial investigating both acute and chronic effects of 
anakinra therapy.  In the acute study they observed the effect of anakinra on the cardiac 
function of 23 RA patients administrated with anakinra or placebo at baseline and after 
3 hours. To serve as control, this was repeated in a double-blinded controlled cross-
over manner after a wash-out period of 48 hours. They observed an improvement of 
the systolic as well the diastolic function assessed by tissue Doppler echocardiography. 
In the chronic study they compared echocardiographic results of 23 RA patients 
before and after 30 days anakinra treatment controlled by 19 prednisolone-treated RA 
patients. Similarly, the chronic study showed a significant improvement of the diastolic 
and systolic cardiac function after anakinra administration. However, no effect was 
observed in the prednisolone-treated control group 21. Furthermore, Santos et al. used 
a non-invasive hemodynamic beat-to-beat monitoring system to observe on the indexed 
cardiac output (CO) and stroke volume (SV) during two hours before and after infusion 
with infliximab in 14 RA patients without history of CHF. The same group served as 
control, as the same procedure was repeated 2 weeks later after infusion with saline. 
They showed a significant reduction of SV and CO output after infusion with infliximab, 
subsequently -13% and -9%. In contrast to the control group which did not show any 
difference after infusion with saline 22.
4.2. CHF prevalence/incidence studies
In addition to the direct effects of bDMARDs on cardiac function, many studies 
focused on the incidence rate of CHF in RA patients treated with bDMARDs. Giles et 
al. conducted a cross-sectional study with cMRI in RA patients with no self-reported 
history of CVD. Patients treated with anti-TNF showed an inverse association with 
mean LV stroke and LV end-diastolic volumes 14. Schau et al. conducted a cross-sectional 
study assessing heart failure by a diagnostic work up according to the European society 
of cardiology recommendations where they found similar prevalences of CHF in RA 
patients treated with bDMARDs and conventional synthetic (cs)DMARD’s. Of the 157 
included RA patients, 90 (57%) were treated with bDMARDs of which 21 (23%) had CHF 
compared to 67 (43%) csDMARD treated RA patients of which 17 (25%) were diagnosed 
with CHF 23. In a nested case-control study, Bernatsky et al. studied the rate of the 
first occurrence of CHF hospitalization in RA patients with no history of CHF derived 
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from two large North-American insurance claims databases. Their analysis showed a 
relative risk of 0.5 (CI 95% CI 0.2-0.9) of hospitalization for patients treated with TNF 
blockers in comparison to RA patients not treated with TNF blockers and DMARD’s 
24. In another large insurance claims database cohort, Solomon et al. compared the 
incidence of CHF hospital admission of csDMARD users with TNF-blocker users in RA 
patients. In this RA population, TNF blockers were not associated with a risk of CHF 
hospital admissions compared with csDMARDs, displayed in a hazard ratio (HR) of 
0.85 (95% CI 0.63 to 1.14) 25. Curtis et al. also investigated administrative claims of 
a large U.S. health care organization for the cumulative incidence of CHF in RA (and 
Crohn’s disease) patients. They observed a not statistically significant increased crude 
relative risk of heart failure among all TNF-α exposed RA patients (relative risk 4.3) 
26. In a large observational cohort of RA patients in the UK, Morgan et al. examined 
the long-term safety of etanercept in comparison with csDMARD’s. They compared 
4453 etanercept users with 3774 csDMARD users. Although the mean disease duration 
and disease activity was significantly higher in the etanercept group compared to 
the csDMARD group, the etanercept group showed approximately half the incidence 
rate for the development of congestive heart failure (unadjusted rate of 1.7 vs 3.3 per 
1000 person-years) 27. Al-Aly et al. examined the effect of anti-TNF on cardiovascular 
outcomes and long-term survival in a large registry cohort from U.S. veterans with RA. 
Their analysis showed no proportional risk of anti-TNF for developing congestive heart 
failure compared to other DMARDs (HR 1.05 95% CI 0.909–1.217) 28. A large German 
register cohort found that anti-TNF treatment did not increase the risk of worsening 
of prevalent heart failure and therefore suggested that anti-TNF is more likely to be 
beneficial than harmful with regards to the risk of heart failure 29.
In pooled health care utilization databases Setoguchi et al. estimated the risk of CHF 
hospitalization in anti-TNF users among elderly patients with RA with and without 
previous CHF. In their cohort, anti-TNF users had a greater risk of CHF hospitalization in 
comparison to MTX users (HR1.7 CI 95% 1.07-2.69) 30. A single center retrospective study 
in Veterans showed similar risk for developing CHF in the anti-TNF treated RA group, 
RA control group and the non-RA control group (respectively 7%, 8%, 7%; p=0.940) 31. 
Wolfe et al. determined the incidence and prevalence of heart failure in patients with 
RA in a two year cohort treated with anti-TNF compared to no anti-TNF therapy and 
found a significant lower adjusted incidence and prevalence in patients treated with 
anti-TNF ( 0.2 vs 0.2-0.3 and 2.8 vs 3.4-3.9, respectively) 32.
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4.3. Cardiac function biomarker studies
Two studies used BNP/NT-proBNP as assessment tool to describe the effect of bDMARDs 
on the cardiac function. In one of these studies, Peters et al. showed a significant 
decrease in NT-proBNP of 18% after 16 weeks of administration of adalimumab in 
RA patients without pre-existent heart conditions 33. Likewise, in a sub analysis of a 
previous described study, Kotyla et al. found a 48% decrease of NT-proBNP levels after 12 
months of administration with infliximab. Thus, indicating an improvement of cardiac 
function after TNF blocking therapy 19.
5. Summary of findings
The major findings of this systematic review are as follows, (1) it is unlikely that anti-
TNF bDMARDs increase the risk of developing CHF, (2) bDMARDs probably have 
favorable effects on the cardiac function in RA, however, larger trials are needed for 
verification, (3) anti-TNF bDMARDs lowered plasma NT-proBNP levels, thus assuming 
an improvement of the cardiac function.
3
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Table 1. Data summary sheet
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Table 1. Continued.
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Table 1. Continued.
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Table 1. Continued.
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APD -44%* p<0.01 Low
Peters et 
al. 33




APD -17%* p=0.004 Medium
RA: Rheumatoid arthritis; IRR: incidence rate ratio; APD: absolute percentage difference; CAD: 
coronary artery disease; CHF: congestive heart failure; cMRI: cardiac magnetic resonance imaging; 
LSt: longitudinal strain; CSt: circumferential strain; RSt: radial strain; RR: relative risk; HR: hazard 
ratio; CI: confidence interval.
*p < 0.05
‡ These authors described two types of analysis in their articles and therefore they are presented 
twice in this data summary table.
6. Discussion
RA patients have a twofold increased risk of developing CHF compared to the general 
population 4. Early recognition of CHF in RA patients is important as these patients have 
increased risk for mortality and comorbidity 34. Therefore, it is necessary to understand 
the pathophysiologic mechanisms of RA induced CHF. Thus far there is strong evidence 
this correlation is partly due to the increased risk of developing ischemic heart disease 
secondary to accelerated atherosclerosis caused by systemic inflammation 35, 36. However, 
this is not solely explained by the increased risk of traditional cardiovascular risk 
factors and/or clinical ischemic heart disease 5. Accumulating evidence suggests a 
direct effect of inflammation on the myocardium. Previous autopsy studies showed 
significantly higher prevalences of subclinical focal or diffuse inflammatory infiltration 
of the pericardium and myocardium compared to the normal population 37, 38. These 
observations support the assumption that ventricular dysfunction may at least partly 
be due to myocardial inflammation. In addition, several studies found increased serum 
levels of cytokines in patients with chronic and/or acute CHF 39. However, one large 
international placebo-controlled trial investigating the effect of etanercept in patients 
with CHF New York Heart Association (NYHA) class II to IV showed no effect on 
hospitalization or mortality 40. Furthermore, a smaller placebo-controlled trial with a 
similar study design investigating the effect of infliximab administrated with 5 mg/kg 
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6. Discussion
RA patients have a twofold increased risk of developing CHF compared to the general 
population 4. Early recognition of CHF in RA patients is important as these patients have 
increased risk for mortality and comorbidity 34. Therefore, it is necessary to understand 
the pathophysiologic mechanisms of RA induced CHF. Thus far there is strong evidence 
this correlation is partly due to the increased risk of developing ischemic heart disease 
secondary to accelerated atherosclerosis caused by systemic inflammation 35, 36. However, 
this is not solely explained by the increased risk of traditional cardiovascular risk 
factors and/or clinical ischemic heart disease 5. Accumulating evidence suggests a 
direct effect of inflammation on the myocardium. Previous autopsy studies showed 
significantly higher prevalences of subclinical focal or diffuse inflammatory infiltration 
of the pericardium and myocardium compared to the normal population 37, 38. These 
observations support the assumption that ventricular dysfunction may at least partly 
be due to myocardial inflammation. In addition, several studies found increased serum 
levels of cytokines in patients with chronic and/or acute CHF 39. However, one large 
international placebo-controlled trial investigating the effect of etanercept in patients 
with CHF New York Heart Association (NYHA) class II to IV showed no effect on 
hospitalization or mortality 40. Furthermore, a smaller placebo-controlled trial with a 
similar study design investigating the effect of infliximab administrated with 5 mg/kg 
or 10 mg/kg showed a significant increased risk for mortality and hospitalization due 
to CHF 41. Obviously, further research in this area is needed.
In this systematic review, we found conflicting results in studies assessing the effects of 
bDMARDs on the cardiac function and the risk for developing CHF. Most of the cardiac 
imaging studies demonstrated favorable effects of bDMARDs on the cardiac function 
after treatment with anti-interleukin-1, anti-interleukin-6 or anti-TNF.
6.1. Cardiac imaging studies
A large number of studies presented in this systematic review described the effect of 
biologics on the cardiac outcome with cardiac imaging. The cMRI is considered as the 
golden standard for LV volumetric and EF (systolic function) assessment. Although 
cMRI is more accurate and reproducible in comparison to echocardiography, it is a very 
expensive and time-consuming examination. Therefore, for routine clinical practice, 
echocardiography is the most used examination tool in assessing cardiac function as 
it is a relatively fast and less costly. However, cMRI is superior in assessing the systolic 
function and echocardiography has the lowest interobserver variability in assessing the 
diastolic function. Furthermore, there is relative inexperience in assessing the diastolic 
function with cMRI compared to echocardiography 42, 43.
6.1.1. Anti-interleukin-1
All studies investigating the effect of anti-interleukin-1 (anakinra) exhibited 
improvement of the cardiac function. Surprisingly, two studies conducted by Ikonomidis 
et al. even demonstrated an improvement a few hours after administration with anti-
interleukin-1. This could be explained by fast reduction of the interleukin-1 driven 
oxidative stress and myocardial damage by complete neutralization of interleukin-1 
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18, 21. In addition, one of these studies showed a greater improvement of the cardiac 
function in RA patients with history of CAD as these patients had higher levels of 
oxidative stress compared to patients without history of CAD. Notably, murine studies 
demonstrated interleukin-1 induced contractile dysfunction in isolated cardiomyocytes 
and a reversible cardiomyopathy 44. Although, anakinra nowadays is used in infrequently 
in RA patients, it is registered as an anti-rheumatic biologic agent medicine and still 
applied in daily clinical practice. Therefore, anakinra studies were included in this 
systematic review.
6.1.2. Anti-interleukin-6
Interleuking-6 acts as a pro-inflammatory cytokine in the inflammatory cascade. 
As interleukin-6 levels are elevated in RA and CHF patients, it is of interest to study 
the effects of neutralizing interleukin-6 on cardiac function. This is supported by 
studies showing maladaptive hypertrophy and decreasing contractile function in the 
myocardia in acute and chronic serum elevation 45. Neutralizing interleukin-6 could 
therefore inhibit the detrimental cardiac effects. Recently, it was demonstrated that 
anti-interleukin-6 treatment in RA patients improved the cardiac function 13, 15.
6.1.3. Anti-TNF
Studies investigating the effect of anti-TNF on the cardiac function in RA patients were 
inconclusive. Only, Santos et al. showed impairment of the LVEF and stroke volume 
(SV) two hours after infusion with infliximab assessed by a non-invasive beat-to-
beat monitoring system. It might be that TNF has a cardio protective role in hypoxic 
cardiac stress 46, that might be dose related. This is supported by the ATTACH trial 
which evaluated the effect of infliximab in CHF patients with stable NYHA III or IV 
treated with Infliximab 5 mg/kg or 10 mg/kg. The 5 mg/kg treatment group showed no 
worsening of symptoms, hospitalization or death compared with the placebo group. The 
10 mg/kg treatment group however showed significant increase in subjective clinical 
worsening and risk for death and hospitalization. Serum analysis in both treatment 
groups showed plasma levels of infliximab 2-100 times the therapeutic drug level, thus, 
describing the 5 mg/kg group as a high dose and 10 mg/kg as a very high dose Infliximab 
infusion. In contrast, infliximab treatment in RA is administrated with 3 mg/kg, making 
the previous results not applicable to RA patients 41. In addition, two large international 
controlled trials named the RENNAISSANCE and the RECOVER trial in which dilated 
cardiomyopathy (non-RA) patients with EF < 50% were given etanercept (1, 2 or 3 weekly 
25 mg s.c.) during 24 weeks, showed no significant effect towards outcome of death/
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worsening heart failure compared to the control group shown by a combined hazard 
ratio of 1.10 (95% CI 0.91 - 1.33) 41. Furthermore, patients in the RECOVER trial receiving 
etanercept in a medium dose (25 mg two weekly) showed no significant effect towards 
outcome of death/worsening heart failure with a hazard ratio of 0.87 (95% CI .61 – 1.24).
The cardiac imaging studies described in this systematic review have relatively small 
populations, often using different assessment tools and susceptible for confounding. 
Furthermore, many of these studies scored low in the quality assessments, mainly due 
to unclear description of the subjects and lack of a (adequate) control group. Albeit, that 
most data indicated improvement of cardiac function after administration of bDMARDs, 
the results should be interpreted cautiously.
It is known that cardiac myocytes and endothelial cells contribute to establishment 
of a pro-inflammatory environment and mobilize inflammatory mediators into the 
myocardium. Through this pathway different cytokines and chemokines (including 
TNF-a, interleukin-1 and interleukin-6) are produced during environmental distress (e.g. 
hypoxia, pathological mechanical stretch, and inflammation) which can lead to cardiac 
hypertrophy and dysfunction 47. Hence, as bDMARDs are strong anti-inflammatory 
drugs, they may also show ameliorating effects on the cardiac function due to their 
anti-inflammatory effects. In fact, all cardiac imaging studies comparing disease activity 
after follow up showed significant improvement in disease activity (CRP, DAS-28, HAQ 
etc.). However, none of these studies addressed the underlying pathways. In this respect 
it is interesting that a comparable decrease in hospitalization was demonstrated in 
RA patients treated with anti-TNF or methotrexate monotherapy, both strong anti-
inflammatory drugs 24.
6.4. CHF prevalence/incidence studies
The long-term retrospective and prospective cohort studies investigated prevalences 
and incidence rates of CHF in only RA patients treated with anti-TNF agents. Based on 
the results of the cardiac imaging studies showing a trend towards a favorable effect on 
the cardiac function, we hypothesize that patients treated with bDMARDs might have 
a lower risk of developing heart failure. Interestingly, in contrast to the results of the 
cardiac imaging studies, incidence and prevalence studies mostly showed no significant 
difference in the clinical risk of developing CHF in RA patients treated with bDMARDs 
compared to non-bDMARDs. The incidence and prevalence studies were, in general, 
higher quality studies compared to the cardiac imaging studies. More importantly, most 
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studies did not show harmful effects by bDMARDs as was found in the ATTACH trial 
(that, however, comprised non-RA patients with severe heart failure). Solely Setoguchi 
et al, in a relatively small study, demonstrated an increased incidence of CHF in elderly 
RA patients, with long-standing disease, treated with anti-TNF. The discrepancy may be 
explained by the higher average population age and the higher prevalence of prevalent 
CVD (~30%) compared to the other studies 30.
6.5. Cardiac function biomarker studies
For the assessment of the cardiac function, BNP and NT-proBNP are the most widely 
used and recommended biomarkers in current guidelines. ProBNP is a neurohormone 
released by the cardiac muscle during hemodynamic stress — that is, when the ventricles 
are dilated, hypertrophic, or subject to increased wall tension. After cleavage by 
circulating endoprotease into BNP and the bio-inactive NT-proBNP, BNP counteracts 
the cardiac hemodynamic distress by increasing arterial vasodilation, diuresis, and 
natriuresis, and reducing activity of the renin–angiotensin–aldosterone system and the 
sympathetic nervous system48. Comparable with most of the cardiac imaging studies, 
biomarker studies also show favorable effects of anti-TNF on the cardiac function. 
These studies found a decrease of serum NT-proBNP after treatment with anti-TNF 
19, 33. As NT-proBNP is a strong predictor for cardiac (dys)function and measurable 
in patients with even asymptomatic heart failure, a decrease of serum NT-proBNP 
indicates improvement of the cardiac function and a decreased risk for developing heart 
failure 33, 48. Another explanation for decrease of serum NT-proBNP could be reduction 
of myocardial stress due to a decrease of circulating volume. However, no study has 
demonstrated this effect induced by biologic treatment. In contrast to the long-term 
decrease of serum NT-proBNP there is a potential acute increase of serum NT-proBNP in 
patients treated with infliximab 49. This was demonstrated by Santos et al. who showed 
an acute decrease of SV and CO after infusion with infliximab 22. The acute decrease 
of cardiac function could be explained by a cytotoxic effect of infliximab, or as result 
of temporary increased circulating volume. Nevertheless, as mentioned above, it is not 
clear whether the decrease of NT-proBNP is primarily due to the effect of anti-TNF or 
(partially) secondary due to decrease of systemic inflammation, as in both studies RA 
patients showed a significant decrease of inflammation parameters.
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7. Strengths and Limitations
This systematic review gives a broad overview of available data of the effect of bDMARDs 
on the cardiac function and the risk for developing CHF in patients with RA. We used 
strict and standardized tools conducting this review as follows: an extensive literature 
search in collaboration with a search specialist, two investigators independently 
assessed the relevance of studies by title and abstract.
The main limitation in our systematic review was the large methodological heterogeneity 
between the studies making valid comparisons of the results difficult. This was mainly 
caused by different assessment tools, different study outcomes, different corrected 
confounders and different bDMARD agents. It was therefore not possible to do a meta-
analysis or a statistical test for publication bias (e.g. egger test). Furthermore, cardiac 
imaging studies were mostly done in too small populations and were mainly of low 
scientific quality. This was partly caused by lack of control groups and high susceptibility 
for confounders. Furthermore, a potential risk for bias is through confounding by 
indication due to the fact anti-TNF is more often used in RA patients with higher disease 
activity than other DMARD treated RA patients. As disease activity is associated with 
increased risk for CVD this could have flawed the results. Another very important point 
is the risk of selection bias, since anti-TNF treated RA patients are possibly less likely 
to develop CHF as physicians are less willing to start anti-TNF in patients with known 
CHF or in high risk for CHF patients. This could explain why the evidence is less strong 
than expected. Another important confounder which was not often adjusted for, was 
co-treatment with MTX and or prednisolone. MTX and prednisolone are associated 
with respectively, a decreased and an increased risk for developing CHF. Therefore, 
it was not possible to conclude about the effects of bDMARDs only regarding CHF. 
This also applies for other DMARDs as well, however, their effects on CVD have not 
been adequately investigated yet. However, in clinical practice the use of bDMARDs are 
often in combination with MTX. It could therefore be discussed whether MTX should be 
considered as confounder or the effect of bDMARDs should be assessed in combination 
with MTX. Furthermore, in prospective cohorts, severe CHF is considered as an exclusion 
criteria and therefore the effect of bDMARDs on RA patients with severe CHF remains 
unknown. Moreover, the relevance might be limited due the relatively short follow up 
period. However, referring to the cardiac imaging studies, bDMARDS have the potential 
to affect the cardiac function measured with cardiac imaging assessment tools in a short 
time period (months-years). This could impact the risk of developing CHF in the longer 
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period. Finally, CHF is a complex diagnosis which was not well defined in all studies. 
Variability in definition and diagnosis might have influenced the correlation.
8. Conclusion
Based on the available literature we concluded that bDMARDs probably do not increase 
the risk for developing CHF and even might have an ameliorating effect on cardiac 
function. However, the literature might be flawed by selection bias, channeling bias 
and confounding. Therefore, firm recommendations cannot be provided. This review 
indicates that rigorously conducted and adequately powered studies are needed, 
especially RCTs, to elucidate the effect of bDMARDs on the risk for developing CHF in 
RA patients.
9. Expert opinion
RA patients have a clinically relevant increased risk of developing CHF which demands 
further attention. There is uncertainty about the safety of bDMARD treatment in RA 
patients with CHF or high risk for CHF, which was the reason to conduct this systematic 
review. Previous studies revealed a potential cellular effect of bDMARDs on myocytes 
through different mode of actions. However, in this research area we found a lack of 
consensus in study design, including description of CHF and cardiac dysfunction, 
an assessment tool for the cardiac function and a representative population. An 
unambiguous conclusion with respect to the clinical impact could therefore not be 
drawn. Only, if future studies overcome these shortcomings valid recommendations 
can be derived about decisions in bDMARD treatment in RA patients with CHF and 
RA patients at a high risk for developing CHF. Furthermore, there is accumulating 
evidence demonstrating that systemic disease activity in general plays a pivotal 
role in de development of cardiac dysfunction. This understanding is important as 
bDMARDs possibly express their effect by two main pathways: through reduction of 
overall myocardial inflammation and possibly by specific antibody mediated cellular 
effect in the myocardium. Until these two pathways are not clearly understood they 
should be distinguished were possible in future studies. For example, future clinical 
studies assessing the effect of anti-TNF should primarily correlate the disease activity 
with cardiac function. Unraveling the role of inflammation on the cardiac function will 
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raise understanding of the role of bDMARDs on cardiac dysfunction. Therefore, more 
studies investigating primarily the correlation between systemic disease activity and 
cardiac dysfunction irrespective of anti-rheumatic treatment are needed. Actually, we 
expect shift from studies assessing the role of bDMARDs on cardiac function to studies 
investigating the systemic inflammatory state on the (preclinical) stage of cardiac 
dysfunction. If future studies succeed in mapping out these pathophysiological and 
pharmacodynamical pathways RA patients with CHF or at high risk for developing CHF 
can be treated more adequately. Thus, reducing the risk of developing or worsening of 
CHF and possibly even improving cardiac dysfunction. As overall bDMARDs do not 
seem to worsen CHF or increase the risk for developing CHF we believe bDMARDs may 
become a future option in RA patients with CHF or a high risk for developing CHF 
without any uncertainty. This would be supported if future studies show reversibility 
of cardiac dysfunction by anti-inflammatory treatment such as bDMARDs. Moreover, 
if some bDMARDs have additional ameliorating cellular effect on myocyte function, 
these bDMARDs could be used as first treatment option in RA patients with CHF or 
increased risk for developing CHF.
3
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Abstract
Objectives – Congestive heart failure (CHF) is the second most prevalent cause of death 
in rheumatoid arthritis (RA). The systemic inflammatory state in RA patients is deemed 
responsible for this finding. Anti-inflammatory treatment with anti-tumor necrosis 
factor (anti-TNF) therapy decreases CV risk and subsequently might improve the cardiac 
function by lowering the overall inflammatory state. This study investigated the effect 
of anti-TNF on the cardiac function in RA patients.
Methods – Fifty one RA patients were included, of which thirty three completed 
follow-up. Included patients were >18 years, had moderate–high disease activity and 
no history of cardiac disease. Patients were assessed at baseline and after six months 
of anti-TNF treatment. Patients underwent conventional Speckle tracking and tissue 
Doppler echocardiography in combination with clinical and laboratory assessments at 
baseline and follow-up.
Results – The left ventricular ejection fraction (LVEF) and global longitudinal strain 
(GLS) showed no changes during follow-up, LVEF 63% (±9) to 62% (±8) p = 0.097 and 
GLS −20 (±4) to −20 (±3) p = 0.79, respectively. Furthermore, E/e’ nor E/A changed 
significantly between baseline and follow-up, respectively 8 (7–9) and 8 (7–9) p = 0.17 
and 1.1 (±0.4) and 1.1 (±0.4) p = 0.94. Follow-up NT-proBNP decreased with 23%, from 89 
ng/L (47–142) to 69 ng/L (42–155), p = 0.10. Regression analysis revealed no association 
between change in inflammatory variables and cardiac function.
Conclusion – Echocardiography showed no effect of anti-TNF treatment on the cardiac 
function in RA patients with low prevalence of cardiac dysfunction. Moreover, NT-
proBNP decreased, possibly indicating (subtle) improvement of the cardiac function.
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Introduction
Patients with rheumatoid arthritis (RA) have a 1.5-fold increased risk of cardiovascular 
(CV) mortality [1,2]. The systemic inflammatory state in RA patients is deemed 
responsible for this increased risk by causing endothelial dysfunction and accelerating 
atherosclerosis [3,4]. Second after myocardial infarction, congestive heart failure 
(CHF) is one of the most prevalent causes of death in RA patients [5,6]. The damage 
caused by a myocardial infarction and formation of subsequent scar tissue might be a 
cause of the elevated incidence of heart failure. However, a direct effect of the systemic 
inflammation itself has also been suggested as a cause for the development of left 
ventricular (LV) dysfunction. The latter is possibly explained by a process in which 
circulating pro-inflammatory mediators, such as tumor necrosis factor (TNF), induce 
coronary endothelial activation leading to stiffness of the myocardium and interstitial 
fibrosis deposition, resulting in impairment of the relaxation of the myocardium 
(diastolic dysfunction) [7]. Particularly, RA studies have shown an increased prevalence 
of left ventricular diastolic dysfunction [8–10]. This explanation is underlined by studies 
demonstrating that the increased incidence of CHF is only partly due to increased 
prevalence of CV risk factors, such as hypertension, dyslipidemia and increased insulin 
resistance. However, even after correction for these traditional risk factors, the increased 
risk for CHF remains [11,12].
Several studies have shown that anti-inflammatory treatment with anti-TNF therapy 
decreases the CV risk in RA [13–15]. It is plausible that anti-TNF therapy improves the 
cardiac function by lowering the overall inflammatory state by decreasing coronary 
endothelial activation and slowing down the process of coronary atherosclerosis [16], 
thus potentially decreasing the risk of developing CHF in RA patients.
However, previous studies assessing the effect of anti-TNF on the cardiac function 
have shown conflicting results [17,18]. Firstly, anti-TNF therapy is contra-indicated in 
(RA) patients with CHF (New York Heart Association class III and IV) [18], following 
trials from the early ‘00s suggesting that anti-TNF possibly worsens CHF and increases 
mortality in non-RA patients with systolic CHF. It must be recognized, however, that 
the interpretation of these results is still controversial to date [18]. Moreover, several 
trials did not show a detrimental effect of anti-TNF therapy on the incidence of newly 
onset CHF in RA patients [19,20]. Two imaging studies assessing the effect of infliximab 
on the cardiac function with echocardiography showed improved measures of systolic 
4
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and diastolic function, subsequently an increased left ventricular ejection fraction 
(LVEF) and a decrease of E/e’ (parameter for diastolic function) after at least 3 months 
treatment, suggesting improvement of the systolic as well as diastolic function [21,22]. 
Finally, one study investigating the effect of anti-TNF on the cardiac function with 
Speckle tracking echocardiography did not show improvement of function [23]. Overall, 
it should be realized that these studies had relatively small sample sizes and altogether, it 
is presently unknown whether and to what extent TNF blocking therapy has a favorable 
effect on the cardiac function in patients with RA.
This study aimed to elucidate the effect of anti-inflammatory therapy, i.e., anti-TNF, on 
the systolic and diastolic cardiac function in RA patients assessed with comprehensive 
echocardiography (including conventional, tissue-Doppler and Speckle tracking) and 
cardiac biomarkers.
Methods
Study population—a prospective study in fifty one RA patients was performed. 
Subjects were recruited randomly from a large rheumatology outpatient clinic (Reade) 
in Amsterdam, the Netherlands and Amsterdam UMC, Vrije Universiteit Amsterdam, 
department of Rheumatology, the Netherlands from December 2014 and June 2018. 
All participants gave written informed consent and the protocol (NL49652.048.14) 
was approved by the medical ethics committee of the Slotervaart hospital and Reade, 
Amsterdam, the Netherlands. Echocardiography and clinical and laboratory assessments 
were done at baseline and after 6 months of anti-TNF therapy. Inclusion criteria consisted 
of patients fulfilling the 1987 ACR criteria for RA [24], being at least 18 years old, having 
moderate–high disease activity (DAS28 ≥ 3,2) or increased inflammatory biomarkers 
(i.e., erythrocyte sedimentation rate (ESR) > 15, C-reactive protein (CRP) > 10) and 
being scheduled for anti-TNF treatment. Patients started subcutaneous treatment with 
adalimumab (40 mg biweekly), etanercept (50 mg weekly), certolizumab pegol (400 
mg biweekly during first two doses followed by 200 mg biweekly) or golimumab (50 
mg monthly). Patients with a medical history of cardiac disease such as myocardial 
infarction and heart failure, and patients who used anti-TNF therapy 3 months prior to 
start of the study were excluded. Patients were assessed at baseline and after 6 months 
of anti-TNF treatment.
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Clinical assessment—disease activity was assessed by the disease activity score DAS28 
[25]. Physical examination included height, weight, blood pressure measurement 
and joint examination. Blood sample measurements (non-fasting) included standard 
hematological assessment, erythrocyte sedimentation rate (ESR), C-reactive protein 
(CRP), triglyceride levels, total cholesterol, high-density lipoprotein (HDL) and low-
density lipoprotein (LDL), NT-proBNP and Troponin-T. All blood samples were assessed 
in a single laboratory. Health Assessment Questionnaire (HAQ) and patients global 
assessment of disease activity (VAS). Furthermore, smoking status, history and family 
history for cardiovascular disease (CVD) were assessed anamnestically.
Echocardiography—transthoracic echocardiography (TTE)—was performed by certified 
echo technicians at the European Society of Cardiology (ESC)-certified department 
of echocardiography of the Amsterdam University medical center, location VUmc, 
using a Philips ultrasound system (Epiq 7 and IE 33, Philips, Amsterdam, NL). All 
echocardiographic recordings were stored digitally and were afterwards analyzed by an 
experienced cardiologist specialized in echocardiography (T.C.K.). TTE was performed 
according to the following protocol based on the guidelines provided by European 
Association of Echocardiography [26]. Assessment of the cardiac function consisted 
of apical four-, three- and two-chamber views, and 2D color and spectral flow Doppler 
recordings. Left ventricular mass (LVM) was computed based on the Devereux and 
Reichek formula [27]. Pulse wave tissue Doppler imaging was assessed in the apical 
views to obtain mitral annular velocities. The sample volume was located at, or within 
1 cm of the septal (e’ sept) and lateral (e’ lat) mitral valve insertion sites. Doppler 
spectral velocity recordings of the mitral inflow were assessed with the sample volume 
aimed at the tips of mitral valves. From the trans mitral Doppler velocity recordings, 
the E wave deceleration time (DT), peak E and A velocities and the E/A ratio were 
acquired. Left atrial volume was obtained using the modified biplane Simpson’s rule. 
LVEF and diastolic and systolic volumes were computed by Simpson’s from the apical 
four- and two-chamber view. The left ventricular global longitudinal strain (GLS) was 
measured using QLab (version 10.3, Philips, Amsterdam, NL) (Figure 1). As the quality 
of echocardiography is subject to external factors such as excessive fat tissue, not all 
cardiac parameters were assessed per patient. The total number of cardiac parameter 
assessments are therefore described per variable in Table 1.
4
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Figure 1. Flowchart of inclusion.
Table 1. Baseline characteristics.
Patient Characteristics n = 47
Age, years 57 (±11)
Gender, female (n, %) 32 (68%)
RA disease duration, years 5 (2–19)
BMI, kg/m2 26.0 (±4.5)
History of vascular disease (n, %) 1 (2%)
Hypertension (n, %) 4 (9%)
Systolic blood pressure, mmHg 130 (±15)
Diastolic blood pressure, mmHg 80 (±10)
Hypercholesterolemia (n, %) 3 (6%)
Diabetes mellitus type 2 (n, %) 1 (2%)
Smoking (n, %) 13 (29%)
Rheumatoid factor positive (n, %) 33 (66%)
Anti-cyclic citrullinated protein positive (n, %) 32 (68%)
LDL, mmol/L 2.93 (±0.90)
HDL, mmol/L 1.57 (±0.50)
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Table 1. Continued.
Patient Characteristics n = 47
Medication
Current oral corticosteroid use (n, %) 13 (28%)
Intra-muscular/intra-articular corticosteroid in the past 3 months (n, %) 9 (19%)
csDMARD use 43 (92%)
 Methotrexate (with or without other csDMARD(s)) 33 (70%)
 Other csDMARD(s) 10 (21%)







CRP, mmol/L 6.3 (3.1–20.0)
ESR, mm/h 22.5 (9.0–42.5)
Health assessment questionnaire (HAQ) 1.25 (0.75–1.50)
Cardiac parameters
E/e’ ratio (n = 46) 7.9 (6.6–9.0)
E/A ratio(n = 46) 1.1 (±0.36)
Deceleration time, ms (n = 43) 0.22 (±0.06)
LA volume index, mL/m2 (n = 33) 28.40 (±7.53)
LV ejection fraction, % (n = 29) 63.1 (±8.8)
GLS (n = 44) −19.8 (±3.5)
Impaired GLS (>−17%) (n, %) (n = 44) 6 (14%)
LV mass index, g/m2 (n = 42) 68.46 (±17.97)
Diastolic LV dysfunction (n, %) (n = 46)
 No diastolic dysfunction 38 (83%)
 grade I 2 (4%)
 grade II 1 (2%)
 grade III 0 (0%)
 indeterminate 5 (11%)
Systolic LV dysfunction (n, %) (n = 29) 2 (7%)
Aortic valve stenosis (n, %) (n = 46) 0 (0%)




Mitral valve stenosis (n, %) (n = 46) 0 (0%)
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Table 1. Continued.
Patient Characteristics n = 47
H2FPEF score
 0–1 points 32 (70%)
 2–4 points 15 (30%)
 5–6 points 0 (0%)
Cardiac biomarkers
Troponin-T, µg/mL 6 (3–8)
NT-proBNP, ng/L 88.6 (47.0–142.0)
Values are displayed as mean ± standard deviation (SD), median (IQR) or frequencies with 
corresponding percentages (%). RA = rheumatoid arthritis, BMI = body mass index, LDL = low 
density lipoprotein, HDL = high density lipoprotein, csDMARD = conventional synthetic Disease 
Modifying Anti Rheumatic Drug(s), DAS28 = disease activity score-28, CRP = C-reactive protein, 
ESR = erythrocyte sedimentation rate, LA = left atrial, LV = left ventricular, GLS = global longitudinal 
strain, NT-ProBNP = N-terminal pro hormone-brain natriuretic peptide.
In addition, the modified H2FPEF score was used to calculate the a priori chance of 
the diastolic dysfunction in this cohort [28]. The peak TRV >2.8 m/s was suggestive for 
pulmonary hypertension.
Electrocardiography (ECG)—ECGs performed were standard 12-lead ECGs, recorded at 
25 mm/s paper speed. ECGs were analyzed by a single investigator (T.C.K.) whom was 
blinded to the clinical status of all the patients.
Definitions—systolic LV dysfunction was defined as an LVEF <50%. Abnormal GLS 
was defined as >−17%. Diastolic function assessment was based on the ASE/EACVI 
2016 guidelines [29] categorized in 4 grades: normal diastolic function and grade 
I-III (or indeterminate).
Statistical analysis—characteristics of the population are expressed as ± standard 
deviation (SD), median (interquartile range) (IQR) or percentages. For comparisons of 
paired continuous variables between baseline and follow-up with normal distribution, 
paired student-s t-test was used. In case of non-normal distribution, the Wilcoxon signed-
ranks test or log transformation was used. For comparisons of dichotomous variables 
between baseline and follow-up, the Pearson’s chi-square test was performed. Regression 
analysis was used to assess the possible effect of change in systemic inflammation on the 
cardiac function with the follow-up cardiac function parameter as a dependent variable 
adjusted for the baseline cardiac function parameter, the baseline inflammatory parameter 
and delta inflammatory parameter (absolute change of the inflammatory variable at 
follow-up). As inflammatory parameters, the DAS28, CRP and ESR were used. LVEF, GLS, 
E/e’, E/A and NT-proBNP were used as values for cardiac function.
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All analyses were done with SPSS version 23 (SPSS, Chicago, IL, USA) and two-sided 
p-values less than 0.05 were considered statistically significant.
The sample size was based on the primary outcome, i.e., diastolic LV function as assessed 
with Doppler echocardiography and was calculated using the McNemar’s test for sample 
size estimation. With an expected improvement of 25% in diastolic LV function during 
anti-TNF therapy [23,30] and a significance level of 5% and 90% power, the total 
calculated sample size was forty four subjects. To account for a loss to follow-up of 
10%, fifty one patients were included.
Results
Patient Characteristics
The baseline characteristics are described in Table 1. A total of fifty one subjects 
participated in the study. Four patients were excluded at baseline for various reasons 
(no show, suspicion of tuberculosis or cardiac disease de novo, arrhythmia and 
cardiomyopathy, depicted in Figure 2). The mean age of the patients was 57 (±11) years, 
of which 68% were female. Median RA disease duration was 5 (2-19) years and disease 
activity was moderate-high, with a mean DAS28 score of 4.44 (±1.23). Overall, the 
patient-s mobility was moderately impaired with a median HAQ score of 1.25 (0.75-1.50). 
One patient had a confirmed vascular event (ischemic CVA) in the history.
4
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Figure 2. Example of calculation of global longitudinal strain (GLS) by speckle tracking for the 
apical four-, three- and two-chamber views (A, B and C). The strain during one cardiac cycle is 
shown for each of the color-coded (red and blue) left ventricular segments. The longitudinal strain 
bull’s eye plot (D) determined from 2D speckle tracking imaging offers a visual overview of the 
regional and global left ventricular myocardial function in a diagram. In this example of one of 
the subjects in this study, the GLS is −27.3%, which is in the normal range.
Cardiac Function at Baseline
At baseline, three (7%) patients had diastolic LV dysfunction, of which two (4%) had 
diastolic dysfunction grade I, and one (2%) had diastolic LV dysfunction grade II. 
Importantly, two cases of diastolic dysfunction (grade I) was due to the presence of 
systolic dysfunction. None of the patients with diastolic dysfunction had hypertension 
nor diabetes mellitus (DM). In comparison, three of the thirty eight (8%) patients 
with normal diastolic function had hypertension and one (3%) had DM. Systolic LV 
dysfunction based on the ejection fraction was seen in two patients (4%). The GLS 
showed impaired systolic LV function in six patients (14%).
A total of thirty seven ECGs were assessed of which three ECGs showed abnormalities. 
These were a left bundle branch block, a pathologic Q-wave (without a known history 
of myocardial infarction) and a first degree atrioventricular block.
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Disease Activity and Cardiac Function at six Months Follow-Up
A total of thirty three patients completed follow-up. Fourteen patients dropped out 
of which eight due to treatment failure (lack of efficacy), three participants withdrew 
out of the study and of two patients fell out of the follow-up date. DAS28 decreased 
significantly after six months anti-TNF therapy, from 4.44 (±1.23) to 2.72 (±1.23), p < 
0.001. Furthermore, on average the patients mobility as scored with the HAQ improved 
from 1.3 (0.8-1.5) to 0.5 (0.0-1.3), p = 0.001. LVEF and GLS showed no change after 6 
months of anti-TNF therapy, respectively 63.0% (±8.7) to 62.0% (±7.9), p = 0.097 and 
−19.8 (±3.5) to -19.9 (±2.6), p = 0.79. See Table 2.
Table 2. Effect of anti-TNF on the cardiac parameters and disease activity parameters.
Baseline (n = 47) Follow-Up (n = 33) p-Value
Cardiac parameters
E/e’ 7.9 (6.6–9.0) 7.7 (7.1–9.1) 0.17
E/A 1.1 (±0.4) 1.1 (±0.4) 0.94
Deceleration time, sec 0,22 (±0.06) 0.22(±0.04) 0.44
LA volume index, mL/m2 28.4 (±7.5) 30.3 (±5.4) 0.21
LV ejection fraction, % 63.0 (±8.7) 62.0(±7.9) 0.097
GLS −19.8 (±3.5) −19.9 (±2.6) 0.79
LV mass index, gram/m2 68.5 (±18.0) 73.0 (±22.4) 0.66
Troponin-T, µg/mL 6 (3–8) 7 (4–9) 0.43
NT-proBNP, ng/L 89 (47–142) 69 (42–155) 0.10
Disease activity parameters
DAS28 4.44 (±1.23) 2.72 ± 1.23 <0.001 *
CRP, mg/L 6.3 (3.1–20.0) 2.6 (0.8–7.6) 0.009 *
ESR, mm/h 23 (9.0–43) 8 (5–15) <0.001 *
HAQ 1.3 (0.8–1.5) 0.5 (0.0–1.3) 0.001 *
Values are displayed as mean ± standard deviation (SD), median (IQR) or frequencies with 
corresponding percentages (%). LA = left atrial, LV = left ventricular, GLS = global longitudinal 
strain, NT-proBNP = N-terminal pro hormone-brain natriuretic peptide, DAS28 = disease activity 
score-28, CRP = C-reactive protein, ESR = erythrocyte sedimentation rate, HAQ = health assessment 
questionnaire. * Significance level of p ≤ 0.05.
From thirty of the thirty three patients with successful follow-up, it was possible to 
grade the diastolic function. Of these patients, twenty eight had normal diastolic 
function, one had diastolic dysfunction grade I and one diastolic dysfunction grade II. 
No patients had diastolic dysfunction grade III. Compared to the baseline, only in one 
case was the diastolic function changed from normal to grade I. Additionally, neither 
the E/e’ nor the E/A showed a significant change after six months of anti-TNF therapy, 
respectively 7.9 (6.6-9.0) to 7.7 (7.1-9.1), p = 0.17 and 1.1 (±0.4) to 1.1 (±0.4), p = 0.94.
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NT-proBNP values decreased, although this did not reach statistical significance, with 
a reduction of 23% at follow-up compared to baseline, respectively 89 ng/L (47-142) to 
69 ng/L (42-155, p = 0.10). Troponin-T did not show any change at follow-up, 6 (3-8) µg/
mL to 7 (4-9) µg/mL, p = 0.43.
The highest quartile for the LV ventricular filling pressure (E/e’) was compared with 
the other three quartiles, respectively E/e’>9 vs E/e’<9. Seven patients had an E/e’>9 at 
baseline who completed follow-up. In these patients, no echocardiographic parameters 
improved nor worsened after anti-TNF therapy (Table 3).
Table 3. Effect of anti-TNF in patients in the highest E/e’ quartile (E/e’>9).
E/e’>9 (n) Baseline Follow-Up p-Value
E/A (6) 1.0 (±0.4) 1.0 (±0.3) 0.97
E/e’ (7) 11.8 (±3.0) 10.9 (±4.2) 0.34
deceleration time, sec (4) 0.23 (±0.06) 0.26 (±0.05) 0.34
ejection fraction (4) 62.0 (±7.4) 62.2 (±9.5) 0.97
LV mass index, gram/m2 (5) 83.0 (±26.1) 100.6 (54.1) 0.28
LA volume index, mL/m2 (4) 36.6 (±3.8) 36.6 (±3.8) 0.87
GLS (6) −18.0 (±3.5) −18.2 (±2.7) 0.90
Values are displayed as mean ± standard deviation (SD) or median (IQR). LA = left atrial, LV = left 
ventricular, GLS = global longitudinal strain, * Significance level of p ≤ 0.05.
Regression analyses showed no association between changes in inflammatory 
parameters, i.e., DAS28 and ESR, and changes in cardiac parameters, i.e., E/e’, E/A, 
GLS and NT-proBNP, between baseline and follow-up.
Discussion
To our knowledge, this is the first and largest study investigating the effect of first 
line anti-TNF therapy on the cardiac function in a Western RA cohort assessed with 
comprehensive echocardiography (including conventional, Speckle tracking and tissue 
Doppler) in combination with cardiac biomarkers. In contrast to what was expected, 
the echocardiographic results did not show improvement but importantly also showed 
no worsening of the cardiac function. Moreover, this study found a 23% decrease 
of NT-proBNP after six months of anti-TNF therapy, although this did not reach 
statistical significance.
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Overall, diastolic function categorized in grades changed in only one case. The E/e’-
ratio, a robust marker for predicting LV filling pressures and indirectly diastolic (dys)
function [31], also did not show a significant change at follow–up compared to baseline, 
not even when comparing the highest quartile with the other quartiles. Examination of 
the systolic ventricular function was done using the LVEF and the more sensitive GLS 
to pick up more subtle changes. However, again, no improvement nor deterioration 
was observed. These unexpected results can be explained by the following causes. 
First, this could have been due to the low prevalence of cardiac dysfunction at baseline 
as only three (7%) patients had diastolic dysfunction. Therefore, the study may have 
been underpowered to show the improvement of the cardiac function. According to 
the literature, RA patients are more likely to have echocardiographic parameters of 
diastolic dysfunction in comparison to the general population [8,32,33]. Unexpectedly, 
our population had a lower-than-expected prevalence of diastolic dysfunction. This 
is explained because in our study diastolic function was assessed according to the 
updated 2016 ASE/EACVI grading criteria [29]. This grading algorithm applies several 
echocardiographic parameters and is more critical than previous grading algorithms 
of the 2009 ASE/EACVI criteria [34] and the Redfield criteria [35]. The primary goal of 
the 2016 ASE/EACVI update was to simplify the approach and hence increase the utility 
of the guidelines in daily clinical practice. However, recent studies also demonstrate 
a higher specificity and a lower sensitivity of the 2016 ESE/EACVI criteria resulting 
in a lower overall prevalence of diastolic dysfunction compared to the 2009 ASE/
EACVI criteria. In addition, the 2016 ASE/EACVI criteria shows superiority over the 
2009 criteria in predicting mortality, myocardial infarction and heart failure [36] and 
importantly in predicting increased left ventricular pressure measured with invasive 
assessment [37], thus making it currently the best available non-invasive diastolic 
dysfunction assessment tool. In comparison, previous studies mostly used the Redfield 
criteria, which is primary focused on the E/A ratio and the E-wave deceleration time 
(DT). When applying the 2009 ASE/EACVI and Redfield criteria in our cohort, the 
prevalence of diastolic dysfunction at baseline is considerably higher with respectively 
fifteen (33%) and eleven patients (23%). However, again, no relevant changes were 
observed at follow-up.
Second, this population had a relatively short disease duration and a relatively low 
disease activity compared to other studies, demonstrating an increased prevalence of 
cardiac dysfunction in RA patients compared to healthy subjects [8,38]. In addition, our 
population was relatively cardiac healthy as patients were relatively young and had low 
4
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prevalence of cardiovascular comorbidities, and were thus less prone to the development 
of cardiac dysfunction. This is also suggested by the low H2FPEF score calculated for 
this cohort. The H2FPEF score is a method to assess the risk of the presence of heart 
failure with preserved ejection fraction (HFpEF) in patients with dyspnea and comprises 
a major risk factor for developing diastolic dysfunction. A large majority of the subjects 
(94%) had a H2FPEF score ranging from 0–2 and thus, a low a priori chance for diastolic 
dysfunction. This is also confirmed by the low serum NT-proBNP at baseline, indicating 
a normal cardiac wall tension. Another possibility could be due to the limitation of 
echocardiography in the assessment of diastolic function and the lacking ability to 
detect subtle diastolic changes. Possibly more sensitive assessment methods, such as 
exercise echocardiography [39], exercise right heart catheterization [40] or cardiac 
magnetic resonance imaging (MRI) [41], could help detect mild diastolic dysfunction and 
subtle diastolic changes. However, GLS analysis, a sensitive assessment method for the 
systolic dysfunction, did not show any alteration of the cardiac function. Furthermore, a 
large number of the patients used corticosteroids prior to the start of anti-TNF therapy, 
thereby affecting the anti-inflammatory effect of anti-TNF. Importantly, we found that 
that anti-TNF therapy had no detrimental effect on the cardiac function in patients with 
normal and relatively mild cardiac dysfunction.
Interestingly, studies assessing the effect of biologic agents with modes of action 
other than TNF-blockade show more evident ameliorating effects on the cardiac 
function. Several studies conducted by Ikonimidos et al. investigating the effect of 
anti-interleukin (IL)-1 therapy (anakinra) showed a significant improvement in cardiac 
function assessed with echocardiography [38,42,43]. Studies assessing the effect of 
anti-IL-6 (tocilizumab) on cardiac function assessed with cardiac MRI also showed an 
ameliorating effect on the diastolic function [44,45]. A possible explanation for this 
could be that IL-1 is produced earlier in the cytokine cascade and is the triggering factor 
of several cytokines including IL-6 and TNF-a [46]. Thus, theoretically, its inhibition 
may be more effective in controlling inflammation and thus improving LV function than 
inhibition of the later-released TNF-a. Whether anti-IL-1 and/or anti-IL-6 therapy have 
indeed more pronounced effects on cardiac function then anti-TNF is not known, as 
direct comparative studies have not been conducted. NT-proBNP is a predictor of CV 
mortality and morbidity in patients with or without a history of CVD and RA patients 
[47–49] and in our study, a 23% NT-pro BNP decrease after 6 months anti-TNF treatment 
was observed. This is in line with the findings of Kotyla et al., and Peters et al., where 
infliximab treatment or adalimumab treatment during 4 months led to comparable 
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decreases of serum NT-proBNP in RA patients [22,50]. There are a few explanations 
for this phenomenon. Firstly, reduction of inflammation could have led to reduced 
ventricular stress. This is confirmed by the literature describing that inflammation 
contributes to arterial stiffening and consecutively increases ventricular load [51,52]. 
Secondly, low grade inflammation of cardiac tissue can lead to a stress response of the 
myocardium, leading to increased NT-proBNP production. This could explain the overall 
relationship between NT-proBNP and systemic inflammation [53,54]. However, a direct 
effect of anti-TNF on the production or secretion of NT-proBNP cannot be ruled out.
A major strength of this study is the comprehensive and prospective approach in the 
assessment of cardiac function with the use of conventional Doppler and Speckle 
tracking echocardiography in combination with cardiac biomarkers. Therefore, this 
study was able to determine the different outcomes assessing the cardiac function. 
The main limitation of this study was, as the prevalence of cardiac dysfunction was 
unexpectedly low, the rather limited sample size.
Conclusions
In conclusion, echocardiography showed no improvement nor deterioration of anti-
TNF treatment on the cardiac function in RA patients with a low prevalence of cardiac 
dysfunction. However, NT-proBNP decreased 23% after anti-TNF treatment, which 
might suggest subtle improvement of the cardiac function.
4
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Summary
We present a 51-year-old Caucasian woman, with a medical history of systemic lupus 
erythematosus (SLE) who had dyspnoea at exertion. The SLE was clinically quiescent 
but serologically active. Echocardiography showed preserved left ventricular (LV) 
systolic function, pseudonormal mitral inflow pattern (diastolic dysfunction grade III), 
absence of wall motion abnormalities and elevated E/e’ at exercise. An exercise right 
heart catheterisation was performed, confirming the diagnosis of heart failure with 
preserved ejection fraction (HFpEF). In the absence of other possible causes, we assumed 
that HFpEF was mediated by systemic inflammation secondary to SLE. Based on the 
Paulus’ paradigm, that systemic inflammation may lead to diastolic dysfunction, we 
decided to add belimumab (a biological agent against soluble B-lymphocyte stimulator 
protein). After 16 weeks of treatment, patient reported an improved condition. Also, 
cardiopulmonary exercise test and echocardiography results improved, confirming 
resolution of the underlying LV diastolic dysfunction. This case supports the idea that 
targeting inflammation has therapeutic potential in a subset of HFpEF-patients.
Background
Currently, heart failure with preserved ejection fraction (HFpEF) represents 50% of 
heart failure cases, and its prevalence is increasing as a result of a growing awareness 
and diagnosis and due to changes in population demographics [1]. Hence, if these trends 
continue, HFpEF may become the most prevalent form of heart failure, underscoring 
the importance of this growing public health problem. HFpEF is associated with 
several factors, including female sex, hypertension, metabolic syndrome and coronary 
artery disease [2]. Importantly, mortality rates in patients with heart failure with 
reduced ejection fraction and HFpEF are comparable. In addition, no therapy in HFpEF 
has yet been shown to improve survival and diuretics only give relief of symptoms 
[3]. The pathogenesis of HFpEF is unknown, but currently several hypotheses are 
available, among which increasing evidence suggests detrimental effects of systemic 
inflammation on the cardiac function in systemic inflammatory disease [4]. Indeed, 
several studies showed favourable effects of strong anti-inflammatory treatment (ie, 
antitumour necrosis factor (TNF) and anti-IL6 drugs) on the cardiac function as well 
as the prevalence and incidence of congestive heart failure in patients with rheumatoid 
arthritis (RA) [5].
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Systemic lupus erythematosus (SLE) is a chronic autoimmune inflammatory connective 
tissue disease characterised by systemic inflammation targeting multiple organs. In 
addition, SLE is associated with an increased risk for cardiovascular disease, which 
is only partially explained by traditional risk factors [6]. Belimumab is a monoclonal 
antibody that specifically inhibits the biological activity of soluble B-lymphocyte 
stimulator protein [7]. This anti-inflammatory drug is indicated as adjuvant therapy in 
SLE patients after standard treatment failure [8].
First of all, this case report describes a case in which a patient with SLE develops HFpEF, 
likely to be secondary to systemic inflammation, as all traditional risk factors such 
as hypertension, obesity and diabetes were absent. Second, this case report describes 
improvement of the cardiac function in a HFpEF patient after anti-inflammatory 
treatment with belimumab.
We describe the first case of a patient with SLE-related HFpEF successfully managed 
with belimumab.
Case presentation
We present a 51-year-old Caucasian woman with a medical history of SLE, presenting 
with complaints of progressive exertional dyspnoea (New York Heart Association 
functional class II/IV). She experienced no limitations in daily life. However, during 
mild sport exercise or sudden exertion, she had symptoms of dyspnoea and palpitations 
without thoracic symptoms, which recovered in rest. These symptoms developed since 
more than a year and were progressive in nature. There were no complaints of coughing, 
sputum or other pulmonary symptoms. Furthermore, she has a slim posture and used to 
sport 2 times a week. The patient had been hospitalised several times due to relapsing 
pleuritis and pericarditis, which were successfully treated with temporary increased 
prednisolone treatment, in combination with several disease-modifying antirheumatic 
drugs and non-steroidal anti-inflammatory drugs: hydroxychloroquine, mycophenolate 
mofetil (later discontinued due to gastrointestinal side effects), azathioprine and 
ibuprofen. Except for a positive family history, she has no traditional risk factors 
for cardiovascular disease. During this period of dyspnoea, her SLE was in clinical 
remission without clinical symptoms, albeit serology was active, and she was treated 
with hydroxychloroquine, low-dose prednisolone and ibuprofen.
5
147647_BaniaamamMilad-BNW_v6.indd   107 03/08/2021   15:52
108 | Chapter 5
Figure 1. Cardiopulmonary exercise test
 VO2 = pulmonary uptake of oxygen per unit of time (mL/min); VCO2 = pulmonary output of carbon 
dioxide per unit of time (mL/min); W = Watt load; RER = respiratory exchange ratio, ratio between 
carbon dioxide output and oxygen uptake (VCO2/VO2); O2 pulse = oxygen uptake per heart beat 
(VO2/heart rate); HR = heart rate; V’E = minute ventilation (L/min), total volume of air exhaled per 
minute (tidal volume x breathing frequency); VTeX = expiratory tidal volume (L); BF = breathing 
frequency (1/min); t-ex = expiration time (sec); t-in = inspiration (sec); PE-O2 = mean partial 
pressure of expired oxygen (kPa); PE-CO2 = mean partial pressure of expired carbon dioxide (kPa); 
PET-O2 = end-tidal partial pressure of expired oxygen (kPa); PET-CO2 = end-tidal partial pressure 
of carbon dioxide (kPa); EqCO2 = ventilatory equivalent for carbon dioxide, number of liters of 
ventilation per liter of carbon dioxide output; EqO2 = ventilatory equivalent for oxygen, number 
of liters of ventilation per liter of carbon oxygen uptake; SpO2 = oxygen saturation (%).
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Figure 2. Rest and exercise echocardiography
Rest and exercise echocardiography. E, peak mitral flow velocity in early diastole; E’, peak mitral 
annular velocity during early filling; E/e’, ratio approximating the left atrial pressure (normal: <14).
Investigations
The patient presented not ill and non-dyspnoeic at rest. The patient’s weight was 49 kg 
with a length of 168 cm, body mass index of 17.4 kg/m2. Physical examination showed 
euvolaemia with a blood pressure of 97/57 mm Hg (normal for her) and a pulse rate 
of 62 bpm. Auscultation of the heart and lungs was unremarkable. ECG was normal. 
Laboratory tests showed a normal blood cell count, normal CK and troponin and a 
slightly increased N-terminal pro-brain natriuretic peptide (NT-proBNP) of 248 ng/L 
(ref: <125 ng/L). SLE serology showed low levels of complement C3 (0.65 g/L, ref: 0.9–1.8 
g/L) and C4 (0.04 g/L, ref: 0.10–0.40 g/L) and high levels of anti-double stranded DNA 
(dsDNA) (118 IU/mL, ref: <15 IU/mL). Furthermore, blood samples ruled out any form of 
infectious, metabolic and haematological pathophysiology and any other intercurrent 
autoimmune disease such as thyroiditis or anti-phospholipid syndrome.
Transthoracic echocardiogram of the heart showed preserved left ventricular (LV) 
and right ventricular systolic function without signs of regional wall abnormalities, 
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pseudonormal mitral inflow pattern (diastolic dysfunction grade III) and normal 
valvular function. Cardiac CT angiography (CCTA) showed a calcium score of 0, no 
coronary plaques and no thickening of the pericardium. Cardiac magnetic resonance 
imaging (CMR) revealed physiological amounts of pericardial effusion, without signs 
of constrictive pericarditis, myocarditis and normal myocardial tissue characteristics 
(based on T1-, T2-mappings and late gadolinium-enhanced imaging). Holter assessment 
showed no signs of relevant supraventricular nor ventricular arrhythmia.
Because of a clinical suspicion for HFpEF, despite a very low H2FPEF-score (a scoring 
system describing the apriori chance for developing HFpEF based on traditional 
risk factors, in her case: 10%), [9] exercise echocardiography in combination with 
cardiopulmonary exercise testing was performed (see figures 1 and 2). The assessment 
showed normal ventilatory parameters (figure 1d–i); a peak VO2 (pulmonary oxygen 
uptake per minute) of 70% of predicted (>80% is normal) with a respiratory exchange 
ratio of 1.3 (>1.1 suggest maximal exercise) (figure 1a and b); maximal heart rate was 
88% of predicted (>85% is normal) (figure 1c), but O2-pulse (a non-invasive estimate 
of oxygen uptake per heart beat) was 75% of predicted (>80% is normal; figure 1c). 
In conclusion, the results showed a normal pulmonary function with exercise 
limitation suggestive for cardiac impairment. Exercise echocardiography showed 
relevant LV diastolic dysfunction, as E/e’ increased to 14 (<14 is normal) (figure 2). 
For definitive diagnosis, an exercise right heart catheterisation was performed 
(figure 3), which revealed normal haemodynamics at rest, but a significant increase 
in pulmonary capillary wedge pressure (PCWP) of 29 mm Hg during exercise 
(≥25 mm Hg=diagnostic; exercise PCWP is considered the gold standard), [9] indicating 
increased LV filling pressure, which in this context is secondary to diastolic impairment, 
as LV ejection fraction was >50% without signs of valvular disease. Thus, the diagnosis 
of (early-stage) HFpEF was confirmed.
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Figure 3. Rest and exercise right heart catheterization
ECG = electrocardiogram; PCWP = pulmponary capillary wedge pressure; RVP = right ventricular 
pressure; RAP = right atrial pressure
Differential diagnosis
In the differential diagnosis, SLE-related and non-SLE-related causes resulting in HFpEF 
were considered. With respect to non-SLE-related causes, traditional risk factors for HFpEF 
were not present, that is, metabolic syndrome including diabetes, hypertension and 
obesity. Furthermore, CCTA ruled out coronary disease. In the light of SLE-related causes, 
cardiac imaging (CCTA and CMR) ruled out pericardial involvement, despite recurrent 
pericarditis in the past. Also, no evidence was found for an underlying cardiac structural or 
infiltrative cardiomyopathy. Furthermore, we considered whether in theory HFpEF might 
have been hydroxychloroquine-induced. However CMR was normal, and a myocardial 
biopsy was refused by the patient when the potential risks of this diagnostic procedure 
were explained in relation to the relative low diagnostic yield in her specific case. As all 
probable causes were ruled out, we hypothesised, based on the Paulus paradigm, that 
the underlying LV diastolic dysfunction in this patient could be related to her systemic 
inflammation secondary to SLE. This was substantiated by the low complement levels 
in combination with high dsDNA levels, suggesting active SLE despite the absence of 
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other clinical signs of active disease. The Paulus paradigm describes the role of systemic 
inflammation in the development of HFpEF, in this case circulating cytokines, which 
leads to endothelial activation, interstitial fibrosis and stiff cardiomyocytes resulting in 
diastolic dysfunction and in severe cases, such as this, HFpEF [4].
Treatment
Considering that systemic inflammation in this patient played a pivotal role in the 
development of HFpEF, strong anti-inflammatory treatment was proposed as a possible 
treatment. After ruling out important differential diagnoses, exercise echocardiography 
and cardiopulmonary exercise testing were indicative but not conclusive for significant 
diastolic impairment. Furthermore, although active serology was indicative for active 
systemic inflammation, the patient did not fulfil all criteria for high disease activity 
to justify strong inflammatory treatment with belimumab yet, as the SLE, without the 
assessment by right heart catheterisation, was considered in clinical remission. Thus, 
certainty was required on the presence of diastolic dysfunction to confirm SLE was not 
clinically in remission, assuming HFpEF/diastolic dysfunction was secondary to SLE-
induced systemic inflammation. In our case, we judged that the additional value of right 
heart catherisation assessment (certainty of diagnosis with direct clinical consequences) 
outweighed the potential risks of an invasive diagnostic procedure. Eventually, after 
HFpEF was confirmed, we decided to start additional anti-inflammatory therapy with 
belimumab, and closely monitored clinical response. Belimumab is monoclonal antibody 
that specifically inhibits the biological activity of soluble B-lymphocyte stimulator 
protein, thereby suppressing immunological activity. Belimumab is a relatively new 
biological treatment and is only initiated in patients with SLE with active disease activity 
after failure of standard therapy.8 Subsequent to consent with the patient treatment 
with belimumab 200 mg/week subcutaneously was started.
Outcome and follow-up
The patient experienced a significant improvement of physical condition after 4 months 
belimumab treatment and she could now perform all physical exercises as before. 
Cardiopulmonary exercise test in combination with exercise echocardiography was 
repeated after 4 months, showing normalisation in peak VO2, O2-pulse and E/e’ at 
exercise. SLE stayed in full remission and improving serology (C3/C4 from 0.65/0.04 g/L 
to 0.98/0.10 g/L, respectively, and anti-dsDNA from 118 IU/mL to 70 IU/mL). NT-proBNP 
reduced to 167 ng/L. Until today (1.5 years after initiation), patient remains in good 
physical health and has no complaints of exertional dyspnoea nor physical limitation 
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under belimumab. At the start of her treatment she experienced mild injections site 
reactions and flare of arthritis which disappeared after 4 weeks. Furthermore, after 
4 months of treatment she had ophthalmic herpes zoster for which was belimumab 
was temporarily stopped, without detrimental permanent effects. After 4 weeks 
belimumab was resumed and until now, she remains in good clinical condition without 
any symptoms.
Patient’s perspective
Since the year 2000 I have experienced several exacerbations of SLE with polymyositis, 
pericarditis, pleuritis, meningitis and mastitis. All of them were treated with a temporary 
high dose prednisolone among some other immune suppressive drugs like azathioprine 
and hydroxychloroquine.
In 2005 suspicion of developing pulmonary hypertension after another period of 
pericarditis/pleuritis was the reason for consulting the pulmonary doctor. During that 
time I experienced irregular heart rates and some small physical limitations during high 
exercise which were confirmed by the lung function test which showed that during high 
exercise my heart was not pumping enough blood and oxygen around. It was thought 
that this was caused by scarring tissue in the pericardium after several inflammations 
of the pericardium and that the heart was therefore limited in space to extent in volume. 
On the hindsight I believe that these were the first mild signs of later complaints that 
got more severe over time.
During 2010–2015 the SLE was in remission. I was on a daily dose of 7 mg prednisolone, 
azathioprine, and 200 mg hydroxychloroquine. I only experienced some mild SLE 
complaints like fatigue and stiff, sometimes painful, joints. Especially hands and knees. 
I was able to work for 75% besides being a mother of two. In my spare time I performed 
sports twice a week and I enrolled in a study in basic medicine for 3 years.
In 2015 I noticed on a more frequent base that I was not able to perform physical exercise 
at the level I used to. Running up the stairs for two levels, biking over a bridge or running 
for more than 100 metres already gave me the feeling of being out of breath and I felt 
very fast runs of heartbeats while I did not have the feeling that my physical condition or 
muscle strength was the limiting factor. I felt that something was not right, but still the 
medical explanation for my complaints was the scar tissue of the pericardium and pleura.
In 2016, after a few months of active SLE, I was in the emergency room again with 
suspicion of another pericarditis. I told the cardiologist on call about my complaints of 
the fast heartbeats during exercise and told him this was probably caused by the scar 
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tissue of the pericardium. He asked me if this had ever been examined, but I told him 
this was not the case, it was an assumption.
The cardiologist was very determined to find out what caused this problem and 
performed several examinations and tests. The result of those examinations (in rest) 
was that everything with my heart and the pericardium was fine. So, the condition or 
thickness of the pericardium was not the problem.
I was then transferred to a cardiologist specialised in heart failure. Many examinations 
like echo’s, exercise tests, holter assessments, MRI etc. followed. The most difficult 
examination of all was the physical exercise where I was lying horizontally on a bed 
and having to bicycle to the max while, at the same time, an intravenous catheter was 
inside my heart (exercise right heart catheterisation)… This was a very unpleasant and 
scary feeling. But above all I was VERY scared of the outcome.
The minutes between the end of the test and the outcome took forever. Unfortunately, 
the outcome was not good. I was diagnosed with heart failure… My world collapsed. I 
cried and I was very worried.
The next months were terrible for me and my family. I cried a lot and I was terrified with 
the prognosis and I was worried for my family, especially for my children. I was very 
afraid to die in a few years. This cannot happen, children need their mom!
However I was told by the cardiologist that I did not have the risk factors for heart failure 
and therefor probably a better prognosis. I tried to hang on to that. The cardiologist also 
told me about the theory of Professor Paulus that heart failure might be caused by the 
chronic systematic inflammation of the SLE. My cardiologist suggested that it would be 
helpful for me to talk with Prof. Paulus and set up a meeting with Prof. Paulus for me and 
my husband. In this meeting Prof. Paulus answered our many questions and explained his 
theory. He emphasised that it was very important to suppress the chronic inflammation.
With this advise and the knowledge that there is a biological (belimumab) especially 
developed for SLE with high success rates to bring SLE to rest, my husband and I went to 
the rheumatologist. However, my situation did not meet the requirements for starting 
belimumab. Finally my case was discussed in a group of rheumatologists and because 
there was no other medicine to treat the heart failure, an exception was made and the 
belimumab treatment was approved. I was so relieved… Finally, after months, hope was 
given back to me.
I started belimumab in August 2018, but after 2 weeks (second dose) I experienced 
side effects. The location of the injection became a large red, swollen and hot circle. 
My hands, fingers and wrist were very painful and swollen. And my right arm was so 
painful, I could not lift it. It was clear there was a negative reaction to the belimumab. I 
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was so sad, because belimumab was my only hope and I was afraid that the belimumab 
treatment had to be stopped. But I did not want to give up on the belimumab, so I 
continued the treatment. Surprisingly the side effects diminished and were gone after 4 
weeks. Somewhere half October, beginning of November, I started to feel improvement; 
my overall condition improved, I noticed I could do more and longer exercises without 
getting out of breath and I had less irregular heartbeats. This was also confirmed by the 
function and echo tests under exercise. I was very happy and relieved. Then in December 
there was another complication and disappointment. The belimumab had suppressed my 
immune system so much that a herpes zoster infected my left eye. I was hospitalised for a 
week, got anti-viral treatment and the belimumab had to be stopped. I felt very hopeless, 
because if this was a recurring side effect, I had to stop the belimumab… After 2 months 
I was allowed to restart the belimumab again and so far no side effects anymore and my 
heart is doing very well! I am very grateful towards my doctors and want to thank them 
for thinking ‘out of the box’ and to reverse the problem of the heart filling by supressing 
the SLE activity. I think it is very important for other doctors all over the world to learn 
that HFpEF can be caused by chronic inflammation and the solution for treating HFpEF 
could be treating the inflammation.
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Discussion
To date, there are no published cases of HFpEF secondary to SLE treated with anti-
inflammatory therapy, in this specific case belimumab.
The differential diagnosis of exertional dyspnoea is broad. In this particular case, 
we needed extensive diagnostic testing to demonstrate that underlying LV diastolic 
dysfunction was the reason for her symptoms. The pretest likelihood chance of 
HFpEF (H2FpEF score), in the absence of the metabolic risk factors for HFpEF, was 
very low. In addition, it is well known that measurements at rest (electrocardiography, 
echocardiography, cardiac markers for heart failure) are very insensitive to detect 
relevant LV dysfunction, especially at the earlier stage of the condition [9, 10]. 
Therefore, in these cases, haemodynamic measurements during exercise are obligatory, 
although these advanced diagnostic tools are only available at centres of expertise. 
Furthermore, for adequate management all possible pathogenetic mechanisms of HFpEF 
were considered. As described in the differential diagnosis section, all probable causes 
including traditional risk factors for HFpEF were ruled out. Therefore, in this case, 
presenting a patient with SLE with active serology, systemic inflammation-induced LV 
diastolic dysfunction seemed as the remaining plausible pathogenetic cause and this 
assumption was confirmed by successful anti-inflammatory treatment.
As presented in this case, the pathogenesis of HFpEF is not yet fully understood. 
However, mounting evidence postulate an important role of systemic inflammation in 
the development and maintenance of diastolic dysfunction [1, 11, 12]. This substantiates 
the Paulus paradigm describing a pivotal role of chronic systemic inflammation in 
myocardial remodelling and the development of diastolic dysfunction and in severe 
cases HFpEF. In this model, circulating inflammatory mediators, including TNF-a 
and IL-6, result in myocardial microvascular dysfunction. Subsequently, it assumed 
endothelial activation leads to deposition of collagen with subsequent stiffness and 
hypertrophy of cardiomyocytes and decreased ability to relax of the myocardium, which 
can evolve in HFpEF [4].
Several studies investigated the effect of anti-inflammatory strategies on the cardiac 
function in patients with HFpEF. Though anti-inflammatory strategies in animal 
models with HFpEF have shown promising results, studies in human HFpEF patients are 
conflicting. In the D-HART study, a randomised, double-blind, placebo-controlled, cross-
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over pilot trial of 12 stable HFpEF patients treated with anakinra (an anti-interleukin 
(IL)-1 drug), patients showed improvement in ventilatory efficiency [13]. The subsequent 
D-HART2 trial, a randomised placebo-controlled blinded trial, seeked to confirm the 
D-HART trial results on exercise tolerance in HFpEF. This study among 28 patients 
showed reduction in C reactive protein and NT-proBNP levels, however, failed to improve 
ventilatory efficiency at 12 weeks [14]. Importantly, the patients in these studies had 
no secondary auto-immune disease. Therefore, the pathophysiology of HFpEF in these 
cohorts may differ in patients with HFpEF secondary to autoimmune disease induced 
systemic inflammation. That is to say, if significant systemic inflammation secondary 
to autoimmune disease is the driving factor in the development of HFpEF, anti-
inflammatory therapy may be of therapeutic value. One study investigated concurrent 
SLE or systemic autoimmune connective tissue disorders in patients with (unexplained) 
HFpEF. In 5 of 44 cases of HFpEF, the investigators were able to diagnose an underlying 
autoimmune disease, suggesting a link between systemic inflammation and HFpEF [15]. 
In RA, several studies investigated the effect of anti-inflammatory treatment on the 
cardiac function. Ikonomidis et al. showed in patients with RA treated with anakinra, 
improvement of the diastolic function (E/e’) 3 hours to 30 days after administration [16]. 
In addition, Cetin et al. [17] demonstrated improvement of diastolic function (E/e’) in 
RA patients after 3 months treatment with infliximab (anti-TNF). However, the latter 
two studies were performed in patients with no HFpEF. To our knowledge, to date, no 
cases of patients with SLE or any other auto-immune disease complicated with HFpEF 
and treated with anti-inflammatory agents have been reported, yet.
The patient presented in this case started with belimumab with the aim to improve 
HFpEF and exertional dyspnoea symptoms in the context of subclinical systemic 
inflammation (low complement levels and high dsDNA levels). There was significant 
improvement of physical fitness after treatment with belimumab, confirmed by improved 
echocardiographic and cardiopulmonary exercise results as well as improvement of 
serological parameters and cardiac markers for heart failure at follow-up.
This case offers opportunities in the limited treatment of patients with HFpEF secondary 
to autoimmune diseases. Possibly, if systemic inflammation has a considerable role in 
HFpEF, anti-inflammatory treatment could be of therapeutic value in a wider range 
of HFpEF patients with underlying inflammation of any cause. Therefore, further 
investigation is advocated to assess the therapeutic potential of anti-inflammatory 
agents in systemic inflammatory diseases and HFpEF.
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Abstract
Objectives – The aim of the present study was to determine the prevalence of specific 
cardiac manifestations, i.e. conduction disorders, valvular disease and diastolic left 
ventricular (LV) dysfunction, in a large cross-sectional controlled cohort of Ankylosing 
Spondylitis (AS)-patients.
Methods – This cross-sectional study assessed the prevalence of valvular disease, 
conduction disorders and LV dysfunction in 193 randomly selected AS–patients 
compared with 74 osteoarthritis (OA) controls aged 50-75 years. Patients underwent 
conventional and tissue Doppler echocardiography in combination with clinical and 
laboratory assessments. Multivariate regression analyses were performed to compare the 
risk of mitral valve regurgitation (MVR) and aortic valve regurgitation (AVR) between 
AS-patients and OA controls. Associations between disease duration, disease activity 
and use of anti-tumour necrosis factor (anti-TNF) drugs and valvular disease were also 
investigated.
Results – The prevalence of AVR was significantly higher in AS-patients compared 
to the controls, respectively 23% (9% trace, 12% mild, 1% moderate, 1% severe, 1% 
prosthesis) vs 11%, p=0.04. After correcting for age, sex and CV risk factors AS-patients 
had an odds ratio of 4.5 (95%CI 1.1-13.6) for AVR compared to the controls. Prevalence of 
MVR, conduction disorders and diastolic LV dysfunction were comparable between AS-
patients and controls. Furthermore, disease duration, disease activity and use of anti-
TNF drugs were not significantly associated with cardiac manifestations in AS-patients.
Conclusion – The prevalence of conduction disorders and diastolic LV dysfunction 
were seldomly found and similar in AS-patients and controls. However, AS-patients 
had an up to five times increased risk to develop AVR compared to controls. Therefore, 
echocardiographic screening of elderly (50-75 years) AS patients should be considered.
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Introduction
Ankylosing spondylitis (AS) is an inflammatory joint disease associated with extra-
articular manifestations including cardiac disease [1, 2]. Previous studies have shown 
an increased mortality in AS-patients compared to the general population with 
cardiovascular diseases as leading cause of death [3, 4]. Chronic inflammation in AS 
contributes considerably to this excess cardiovascular risk, besides progression of 
atherosclerosis, it may lead to structural changes of the heart thereby causing cardiac 
disease [5, 6]. Indeed, previous studies suggest that AS-patients are at increased 
risk to develop aortic valve regurgitation (AVR), conduction disorders and diastolic 
left ventricular (LV) dysfunction. Although some of previous studies suggested that 
these cardiac manifestations occur more frequently in AS-patients, results varied 
and altogether inconclusive [7-15]. Furthermore, therapeutic treatment in AS has 
significantly improved in the last decades and this may have altered the CV burden. As 
recent data regarding the prevalence of cardiac manifestations in AS are lacking, clear 
guidelines regarding cardiovascular screening of AS-patients are still absent. Hence, 
current cardiovascular risk management guidelines make no distinction between 
AS patients and healthy persons, and the EULAR only recommends to make a CVD 
risk assessment once per 5 years [16]. Therefore, the aim of the present study was to 
determine the current prevalence of diastolic LV dysfunction (primary objective), cardiac 
valve regurgitation and conduction disorders (secondary objectives) in a large cohort of 
AS-patients, and compare these results to findings in controls without an inflammatory 
joint disease i.e. osteoarthritis (OA) patients. As cardiac disease is more prominent with 
older age we assessed the prevalence of cardiac disease in subjects between 50-75 years.
Methods
Study population
A cross-sectional controlled study was conducted in randomly selected AS-patients and 
age, sex and smoking status matched controls in a 2:1 ratio. Control patients with OA 
were selected as they also suffer from joint problems and subsequent mobility issues 
(physical activity) however without auto-inflammatory characteristics. Subjects were 
randomly recruited between March 2014 and February 2020 at a large rheumatology 
outpatient clinic (Reade) in Amsterdam, the Netherlands.
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Patients were eligible for inclusion if they were between 50-75 years of age. AS-patients 
needed to be diagnosed according to the 1984 modified New York [17] criteria and OA-
controls with active hip-, knee- or polyosteoarthritis had to be diagnosed by a general 
practitioner or rheumatologist. Patients with a history of chemotherapy (for malignant 
disease) were excluded due to presence of potential cardiotoxicity.
All patients gave written consent prior to inclusion in the study. This study was conducted 
in accordance with the Helsinki Declaration, and the protocol (NL44202.048.13) was 
approved by the medical ethics committee of the Slotervaart hospital and Reade, 
Amsterdam, the Netherlands.
Echocardiography
Transthoracic echocardiography (TTE) was performed by certified echo technicians at 
the European Society of Cardiology (ESC)-certified department of echocardiography of 
the Amsterdam University medical center, location VUmc, using a Philips ultrasound 
system (Epiq 7 or IE 33). Furthermore, the echo technicians were not informed about to 
the clinical diagnosis of the subject. To exclude inter-observer variability, all recordings 
of echocardiographic images and data were assessed afterwards by an experienced 
cardiologist of the VUmc specialized in echocardiography (TK). The cardiologist graded 
diastolic dysfunction, AVR and MVR. TTE was performed according to the guidelines 
provided by the American Society of Echocardiography (ASE) and the European 
Association of Cardiovascular Imaging (EACVI) [18]. Furthermore, the severity of AVR 
and MVR was graded according to the EACVI guidelines [19, 20].
Left atrial-volume (LA–volume; ml)-index and left ventricular mass (LVM; g)-index were 
calculated with body surface area (BSA; m2) LA-volume or LVM / BSA; g/m2).
The aortic root was measured at sinuses of Valsalva during diastole. Furthermore, aortic 
root diameter was corrected for BSA according to the Dubois method (aortic root index) 
[21]. An aortic root index of ≥ 2.1 cm/m2 was considered as aortic root dilatation [22, 23].
Electrocardiography
Electrocardiography (ECG) was performed using standard 12-lead ECGs, recorded at 
25mm/s paper speed. ECGs were analysed by a single cardiologist (TK) whom was 
blinded to the clinical status of all patients.
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Disease specific parameters
The following disease specific parameters were collected.
In AS: HLA-B27 status, extra-articular manifestations, disease activity (Bath AS 
Metrology Index (BASMI), Bath AS Disease Activity Index (BASDAI), AS Disease Activity 
Score-C-reactive protein (ASDAS-CRP). In AS, high disease activity was defined as an 
ASDAS-score of ≥2.1.
In OA: disease severity was assessed with the Western Ontario and McMaster Universities 
Osteoarthritis index (WOMAC) questionnaire [24].
Cardiovascular history and risk factor parameters
Cardiovascular risk factors were assessed including smoking status, body mass index 
(BMI), hypertension, hypercholesterolemia, diabetes mellitus type II and family history 
for cardiovascular disease. Furthermore, data history for cardiovascular disease was 
collected, i.e. angina pectoris, myocardial infarction, congestive heart failure, stroke 
(cerebrovascular accident (CVA) and/or transient ischemic attack (TIA)), peripheral 
ischemia and coronary arterial bypass grafting (CABG).
Other study parameters
Anthropometric data including length, weight, waist/hip ratio and blood pressure were 
assessed during physical examination. Demographic data were collected, i.e. age, race, 
ethnicity and sex. Blood sample measurements (non-fasting) consisted of standard 
haematological assessment, erythrocyte sedimentation rate (ESR), CRP, triglyceride, 
total cholesterol, high-density lipoprotein (HDL), low-density lipoprotein (LDL) and 
HLA-B27 status. Furthermore, medical history, current and historic medication use and 
disease specific data (i.e. year of onset, disease duration) were documented.
Definitions
Systolic LV dysfunction
Systolic LV dysfunction was defined as a left ventricular ejection fraction (LVEF) less 
than 50%.
Diastolic LV dysfunction
Diastolic LV dysfunction was evaluated according to the 2009 ASE/EACVI 
recommendations and 2016 ASE/EACVI recommendations, and both categorized in 4 
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grades: normal diastolic LV function and grade I-III (or intermediate) [25, 26]. Regarding 
the 2016 ASE/EACVI recommendations, for patients with a preserved ejection fraction, 
four variables were evaluated; average mitral E/e’ velocity, septal and lateral e’ velocity, 
tricuspid regurgitation-velocity (TR-velocity; cm/s) and LA-volume index. Patients with 
at least three aberrant values were diagnosed with diastolic LV dysfunction. Patients 
with more than one missing variable were not classified.
Hypertension
Patients were diagnosed with hypertension when they had a systolic blood pressure 
≥ 140 mmHg or diastolic blood pressure ≥ 90 mmHg measured during the physical 
examination, or when they were using antihypertensive medication.
Family history
A positive family history for cardiovascular events or cerebrovascular events was defined 
as having a first degree female relative under 65 years old or a male relative under 55 years 
old diagnosed with angina pectoris / myocardial infarction or TIA / CVA respectively.
Cardiovascular diseases
A positive history of cardiovascular disease was defined as a history of angina pectoris, 
myocardial infarction, coronary artery bypass grafting (CABG), congestive heart failure, 
CVA/TIA and/or peripheral ischemia.
Obesity
BMI ≥ 30 kg/m2.
Statistical analysis
Continuous variables are expressed as mean ± standard deviation (SD) for normally 
distributed variables or median (interquartile range) for non-normally distributed 
variables. Differences were compared between subjects using independent samples 
t-test for normally distributed variables and a Mann-Whitney U test for non-normally 
distributed variables. Dichotomous and categorical data are presented as frequencies 
(percentages). These variables were compared using a Chi-square test or Fisher’s exact 
test where applicable.
Logistic multivariate regression analyses were performed to investigate the association 
between AS and valve regurgitation. In addition, subgroup analyses using linear or 
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logistic multivariate regression analyses were performed to investigate the relationship 
of disease duration, disease activity and anti-tumour necrosis factor (TNF) with valve 
regurgitation. All statistical analyses were performed using SPSS software, version 23.0.
Results
Patient characteristics
Baseline characteristics are shown in table 1. A total of 193 AS-patients and 74 matched 
controls were included in the study. Matching was done in the best way possible within 
logistical limitations. The mean age of the AS-patients and the controls was respectively 
60 (±7) years and 62 (±7) years and 72% and 58% were male, respectively. AS-patients 
had a lower BMI and BSA than controls, respectively 26.6 ± 4.1 vs. 28.6 ± 5.5 kg/m2 and 
1.9 ± 0.20 vs. 2.0 ± 0.2 m2. Furthermore, obesity and hypercholesterolemia were seen 
less often in AS-patients compared to controls, respectively 22% vs 30% and 19% vs 
30%. AS-patients used more antihypertensives compared to controls, respectively 44% 
vs 27%. The prevalence of other cardiovascular diseases, comorbidities and risk factors 
were comparable in both groups.
Table 1.  Patient characteristics of AS and OA-controls
AS-patients (n = 193) OA-controls (n = 74)
Patient characteristics
Gender, male (n, %) 138 (72) 43 (58)
Age, years (mean ± SD) 60 ± 7 62 ± 7
Race, Caucasian (n, %) 162 (84) 65 (88)
BMI, kg/m2 (mean ± SD) 26.6 ± 4.1 28.6 ± 5.5
BSA, m2 (mean ± SD) 1.9 ± 0.2 2.0 ± 0.2
Blood pressure, mmHg
 Systolic (mean ± SD)







 current (n, %)
 ever (n, %)
 never (n, %)








12 (6 – 31)
Obesity (n, %) 42 (22) 26 (35)
Hypertension (n, %) 118 (61) 45 (61)
Hypercholesterolemia (n, %) 36 (19) 22 (30)
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Table 1.  Continued.
AS-patients (n = 193) OA-controls (n = 74)
Diabetes Mellitus type II (n, %) 22 (11) 10 (14)
Total history CVD (n, %) 21 (11) 8 (11)
Angina Pectoris (n, %) 5 (3) 2 (3)
Myocardial infarction (n, %) 12 (6) 4 (5)
Stroke
 TIA (n, %)





Peripheral ischemia (n, %) 1 (1) 1 (1)
CABG (n, %) 8 (4) 2 (3)
Family history (first degree)
 AP / MI (n, %)






















Antihypertensives (n, %) 85 (44) 20 (27)
Lipid modifying drugs (n, %) 40 (21) 19 (26)
NSAIDs (n, %) 108 (56) 37 (50)
Anti-TNF drugs
 current (n, %)
 ever (n, %)







Values are displayed as mean ± standard deviation (SD), median with corresponding interquartile 
range (IQR) or frequencies with corresponding percentages (%). AS = ankylosing spondylitis, 
OA = osteoarthritis, BMI = body mass index, BSA = body surface area, CVD = cardiovascular disease, 
TIA = transient ischemic attack, CVA = cerebrovascular attack, CABG = coronary artery bypass graft, 
AP = angina pectoris, MI = myocardial infarction, NSAIDs = non-steroidal anti-inflammatory drugs, 
anti-TNF = anti-tumour necrosis factor, N.A.= not applicable.
Disease characteristics
Disease characteristics are shown in table 2. A total of 82% of the AS-patients were 
HLA-B27+. AS-patients had a moderate to high disease activity with a mean ASDAS-CRP 
of 2.1 (±1.0) and a mean disease duration of 22 (±12) years. Most of the OA controls had 
knee osteoarthritis (82%) and/or polyosteoarthritis (81%) compared to hip osteoarthritis 
(24%). Disease duration (since diagnosis) was 5 (2-8) years. OA-patients had median a 
WOMAC score of 42 (±23).
147647_BaniaamamMilad-BNW_v6.indd   130 03/08/2021   15:53
Cardiac diseases in AS | 131
Table 2.  Disease characteristics of AS and OA-controls
Ankylosing spondylitis n = 193
HLA-B27 positive (n, %)
Disease activity and severity
 ASDAS-CRP (mean ± SD)
 BASMI (mean ± SD)
 BASFI (mean ± SD)





3.1 (1.6 – 5.0)
Time since diagnosis, years (mean ± SD) 22 ± 12
Osteoarthritis n = 74
Affected joints
 Knee (n, %)
 Hip (n, %)
 Polyosteoarthritis (n, %)





WOMAC (mean ± SD)
Time since diagnosis (median; IQR)
42 (23)
5 (2-8)
Values are displayed as mean ± standard deviation (SD), median with corresponding interquartile range 
(IQR) or frequencies with corresponding percentages (%). AS = ankylosing spondylitis, OA = osteoarthritis, 
HLA = Human leukocyte antigen, ASDAS-CRP = Ankylosing Spondylitis Disease Activity Score-C-reactive 
protein, BASMI = Bath Ankylosing Spondylitis Metrology Index, BASFI = Bath Ankylosing Spondylitis 
Functional Index, BASDAI = Bath Ankylosing Spondylitis Disease Activity Index, WOMAC = Western 
Ontario and McMaster Universities Osteoarthritis.
Electrocardiography
Electrocardiographic results are shown in table 3. No differences were found in 
conduction disorders between AS-patients and controls.
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Table 3.  Electrocardiographic results
AS patients (N = 193) OA-controls (N = 74) p Value a
Atrial fibrillation (n, %) 3 (2) 4 (5) 0.10
Atrial flutter (n, %) 0 (0) 0 (0) 1.0
AV-block degree
 1st degree (n, %)
 2nd degree, Mobitz type 1 (n, %)
 2nd degree, Mobitz type 2 (n, %)





Pathologic Q waves (n, %)
LVH (n, %)


































Pacemaker (n, %) 2 (1) 0 (0) 1.0
Other (n, %) 5 (3) 0 (0) 0.33
Total (n, %) 44 (23) 18 (24)
Values are displayed as frequencies with corresponding percentages (%). AS = ankylosing spondylitis, 
OA = osteoarthritis, AV block = atrioventricular block, LBBB = left bundle branch block, LAFB = left 
anterior fascicular block, RBBB = right bundle branch block, iRBBB = incomplete right bundle branch 
block, LVH = left ventricular hypertrophy, IVCD = intraventricular conduction delay. a p values of 
chi-square test. * Significance level of p < 0.05.
Echocardiography
Table 4 provides an overview of echocardiographic parameters. An increased aortic root 
index was seen in AS-patients compared to controls, though both in the normal range, 
respectively 1.74 (±0.20) cm/m2 vs 1.68 (±0.22) cm/m2, p=0.08. The prevalence of aortic 
root dilatation (≥ 2.1 cm/m2) was comparable in both groups with a prevalence of 7% 
in AS-patients and 4% in controls, p=0.53. Furthermore, AS-patients had more often 
AVR compared to controls, 41 (23%) vs 8 (11%), p=0.04. No difference was observed in 
MVR between AS-patients and controls.
The prevalences of systolic and diastolic LV dysfunction (both 2009 and 2016 ESE/EACVI 
grading criteria) were low and comparable between AS-patients and controls.
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Table 4. Echocardiographic results





Aortic root index, cm/m2 (mean ± SD) 1.74 ± 0.20 1.68 ± 0.22 0.08
Aortic root dilatation, ≥ 2.1 cm/m2 (n, %) 12 (7) 2 (4) 0.53
**Mitral valve regurgitation
 Mild (n, %)
 Moderate (n, %)
 Severe (n, %)











 Trace (n, %)
 Mild (n, %)
 Moderate (n, %)
 Severe (n, %)













LV mass index, g/m2 (mean ± SD) 75 ± 20 76 ± 19 0.79
LA volume index, ml/m2 (mean ± SD) 29 ± 9 32 ± 13 0.11
EDV index, ml/m2 (mean ± SD) 62 ± 15 55 ± 18 0.01*
ESV index, ml/m2 (mean ± SD) 27 ± 8 22 ± 10 <0.01*
Ejection fraction (mean ± SD) 57 ± 6 60 ± 8 0.02*
E/e’ average, cm/s (mean ± SD) 8.5 ± 2.5 8.0 ± 2.1 0.16
E-max, cm/s (mean ± SD) 69 ± 17 65 ± 17 0.06
A-max, cm/s (mean ± SD) 71 ± 17 71 ± 17 0.95
E/A ratio (mean ± SD) 1.0 ± 0.3 0.9 ± 0.2 0.03*
MV deceleration time, m/s (mean ± SD) 0.22 ± 0.05 0.22 ± 0.04 0.83
Septal e’ velocity, cm/s (mean ± SD) 7.8 ± 1.9 7.4 ± 1.7 0.12
Lateral e’ velocity, cm/s (mean ± SD) 9.5 ± 2.7 9.5 ± 2.2 0.94
TR velocity, cm/s (mean ± SD) 219 ± 26 229 ± 30 0.23
Systolic LV dysfunction (n, %) 10 (5) 2 (3) 0.74
Diastolic LV dysfunction – 2016
 Grade I (n, %)
 Grade II (n, %)








Diastolic LV dysfunction – 2009
 Grade I (n, %)
 Grade II (n, %)








Values are displayed as mean ± standard deviation (SD) or frequencies with corresponding percentages 
(%). Indexed values are corrected for BSA. AS = ankylosing spondylitis, OA = osteoarthritis, 
BSA = body surface index, LVMI = left ventrical mass index, LV = left ventricular, EDV = end diastolic 
volume, ESV = end systolic volume, MV = mitral valve, TR = tricuspid regurgitation. a p values of 
Student’s t-test or chi-square test. * Bold, significance level of p ≤ 0.05. ** A trace MVR is considered 
as physiological regurgitation and is therefore not added in the table.
6
147647_BaniaamamMilad-BNW_v6.indd   133 03/08/2021   15:53
134 | Chapter 6
Results of regression analyses
Results of logistic and linear multivariate regression analyses are presented in table 5. 
The relationship between AVR and AS was statistically significant and became more 
pronounced after adjusting for age, sex and CV risk factors. It revealed that AS-patients 
had an increased risk of AVR compared to controls, OR: 4.5; 95% CI: 1.1 – 13.6. In 
contrast, AS-patients did not have an increased risk of MVR compared to controls, OR: 
1.9; 95% CI: 0.8 – 4.5. Lastly, subgroup analyses in AS showed no significant relationship 
between disease duration, ASDAS-CRP and anti-TNF drugs and the presence of AVR or 
MVR (data not shown).
Table 5. Association of AS with valve regurgitation.
Crude model Adjusted model a Fully adjusted model b
Aortic valve regurgitation 2.3 (1.0 – 5.3) * 2.9 (1.3 – 6.8) * 4.5 (1.1 – 13.6) *
Mitral valve regurgitation 1.2 (0.7 – 2.2) 1.4 (0.8 – 2.5) 1.9 (0.8 – 4.5)
Values are displayed as odds ratio with corresponding 95% confidence interval.
 a Adjusted for age and gender. b Adjusted for age, gender, current smoking status, pack years, systolic 
blood pressure, diastolic blood pressure, hypercholesterolemia, BMI, Diabetes Mellitus type 2, family 
history of cardiovascular diseases.
* Significance level of p ≤ 0.05.
Discussion
The results of this study revealed that AS-patients had an up to five times increased 
risk of AVR compared to OA controls. Disease activity, disease duration and use of 
TNF-inhibitors were not associated with AVR. In addition, conduction disorders and 
diastolic LV dysfunction, based on the 2016 criteria of the ASE/EACVI, were rare in both 
AS-patients and controls, and the prevalence was comparable for both groups.
Aortic valve regurgitation
We found a prevalence of 23% of AVR in AS-patients and thus a 4-5 times increased 
risk for AVR in comparison to controls. Previous echocardiographic studies showed 
varying prevalences of AVR in AS-patients, ranging from 6 to 31% [6, 8-10, 27, 28]. 
However, as the presence of AVR is associated with age and cardiovascular risk factors, 
and these differed greatly between the available studies, these prevalence data are 
not well comparable. Overall, the AS patients of these cohort studies were younger, 
had a shorter disease duration and one study did not include trace AVR, thus likely 
underestimating the prevalence of AVR. Brunner et al. observed that AVR was present 
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in 10% of AS-patients, but they included patients aged 32 – 86 years and did not assess 
CV risk factors or comorbidities [8]. And again, trace regurgitation was not taken into 
account likely leading to a considerable underestimation of the prevalence.
Our most important observation was that elderly AS-patients (50-75 years) have an 
up to five times increased risk of having AVR compared to controls after correction 
for age, sex and CV risk factors. In addition, OA patients have an increased CV burden 
due to increased CV comorbidities, the increased risk that we observed in AS patients 
is probably an underestimation compared to when healthy subjects would have been 
used as controls [22].
In this study we observed a significant difference in the prevalence of AV regurgitation 
between AS patients and controls, but manifestations were mostly mild. Nevertheless, 
chronic AVR is a slow progressive disease, and the chronic state of inflammation that 
is present in AS patients may further accelerate progression . Moreover, the American 
Heart Association/American College of Cardiology (AHA/ACC) and the European 
Association of Cardiovascular Imaging (EACVI) state that regurgitation of the aortic 
valve is pathological, regardless of its grade [29, 30]. Hence, echocardiographic follow-up 
once per 3 – 5 years for trace or mild regurgitation, once per 1 – 2 years for moderate 
regurgitation and once per 0.5 – 1 year for severe regurgitation is recommended. 
Severe AR and rapid progression of the disease can be treated by valve replacement if 
recognized timely.
The current hypothesis on the valve involvement in AS is that entheses, the region where 
ligaments and tendons attach to bones, are the structures where inflammatory processes 
in AS mainly take place [31]. Pro-inflammatory cytokines, such as Interleukin (IL)- 23 
and IL-17 have an important role in this inflammatory process and IL-23 stimulates IL-17 
production by Th17-cells that further amplifies this inflammation [32-34]. The relevance 
for cardiac involvement in AS, is that entheses and the part of the aortic valve that 
inserts into the aortic root are histologically similar [34]. Sherlock et al. demonstrated in 
mice that both, entheses and this part of the aortic root, contain IL-23 receptor positive 
T-cells that can induce local inflammation after systemic exposure to Il-23 [34]. In the 
aortic root, inflammation may cause root dilatation and the inflammation may extend 
to the annulus, resulting in basal thickening and downward retraction of the cusps, also 
resulting in AVR [27, 35, 36]. The thickening of the annulus itself could also disturb the 
laminar blood flow resulting deterioration of valve function. In line with the increased 
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prevalence of AVR in AS-patients, we observed a trend towards a significantly greater 
aortic root index compared to OA controls, respectively 1.74 ±0.20 cm/m2 vs 1.68 ± 0.22 
cm/m2, p=0.08. This is consistent with small-sized studies of Roldan et al. and Yildirir 
et al. as they also showed increased aortic root diameter, as well as increased prevalence 
of AVR in AS patients compared to controls [27, 37].
Conduction disorders
Major electrical conduction elements, such as the atrial-ventricular (AV) node and the 
bundle branches (BBs) are located in very close proximity to the heart valves. In addition to 
the aortic root and the cusps of the aortic valve, in AS the inflammatory process therefore 
may extend to the atrial ventricular node (AV-node) and interventricular septum, leading 
to AR, AV-blocks and bundle branch blocks (BBB’s) [27]. However, most of the existing 
studies regarding conduction disturbances in AS-patients were relatively small, some 
lack controls and the results are inconsistent [8, 11, 12, 28, 38]. Our study assessed the 
clinically relevant and significant conduction disturbances in a large cohort AS-patients. 
We found a very low prevalence of, mostly mild, conduction disturbances with limited 
clinical relevance in the AS population comparable to the controls which is in contrast 
to the existing literature [11, 12, 38]. A Swedish prospective, nationwide populations-
based cohort showed AS-patients have a two-fold increased risk to develop an AV-block. 
However, the clinical relevance of this result is limited as this corresponds with an AV-
block prevalence of 0.5% in AS patients compared to 0.4% in healthy subjects after a 
follow-up duration of 6 years [11]. Two other studies performed by Forsblad-d’Elia et al. 
and Dik et al. demonstrated in clinical trials that first degree AV-blocks and BBB’s are 
common in AS-patients [12, 38]. However, both studies had no control group to compare 
their results to, and after specifying the type of BBB, the total prevalence of BBB’s dropped 
under 10% with both studies reporting primarily incomplete BBB’s. In fact Dik et al. 
demonstrated only 0.8% (1) of the AS patients with a complete right BBB and none with a 
complete Left BBB or left hemi block [38], though, their subjects were younger. Therefore, 
based on our results and in context of existing literature, we conclude that conduction 
disturbances are mostly mild with limited clinical relevance, and conduction disorders 
do not occur more frequently in AS-patients compared to controls.
Diastolic LV dysfunction
It is hypothesized that development of diastolic LV dysfunction may result from coronary 
endothelium activation caused by systemic inflammation [39]. The activated endothelial 
cells cause cardiomyocytes to hypertrophy and stiffen, but also enable monocytes to 
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enter cardiac tissue where they trigger collagen production. The combined effect of 
these processes may lead to microvascular rarefaction, interstitial fibrosis and stiff 
cardiomyocytes, which impairs relaxation of the ventricles and thus induces diastolic 
LV dysfunction [39, 40].
The current literature supports evidence for an increased risk of diastolic LV dysfunction 
in AS-patients, albeit that varying prevalences have been reported (9-45%) [14, 15]. 
Three studies assessed diastolic LV dysfunction using the combined set of parameters as 
recommended by the ASE/EACVI in 2009 ranging from 12-45%, though cut-off values of 
single parameters differed slightly between studies [15, 41, 42]. Other studies reported 
prevalences ranging from 20% to 49%, but those studies were not specifically designed to 
assess diastolic LV dysfunction or only used a single or few echocardiographic parameter 
for assessing diastolic LV dysfunction, which differs from the ASE/EACVI guidelines 
[8, 14, 26, 43-46]. Nowadays, the most appropriate way, recommended by American 
and European echocardiography organizations (ASE and EACVI) to asses diastolic LV 
dysfunction, is to combine specific echocardiographic parameters [47]. Thus far there 
have been no studies assessing diastolic LV function in AS patients with the updated 
ASE/EACVI 2016 guidelines.
However, the 2009 algorithms were considered too complex and had a substantial inter-
observer variability, which possibly caused the wide variation in the observed prevalence 
of diastolic LV dysfunction. Therefore, the guidelines to assess diastolic LV dysfunction 
were upgraded in 2016 by the ASE/EACVI with the purpose of simplifying the approach 
[48]. It has been shown that the 2016 algorithm is superior to the 2009 algorithm with 
regards to specificity, correlation with clinical outcomes and inter-observer variability, 
but had a lower sensitivity [49]. The above-mentioned studies mostly used the 2009 
criteria and when using the 2009 algorithm we found a prevalence of diastolic LV 
dysfunction of 53% in AS-patients and 46% in OA-patients, respectively. When applying 
the 2016 criteria, these prevalences, declined to 3.8% and 3.3%, respectively. Moreover, 
eight of the nine patients with diastolic LV dysfunction also had systolic LV dysfunction. 
According to the 2016 criteria, all patients with systolic LV dysfunction are defined 
to have also diastolic LV dysfunction. For our study this means that only one patient 
in the entire cohort was diagnosed with diastolic LV dysfunction because of aberrant 
echocardiographic Doppler values. Altogether, our results indicate that diastolic LV 
dysfunction in AS-patients is infrequent and that previous studies overestimated the 
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prevalence of impaired diastolic LV function in AS-patients due to the low accuracy of 
the diagnostic/grading tool.
Strengths and limitations
Our study has several strengths and limitations. First, to our knowledge, this is the 
largest study undertaken in AS-patients assessing LV function by echocardiography. 
Second, this is the first study to assess diastolic LV dysfunction in AS-patients based 
on the 2016 guidelines of the ASE/EACVI.
Nonetheless, there are also limitations of the present study. First of all, due to the cross-
sectional study design, the described associations found in this study are not necessarily 
causal. We were therefore unable to determine long-term consequences of the cardiac 
manifestations we observed in our patients. Secondly, complete matching of groups on a 
ratio of 2:1 based on age, sex and current smoking status, was not completely achieved, 
introducing minor differences in patient characteristics. Therefore, we adjusted for 
these variables in our regression analyses, thereby limiting the consequences thereof.
Conclusions
In conclusion, AS-patients have an up to five times increased risk of AVR, although 
this was mostly mild. However, it is important to realize that any stage of AVR is 
considered to be pathological as mild regurgitation may progress and result into 
severe complications. When timely recognized it can be treated adequately (aortic 
valve replacement). Therefore, our findings indicate that echocardiographic screening 
of elderly AS patients (50-75 years) should be considered. Obviously, prospective studies 
should assess the cost-effectiveness of screening of all AS patients as well as the long-
term complications of AVR in AS patients. In contrast, AS-patients did not have an 
increased risk of conduction disorders nor LV diastolic dysfunction compared to controls.
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Abstract
Objective
To assess the association between the aortic root diameter in HLA-B27 positive (+) and 
HLA-B27 negative (-) ankylosings spondylitis (AS) patients from the CARDAS cohort.
Methods
The CARDAS study is a cross-sectional study in AS patients between 50-75 years 
who were recruited from a large rheumatology outpatient clinic. Patients underwent 
cardiovascular screening including echocardiography, with 2D, spectral and color flow 
Doppler measurements. The aortic root was measured at sinuses of Valsalva during 
diastole. The aortic root diameter was adjusted for body surface area (BSA) (aortic root 
index, cm/m²).
Results
193 Consecutive AS patients were included of whom 158 (82%) were HLA-B27 positive. 
The aortic root index was significantly higher in HLA-B27+ patients compared to HLA-
B27- patients, respectively 1.76 cm ± 0.21 vs. 1.64 cm ± 0.14, p<0.001. No difference was 
seen in the prevalence of aortic valve regurgitation (AVR), p=0.8. Regression analysis 
showed a significant association between HLA-B27 and aortic root index corrected for 
age, sex and cardiovascular risk factors (β 0.091, 95%CI 0.015-0.168, p=0.02). Especially, 
male HLA-B27+ patients had a significantly increased aortic root index compared to male 
HLA-B27- AS patients, respectively 1.76 cm (1.63-1.88) and 1.59 cm (1.53-1.68), p<0.001.
Conclusion
We found an increased aortic root index in elderly HLA-B27+ AS patients compared 
to HLA-B27- AS patients, especially in male patients. No difference was seen in the 
prevalence of AVR. However, as AVR can be progressive, echocardiographic monitoring 
in elderly male HLA-B27+ AS might be considered.
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Introduction
Ankylosing spondylitis (AS) is an inflammatory joint disease associated with cardiac 
involvement. Aortic valve regurgitation (AVR) is a well-known cardiac complication 
described in AS patients [1, 2]. Inflammation of the aortic root might weaken aortic 
wall strength with subsequent dilatation of the aortic root causing fibrotic thickening 
of the aortic cusps. In combination with shortening of the aortic cusps this might 
ultimately lead to AVR [3-5]. In the majority of patients with AVR, the disease course is 
chronic and slowly progressive and in severe cases can lead to congestive heart failure, 
arrhythmia and sudden death [6-8]. The American Heart Association/American College 
of Cardiology (AHA/ACC) and the European society of cardiology (ESC) state that AVR 
is pathological, regardless of its grade of severity [8, 9]. Timely intervention with life 
style changes, pharmaceutical and/or surgical treatment of the aortic valve reduces the 
risk for severe complications [10]. Hence, follow up is indicated in all cases of AVR [8, 9]. 
In this light, some advocate regular echocardiographic screening for AS patients [11]. 
However, the cost-benefit of echocardiographic screening in AS is currently unknown 
and to what extent AS specific (subclinical) cardiac pathology leads to clinically 
overt cardiovascular morbidity and mortality remains to be elucidated. Therefore, it 
is needed to identify a specific at risk AS population that might benefit from routine 
echocardiographic monitoring.
HLA-B27 genotype is associated with AS. Eighty to 90% of AS patients in the Western 
World, carry the HLA-B27 allele compared to the a 5% prevalence in the general Western 
population [12]. Interestingly, the HLA-B27 genotype has also been associated with 
cardiac diseases including AVR in non-rheumatic patients [4, 5]. The question rises 
whether the increased risk for cardiac diseases in AS patients is linked to the HLA-B27 
genotype. Therefore, the presence of the HLA-B27 genotype may be a screening feature 
to identify AS patients at risk for AVR. Hence, we hypothesized that HLA-B27 positive 
(+) AS patients have a higher risk of developing AVR compared to HLA-B27 negative (-) 
AS patients.
7
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Patients and Methods
Study population
Data of AS patients of the Cardiac disease in Ankylosing Spondylitis (CARDAS) cohort 
were used. The CARDAS cohort included AS patients aged between 50 and 75 years 
old who had a comprehensive cardiovascular screening. Subjects were consecutively 
recruited between March 2014 and September 2019 from the Rheumatology department 
of Reade, Amsterdam, and the Netherlands. All patients fulfilled the 1984 Modified 
New York criteria for AS [13]. This study was conducted in accordance with the Helsinki 
Declaration and the approval was obtained from the ethics committee of the Slotervaart 
Hospital and Reade, Amsterdam, The Netherlands (NL44202.048.13). All participating 
patients gave written consent.
Patient and disease characteristics
All patients underwent a complete AS workup and cardiovascular screening including 
transthoracic echocardiographic (TTE) screening. Medical history was obtained by 
questionnaires and medical charts, including medication use, cardiovascular risk factors 
including smoking, hypertension and dyslipidemia and history of cardiovascular disease. 
Hypertension was defined as present if a patient was treated with antihypertensive 
medication, had a systolic blood pressure ≥ 140mmHg or a diastolic blood pressure ≥ 
90mmHg measured during physical examination. Furthermore, physical examination 
included height, weight and blood pressure measurements. Body mass index (BMI) was 
calculated. Blood sample measurements included standard hematological assessment, 
C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR). Disease activity 
was measured with the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), 
Bath Ankylosing Spondylitis Functional Index (BASFI), and the Ankylosing Spondylitis 
Disease Activity Score - CRP (ASDAS-CRP).
Transthoracic echocardiography
TTE was performed by experienced echo technicians at the Amsterdam UMC, location 
VUmc, a European Society of Cardiology certified echo-lab. To exclude inter-observer 
variability, all recordings of echocardiography data from both AS patients and controls 
were stored digitally and were afterwards analysed offline by a single cardiologist 
(T.C.K.). TTE was performed according to the protocol based on the guidelines provided 
by European Association of Echocardiography. Evaluation of cardiac function consisted 
of 2D, spectral and color flow Doppler recordings. 2D recordings were performed in 
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parasternal long- and short-axis views, and apical four-, three- and two-chamber views. 
The aortic root was measured at sinuses of Valsalva during diastole. The aortic root 
diameter was corrected for body surface area (BSA) according to the Dubois method 
(aortic root index) [14]. An aortic root index of ≥ 2.1 cm/m2 was considered as aortic 
root dilatation [15, 16].
Statistical analysis
For data analysis SPSS Version 24.0 (IBM Corp., Armonk, New York) was used. 
Demographic and disease characteristics were summarized using descriptive statistics. 
Distribution of data was displayed by histograms. Values are expressed as mean ± 
standard deviation (SD), median (interquartile range, IQR) or numbers (percentages, %) 
where appropriate. Independent samples t-tests were used for comparisons of normally 
distributed continuous variables and the Mann-Whitney U-test for non-normally 
distributed variables. The Chi-square test or Fisher’s exact test (n<10) was performed 
on dichotomous variables. Echocardiographic data were analysed using the unpaired 




In total, 193 consecutive AS patients were included of whom 158 were HLA-B27+ and 
35 HLA-B27-. AS patients had respectively a mean age of 60 (±7) years and 61 (±7) 
years and 44 (28%) and 11 (31%) were female, respectively (Table 1). Both groups had 
a comparable disease duration (time since diagnosis), 36 (±11) and 30 (±14) years, and 
a moderate disease activity assessed with the ASDAS-CRP, 2.1 (±1.0) and (2.3 ±1.0) 
(table 1). Furthermore, obesity and diabetes type II were more common in HLA-B27- AS 
patients, respectively 18% vs 40% and 9% vs 20%. History for cardiovascular disease 
was similar in both groups.
7
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Table 1. Baseline characteristics
Patient characteristics HLA-B27 + HLA-B27 -
n 158 35
Age, years (mean ±SD) 60 ±7 61 ±7
Sex, female (n, %) 44 (28) 11 (31)
BSA, m² (mean ±SD) 1.91 ±0.19 2.00 ±0.20
BMI, m²/kg (mean ±SD) 26.2 ±4.1 28.7 ±3.9
Systolic blood pressure, mmHg (mean ±SD) 133 ±16 136 ±15
Diastolic blood pressure, mmHg (mean ±SD) 83 ±7 86 ±8
Disease activity and severity   
Disease duration, years (mean ±SD) 36 ±11 30 ±14
ESR, mm/hr (median; IQR) 7 (4-14) 9 (5-17)
CRP, mg/L (mean ±SD) 2.7 (1.2-7.6) 3.3 (1.1-8.1)
ASDAS-CRP (mean ±SD) 2.1 ±1.0 2.3 ±1.0
BASDAI (mean ±SD) 3.3 ±2.2  4.0 ±2.4
BASFI (mean ±SD) 3.6 ±2.4 4.0 ±2.6
Cardiovascular risk factors   
Smoking   
    Current (n, %) 33 (21) 6 (17)
    Ever (n, %) 111 (70) 23 (66)
    pack years, years (mean ±SD) 26.2 ±14.0 26.4 ±16.8
Hypertension   
     Criteria (n, %) 93 (59) 25 (71)
     Patient history (n, %) 59 (37) 17 (49)
Obesity (n, %) 28 (18) 14 (40)
Hypercholesterolemie (n, %) 28 (18) 8 (23)
Diabetes type II (n, %) 15 (9) 7 (20)
History of cardiovascular disease  
Angina Pectoris (n, %) 2 (1) 3 (9)
Myocardial infarction (n, %) 10 (6) 2 (6)
Stroke (n, %) 5 (3) 2 (6)
     TIA (n, %) 3 (2) 1 (3)
     CVA (n, %) 2 (1) 1 (3)
Peripheral ischemia (n, %) 1 (1) 0 (0)
CABG (n, %) 6 (4) 2 (6)
Family history (first degree)   
    AP / MI (n, %) 19 (12) 5 (14)
   CVA/TIA (n, %) 11 (7) 3 (9)
Medication   
Lipid modifying drug (n, %) 29 (18) 9 (26)
Antihypertensives (n, %) 68 (43) 17 (49)
Biologic DMARDs (anti-TNF) (n, %) 58 (37) 12 (34)
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Values are displayed as mean ± standard deviation (SD), median (IQR) or frequencies with corresponding 
percentages (%). BSA=body surface area, BMI=body mass index, ESR=erythrocyte sedimentation rate, 
CRP=C-reactive protein,  ASDAS=ankylosing spondylitis disease activity score,
 BASDAI=bath ankylosing spondylitis disease activity score,  BASFI=bath ankylosing spondylitis 
functional index,  TIA=transient ischemic attack, CVA=cerebral vascular accident,  CABG=coronary 
artery bypass graft, AP=angina pectoris, MI=myocardial infarction. * Significance level of p ≤ 0.05.
Aortic root Measurement and valvular disease
The median aortic root index was significantly higher in HLA-B27+ patients compared 
to HLA-B27- patients: 1.76 (±0.21) cm/m2 vs 1.64 (±0.14) cm/m2, p<0.001. Furthermore, 
HLA-B27+ AS patients compared to HLA B27- AS patients had more often aortic root 
dilatation (≥2.1 cm/m²), 11 (8%) and 1 (3%), p=0.3, respectively (table 2). The presence 
of aortic root dilatation in HLA-B27+ AS patients was seen significantly more often in 
patients with aortic valve regurgitation, p=0.003. The single case of aortic root dilatation 
in the HLA-B27- cohort had a mild AVR. Of the eleven cases of aortic root dilatation in 
HLA-B27+ AS patients four had no AVR, one had AVR, five had mild AVR, one severe 
AVR and in one AS patient had an aortic valve prosthesis. None of the AS patients had 
aortic valve stenosis and one AS patient had mitral valve stenosis.
Table 2. Echocardiographic parameters   
 HLA-B27 + HLA-B27 - p value
Echocardiography    
Aortic root, cm (mean ±SD) 3.35 ±0.43 3.25 ±0.28 0.12
Aortic root index, cm/m² (mean ±SD) 1.76 ±0.21 1.64 ±0.14 <0.001*
Aortic root dilatation (≥2,1 cm/m²) (n, %) 11 (8) 1 (3) 0.5
Aortic valve regurgitation (n, %) 34 (22) 8 (24) 0.8
 Trace (n, %) 13 (8) 3 (9)  
 Mild (n, %) 18 (12) 5 (15)  
 Moderate (n, %) 4 (3) 0  
 Severe (n, %) 1 (1) 0  
 Prothesis (n, %) 1 (1) 0  
Mitral valve regurgitation (n, %) 52 (34) 17 (49) 0.25
 Mild (n, %) 49 (32) 16 (46)  
 Moderate (n, %) 3 (2) 1 (3)  
 Severe (n, %) 0 (0) 0 (0)  
 Prothesis (n, %) 0 (0) 0 (0)  
Values are displayed as mean ± standard deviation (SD) or frequencies with corresponding 
percentages (%). No cases of aortic valve stenosis and only one case of mitral valve stenosis 
were assessed. * Significance level of p ≤ 0.05.
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Association between HLA-B27 and aortic root index
The results of the linear regression analysis (crude, adjusted and fully adjusted) are 
presented in table 3. The relation between HLA-B27 genotype and the aortic root index 
remained significant in the fully adjusted model corrected for age, sex and cardiovascular 
risk factors, B 0.091 (95%CI 0.091-0.168), p=0.02.
Table 3. Association of HLA-B27 genotype with the aortic root index 
Crude model Adjusted modelᵅ Fully adjusted modelᵇ












Values are displayed as odds ratio with corresponding 95% confidence interval. BSA=body surface 
area. - Adjusted for age and gender. - Adjusted for age, gender, systolic blood pressure, diastolic blood 
pressure, hypercholesterolemia, BMI, Diabetes Mellitus type 2 and family history of cardiovascular 
diseases. * Significance level of p ≤ 0.05.
Aortic root index, HLA-B27 genotype and sex
The differences in aortic root index and sex and HLA-B27 genotype are shown in table 
4. Male HLA-B27+ patients had a significant increased aortic root index compared to 
male HLA-B27- AS patients, respectively 1.76 (1.63-1.88) and 1.59 (1.53-1.68), p<0.001. 
No difference was seen in female HLA-B27+ and HLA-B27- AS patients, respectively 1.66 
(1.53-1.92) and 1.64 (1.54-1.83), p=0.91. Furthermore, male HLA-B27+ AS patients also 
had an increased aortic root index compared to female HLA-B27+ AS patients.
Table 4. Gender differences in aortic root index, aortic root dilatation and aortic valve regurgitation
Male p value Female p value
HLA-B27 + HLA-B27 - HLA-B27 + HLA-B27 -
n= 114 24 44 11











dilatation, n (%) 7 (7) 0 0.35 4 (11) 1 (10) 1.00
Aortic valve 
regurgitation, n (%) 23 (20) 5 (23) 0.80 11 (26) 3 (27) 0.94
Values are displayed as median (IQR) or frequencies with corresponding percentages (%). No cases 
of aortic valve stenosis and only one case of mitral valve stenosis. * Significance level of p ≤ 0.05.
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Discussion
In the present study, the association between HLA-B27 genotype and aortic root 
diameter in AS patients was investigated. HLA-B27+ AS patients had a significantly 
increased aortic root index compared to HLA-B27- AS patients. This association was 
not explained by difference in age, sex nor cardiovascular risk factors. The prevalence of 
AVR was however similar in both groups. Furthermore, aortic dilatation was seen more 
often in HLA-B27+ AS patients, albeit this reached no statistical significance. Finally, 
our data suggest a sex and HLA-B27 genotype linked difference in aortic root index as 
male HLA-B27+ patients had an increased aortic root index compared to the HLA-B27- 
male patients and the overall female AS patients.
The HLA-B27 antigen is assumed to misfold causing an unfolded protein response 
(UPR). This might result in IL-23 upregulation by macrophages and lamina propria 
mononuclear cells and leading to activation of the IL-23/IL-17 inflammatory pathway, 
increasing susceptibility to AS [17-19]. Pathology studies have shown that IL-23–
Dependent -/- T-Cells (IL23+ T-cell) are specifically expressed in entheseal organs such 
as entheses (the primary inflammatory target in AS), ciliary body of the eye, and aortic 
root and aortic valves [17, 20]. Entheseal organs are avascular in their fibrocartilaginous 
regions, however microdamages of entheseal tissue due to continuous exposure to 
mechanical forces are common and appear to be associated with tissue repair responses 
and vessel ingrowth [21, 22]. It is assumed that enthesis-resident IL23+ T-cells have a 
homeostatic role in entheseal tissue repair. However, enthesis-resident IL23+ T-cells 
can also trigger a pro-inflammatory cascade as IL-23 binding induces IL-17 and IL-22 
production leading to inflammation, bone loss and ossification [17, 23]. Therefore, IL-23 
upregulation possibly also results in activation of in situ IL23+ T-cells in aortic root and 
valves leading to local inflammation with subsequently inflammation of the aortic root 
and valves. In fact, murine studies have shown inflammation of entheses and aortic root 
and valves after infusion with IL-23 [20].
Our study partially confirms our hypothesis as HLA-B27+ AS patients didn’t not have 
an increased prevalence of aortic valve disease as was expected. However, HLA-B27+ 
AS patients did have an increased aortic root index and had more often aortic root 
dilatation. To our knowledge, this finding has not been reported before. Our results may 
be indicative for the preclinical state of aortic valve disease in HLA-B27+ AS patients. 
At an older age HLA-B27+ AS patients may have a higher risk at developing aortic 
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valve disease as inflammation of the aortic root and valves is progressive of nature [7]. 
Klingberg et al. found also no relation between HLA-B27 genotype and aortic valve 
regurgitation [11]. However, in this study assessment of this relation was not the primary 
objective and the AS subjects were 10 years younger. Moreover, Huppert et al. found, in 
HLA-B27+ juvenile arthritis patients, a higher prevalence of aortic valve regurgitation 
compared to HLA-B27- non-rheumatic controls, respectively 10% (4/40) vs 0% (0/40) 
[24]. However, this study was performed in children <18 years of age and the control 
group consisted of non-rheumatic HLA-B27- subjects.
Our data suggest a sex and HLA-B27 genotype linked difference in aortic root index 
in disadvantage for male HLA-B27+ patients. In this light, the findings of Bergfeldt 
et al. are important as they showed that patients needing a pacemaker due to severe 
conduction disturbances were primarily male HLA-B27+ patients [25].
Our study did have some limitations. Firstly, due to the cross-sectional study design, the 
associations found in this study are not necessarily causal. Therefore, the (potential) 
long-term consequences of the cardiac manifestations we observed in our patients still 
need to be demonstrated. AS is predominant in male AS patients therefore the female 
subgroup was relatively small what could have masked differences between HLA-B27 
+ and HLA-B27 women.
In conclusion, our study demonstrated an increased aortic root index in elderly HLA-B27+ 
AS patients, especially in male patients. This did not already translated in an increased 
prevalence of aortic valve regurgitation in this subgroup. However, this finding is 
important as inflammation of the aortic root and valve in chronic inflammatory disease 
are progressive and may evolve in severe complications. Therefore, to recognize the 
AS patients at risk for this cardiac disease, echocardiographic monitoring, particularly 
in elderly male HLA-B27+ AS subjects should be considered. Obviously, prospective 
studies should determine the long term outcomes as well the cost effectiveness of 
echocardiographic screening in this subgroup.
147647_BaniaamamMilad-BNW_v6.indd   154 03/08/2021   15:53
Association between HLA-B27 and aortic root diameter in AS | 155
References
1. Roldan CA, Chavez J, Wiest PW, Qualls CR, Crawford MH. Aortic root disease 
and valve disease associated with ankylosing spondylitis. J Am Coll Cardiol. 
1998;32(5):1397-404.
2. Palazzi C, S DA, Lubrano E, Olivieri I. Aortic involvement in ankylosing 
spondylitis. Clin Exp Rheumatol. 2008;26(3 Suppl 49):S131-4.
3. Bulkley BH, Roberts WC. Ankylosing spondylitis and aortic regurgitation. 
Description of the characteristic cardiovascular lesion from study of eight 
necropsy patients. Circulation. 1973;48(5):1014-27.
4. Bergfeldt L, Insulander P, Lindblom D, Moller E, Edhag O. HLA-B27: an important 
genetic risk factor for lone aortic regurgitation and severe conduction system 
abnormalities. Am J Med. 1988;85(1):12-8.
5. Bergfeldt L. HLA-B27-associated cardiac disease. Ann Intern Med. 1997;127(8 Pt 
1):621-9.
6. Rigolin VH, Bonow RO. Hemodynamic characteristics and progression to heart 
failure in regurgitant lesions. Heart Fail Clin. 2006;2(4):453-60.
7. Flint N, Wunderlich NC, Shmueli H, Ben-Zekry S, Siegel RJ, Beigel R. Aortic 
Regurgitation. Curr Cardiol Rep. 2019;21(7):65.
8. Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP, 3rd, Guyton RA, et 
al. 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart 
Disease: a report of the American College of Cardiology/American Heart Association 
Task Force on Practice Guidelines. Circulation. 2014;129(23):e521-643.
9. Vahanian A, Alfieri O, Andreotti F, Antunes MJ, Baron-Esquivias G, Baumgartner 
H, et al. Guidelines on the management of valvular heart disease (version 2012): 
the Joint Task Force on the Management of Valvular Heart Disease of the European 
Society of Cardiology (ESC) and the European Association for Cardio-Thoracic 
Surgery (EACTS). Eur J Cardiothorac Surg. 2012;42(4):S1-44.
10. Baumgartner H, Falk V, Bax JJ, De Bonis M, Hamm C, Holm PJ, et al. 2017 ESC/
EACTS Guidelines for the management of valvular heart disease. Eur Heart J. 
2017;38(36):2739-91.
11. Klingberg E, Svealv BG, Tang MS, Bech-Hanssen O, Forsblad-d’Elia H, Bergfeldt 
L. Aortic Regurgitation Is Common in Ankylosing Spondylitis: Time for Routine 
Echocardiography Evaluation? Am J Med. 2015;128(11):1244-50 e1.
12. Reveille JD. HLA-B27 and the seronegative spondyloarthropathies. Am J Med Sci. 
1998;316(4):239-49.
13. van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for 
ankylosing spondylitis. A proposal for modification of the New York criteria. 
Arthritis Rheum. 1984;27(4):361-8.
14. Du Bois D, Du Bois EF. A formula to estimate the approximate surface area if 
height and weight be known. 1916. Nutrition. 1989;5(5):303-11; discussion 12-3.
7
147647_BaniaamamMilad-BNW_v6.indd   155 03/08/2021   15:53
156 | Chapter 7
15. Saura D, Dulgheru R, Caballero L, Bernard A, Kou S, Gonjilashvili N, et al. Two-
dimensional transthoracic echocardiographic normal reference ranges for 
proximal aorta dimensions: results from the EACVI NORRE study. Eur Heart J 
Cardiovasc Imaging. 2017;18(2):167-79.
16. Evangelista A, Flachskampf FA, Erbel R, Antonini-Canterin F, Vlachopoulos C, 
Rocchi G, et al. Echocardiography in aortic diseases: EAE recommendations for 
clinical practice. Eur J Echocardiogr. 2010;11(8):645-58.
17. Reinhardt A, Yevsa T, Worbs T, Lienenklaus S, Sandrock I, Oberdorfer L, et al. 
Interleukin-23-Dependent gamma/delta T Cells Produce Interleukin-17 and 
Accumulate in the Enthesis, Aortic Valve, and Ciliary Body in Mice. Arthritis 
Rheumatol. 2016;68(10):2476-86.
18. DeLay ML, Turner MJ, Klenk EI, Smith JA, Sowders DP, Colbert RA. HLA-B27 
misfolding and the unfolded protein response augment interleukin-23 production 
and are associated with Th17 activation in transgenic rats. Arthritis Rheum. 
2009;60(9):2633-43.
19. Colbert RA, Navid F, Gill T. The role of HLA-B*27 in spondyloarthritis. Best Pract 
Res Clin Rheumatol. 2017;31(6):797-815.
20. Sherlock JP, Joyce-Shaikh B, Turner SP, Chao CC, Sathe M, Grein J, et al. IL-23 
induces spondyloarthropathy by acting on ROR-gammat+ CD3+CD4-CD8- 
entheseal resident T cells. Nat Med. 2012;18(7):1069-76.
21. Benjamin M, McGonagle D. The enthesis organ concept and its relevance to the 
spondyloarthropathies. Adv Exp Med Biol. 2009;649:57-70.
22. Bridgewood C, Sharif K, Sherlock J, Watad A, McGonagle D. Interleukin-23 
pathway at the enthesis: The emerging story of enthesitis in spondyloarthropathy. 
Immunol Rev. 2020;294(1):27-47.
23. Gravallese EM, Schett G. Effects of the IL-23-IL-17 pathway on bone in 
spondyloarthritis. Nat Rev Rheumatol. 2018;14(11):631-40.
24. Jimenez-Balderas FJ, Garcia-Rubi D, Perez-Hinojosa S, Arellano J, Yanez P, Sanchez 
ML, et al. Two-dimensional echo Doppler findings in juvenile and adult onset 
ankylosing spondylitis with long-term disease. Angiology. 2001;52(8):543-8.
25. Bergfeldt L, Moller E. Pacemaker treated women with heart block have no 
increase in the frequency of HLA-B27 and associated rheumatic disorders in 
contrast to men--a sex linked difference in disease susceptibility. J Rheumatol. 
1986;13(5):941-3.
147647_BaniaamamMilad-BNW_v6.indd   156 03/08/2021   15:53
Association between HLA-B27 and aortic root diameter in AS | 157
7
147647_BaniaamamMilad-BNW_v6.indd   157 03/08/2021   15:53
147647_BaniaamamMilad-BNW_v6.indd   158 03/08/2021   15:53
Beyond the heart
147647_BaniaamamMilad-BNW_v6.indd   159 03/08/2021   15:53
147647_BaniaamamMilad-BNW_v6.indd   160 03/08/2021   15:53
Microvascular changes of the 
retina in Ankylosing Spondy-
litis, and the association with 
cardiovascular disease – 
the Eye for a Heart study.
Rianne E. van Bentum
Milad Baniaamam
Buket Kinaci-Tas









Irene E. van der Horst-Bruinsma
Published in: Seminars in Arthritis and Rheumatism 2020 
Sep; 2;S0049-0172(20)30241-9.
 
147647_BaniaamamMilad-BNW_v6.indd   161 03/08/2021   15:53
162 | Chapter 8
Abstract
Objective
Ankylosing spondylitis (AS) is associated with an increased risk of cardiovascular disease 
(CVD). Microvasculature changes can precede overt CVD, but have been studied poorly 
in AS. The retinal vasculature is easily accessible and changes are associated with CVD 
(e.g. arteriolar narrowing, venular widening, loss of tortuosity). This proof of concept 
study compared the retinal microvasculature of AS patients with healthy controls, and 
the influence of gender.
Methods
Cross-sectional case-control study comparing AS patients with healthy controls. Main 
inclusion criteria were: age 5075 years, no diabetes mellitus and, for AS, fulfillment of 
the modified New York criteria. All subjects underwent fundus photography, analyzed 
with Singapore I Vessel Assessment software, and Optical Coherence Tomography 
Angiography (OCTA). Subjects were compared with generalized estimating equations 
(GEE). Multivariable analyses were adjusted for demographics and cardiovascular risk, 
and stratified for gender.
Results
Fifty-nine AS patients and 105 controls were included (50% women). Controls were 
significantly older than patients (68 versus 60, p<0.01), but did not differ in cardiovascular 
profile. Patients had a lower retinal arteriolar tortuosity (b--0.1, 95%CI [-0.2; -0.01], 
p = 0.02), and higher vessel density (b 0.5, 95% CI [0.1; 0.9], p = 0.02). In addition, male 
AS patients showed a lower arteriovenular ratio compared to male controls (b -0.03, 
p = 0.04, 95%CI [-0.05; -0.001]). There were no differences found between women with 
and without AS.
Conclusion
This study detected several retinal microvascular changes, in AS patients compared to 
controls, which have been associated with CVD. Retinal imaging might be an interesting 
tool for future CVD screening.
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Introduction
Patients with ankylosing spondylitis (AS) have an 1.5 times increased risk of 
cardiovascular comorbidity and mortality.(1-3) Current research suggests that chronic 
systemic inflammation contributes to the development of cardiovascular risk factors, 
such as hypertension and dyslipidaemia, and ischemic heart disease.(1, 4-6) Changes in 
the microvasculature can precede clinically overt cardiovascular disease (CVD), but have 
been studied poorly in AS. The retinal vasculature is easily accessible and may provide 
an unique opportunity to timely recognize microvascular changes in AS patients.
Microvascular abnormalities, such as endothelial dysfunction and vascular remodeling, 
can precede macrovascular CVD and systemic endothelial dysfunction can reveal CVD.
(7, 8) In addition, microvascular disease itself is increasingly recognized as an important 
contributor to myocardial ischaemia.(9, 10) Mounting evidence has pointed out the 
importance of microvascular abnormalities in relation to CVD in women, aside from 
macrovascular disease.(11, 12) Interestingly, this pathophysiology was also suggested 
for patients with rheumatic diseases.(4, 9)
In AS, several studies have demonstrated increased signs of macrovascular abnormalities 
(atherosclerosis) but the literature on microvascular changes is limited.(13) The few 
studies available so far, have shown an impairment of the microcirculation in structure 
and function.(13-15) These studies mostly use experimental methodology, such as 
capillary microscopy and laser Doppler fluxmetry, which are influenced by blood pressure 
and temperature.(14, 15) In contrast, the retinal blood flow is mostly auto-regulated and 
is easily accessible for non-invasive visualization, which is part of standard care.(16, 17)
Retinal vascular parameters, measured through fundus photography and ocular 
coherence tomography angiography (OCT-A), could provide interesting biomarkers 
of (early) CVD in AS. Several large population studies have described associations 
between retinal vascular changes and CVD. In particular, changes of vascular diameter 
(narrower arterioles and wider venules), a lower tortuosity of the arterioles, a lower 
fractal dimension and a lower vessel density were reported in this context.(16, 18-22) 
Some studies describe the abovementioned diameter changes to be especially associated 
with CVD in women, independent of other risk factors.(11, 16, 23) In the few studies 
in rheumatic diseases (not AS), similar vascular diameter changes were found, with 
widening of the venules being particularly associated with systemic inflammation.(24-
8
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28) The vascular tortuosity, -fractal dimension and vessel density have not yet been 
studied in patients with rheumatic diseases.
In AS, many patients visit the ophthalmologist multiple times in their lives, due to 
Acute Anterior Uveitis attacks (this does not involve the posterior part of the eye, which 
contains the retinal vasculature). Consequently, using ophthalmic evaluation, such as 
retinal imaging, for early recognition of CVD might be a good opportunity. However, 
currently, there are no reports available on the retinal vasculature in AS specifically. The 
primary aim of this study was to investigate the differences between the retinal vessels 
of AS patients compared with healthy controls, and whether this differs for men and 
women. Secondary, it evaluates the association of the retinal vasculature with disease 
activity and other cardiovascular risk factors in AS patients.
Materials and methods
Design and study population
This cross sectional, case-control study is a proof of concept study which applied two 
retinal imaging modalities: fundus photography (vascular morphology) and optical 
coherence tomography angiography (OCT-A; retinal vessel density). Both AS patients 
and healthy control subjects were included, with an equal male-to-female ratio, and aged 
between 50-75 years, to increase the chance of detecting CVD associated vascular changes.
AS patients were consecutively recruited from the Rheumatology outpatient clinics 
of the Amsterdam Rheumatology and immunology Centre (ARC) locations Reade and 
Amsterdam UMC-VUmc, the Netherlands. Patients had to fulfil the 1984 modified 
New York criteria, and auto-immune disorders other than AS-related (e.g. psoriasis, 
inflammatory bowel disease) were excluded.(29)
Healthy control subjects were selected from the two year follow up visit of the Dutch 
EMIF-AD PreClinAD cohort of the Amsterdam UMC-VUmc, that contains cognitively 
healthy, monozygotic twins of ≥60 years, from the “Netherlands Twin Registry”.(30) 
Control group data were collected previously.(30) Controls were eligible if they did 
not have a history of any rheumatic disease (including inflammatory bowel disease 
or psoriasis) and had undergone at least one ophthalmologic examination (fundus 
photography or OCT-A).
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Exclusion criteria for all subjects were conditions interfering with ocular evaluation 
(diabetes mellitus, current anterior uveitis, glaucoma, significant cataract or eye surgery ≤6 
months ago) and cerebrovascular events resulting in permanent disabilities (pre-existing 
exclusion criterion of the control group). Current use of non-steroidal anti-inflammatory 
drugs (NSAIDs) and biologicals was allowed, but corticosteroids (systemic/topical ocular 
corticosteroids, or injections in the previous three months) were not permitted.
All subjects underwent fundus photography and OCT-A, preferably of both eyes. Study 
procedures were performed consecutively on the same day, at the Amsterdam University 
Medical Centre (UMC) VUmc. The protocol (NL66784.048.18) was approved by the medical 
ethics committee of the Slotervaart hospital & Reade, Amsterdam, the Netherlands. All 
patients gave written informed consent according to the Helsinki Declaration.
Study parameters
Retinal vasculature assessment
Imaging was performed after application of tropicamide 0.5% eye drops for pupil dilation.
Retinal vessel morphology
Fundus photos (508 field of view, centred on the optic nerve head; Topcon TRC 50DX 
type IA) were analysed with Singapore I Vessel Assessment (SIVA) software (version 
3.0; National University of Singapore, Singapore). SIVA automatically identifies retinal 
arterioles and venules, in the zone 0.5-2 disc diameters around the optic nerve head 
(Figure 1). An experienced grader examined the traced vessels and made manual 
corrections if necessary (same grader for all subjects; intra-observer intra-class 
correlation, absolute agreement, of >0.80 (31)). Ungradable images were excluded. 
SIVA analyses resulted in: vascular diameter (central retinal arterioles, venules; and 
arteriovenous ratio), vascular curvature tortuosity (of the arterioles and venules) and 
fractal dimension. The latter is a measure of the branching complexity of the retinal 
vessels. SIVA skeletonizes the retinal vessels and uses a box-counting method to 
calculate the fractal dimension.
Retinal vessel density
OCT-A (Zeiss Meditec, Inc, Germany) registers the retinal microvascular network 
through movement detection of blood cells, enabling calculation of the vessel density 
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(vessel area versus total area). Macula images (6x6 mm area around the fovea) were 
analysed automatically with accompanying software (Cirrus 5000 Angioplex, version 
11), applying an ETDRS grid (three rings of 1 mm, 3 mm and 6 mm centred around the 
fovea). This divides the macula in a central foveal region, an inner and outer region, to 
calculate two parameters: macular inner- and outer region vessel density (mm/mm2). 
The image quality was evaluated based on the software reported quality score (0-10; 
≥8=potentially eligible) and visual inspection. Images of insufficient quality, and ocular 
diseases interfering with OCT-A quality or vessel density (e.g. severe cataract/ametropia, 
glaucoma, epiretinal membrane) were excluded.
Cardiovascular history
Cardiovascular risk factors were recorded: Body Mass Index (BMI), current smoking, 
and history of dyslipidemia and hypertension. In addition, the history of previous CVD 
(myocardial infarction, coronary disease, peripheral artery disease, transient ischemic 
attack) was recorded.
Other study parameters
During the study visit, data were collected on demographics (gender, age), hip- and 
waist circumference, blood pressure, medication (daily use of NSAIDs, nonsteroidal 
anti-inflammatory drugs; DMARDs, conventional disease modifying antirheumatic 
drugs; biologicals) and lipid profile. The latter was collected for AS patients within 12 
months, and for healthy controls within 24 months prior to the study visit.
In addition, for AS patients, data were collected on disease duration, HLA-B27, extra-
articular manifestations, C-reactive protein (during or within 3 months prior/after 
study visit) and disease activity (Bath AS Disease Activity Index (BASDAI), AS Disease 
Activity Score (ASDAS). High disease activity was defined as an ASDAS-score of ≥2.1 
or, if unavailable, a BASDAI of ≥4.
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Figure 1. Overview of the imaging modalities for the evaluation of the retinal vasculature*. Ret-
inal vascular parameters were derived from fundus photography analysed with SIVA software 
(Singapore I Vessel analysis, resulting in vascular morphology parameters) and Optical Coherence 
Tomography Angiography (OCT-A; resulting in capillary density parameters). *Image adapted, 
with permission, from Haan et al. (32).
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Figure 2. Flowchart study population (AS patients and healthy controls). As, Ankylosing Spondy-
litis; CS, healthy control subjects; OCT, Optical Coherence Tomography; SIVA, Singapore I Vessel 
Assessment software.
Statistical analyses
Data are presented as mean (standard deviation, SD), number (with percentage) 
or percentage only. Non-normally distributed variables were presented as median 
(interquartile range, IQR) and transformed with the natural logarithm (Ln) for further 
analyses. For all retinal parameters, the mean of both eyes was used. If only one eye 
was available (due to unavailability, failed imaging or ocular disease), only data of the 
available eye was used.
Differences between AS patients and healthy controls were tested with Generalized 
Estimating Equations (GEE) analyses, correcting for genetic relatedness within twin-
pairs of the control group. AS patients and controls were compared in univariable 
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and multivariable analyses, with stepwise addition of cardiovascular risk factors: 
demographics and lifestyle (model 1: age, gender, BMI and current smoking status), 
and factors that could also be part of the pathophysiological pathway between AS 
and CVD (model 2: model 1 plus hypertension and dyslipidaemia). In addition, OCT-A 
data were always corrected for software-reported scan quality, as scan quality can 
significantly influence the vessel density measurement. Next, the influence of gender 
on the differences between AS and controls in retinal parameters was evaluated by 
including a cross-product interaction term (gender*patient) as independent variable in 
the final multiple regression model (model 2). For parameters with an interaction term 
of p < 0.10, the gender-specific regression coefficients were reported as well. Last, within 
the AS population, the association between retinal parameters and disease parameters 
(ASDAS, high disease activity, biological use) or cardiovascular risk (hypertension, 
dyslipidemia, previous cardiovascular disease) was evaluated with linear or logistic 
regression, corrected for age and gender.
RESULTS
Study population
Sixty-one AS patients were recruited, of whom two were excluded because of active 
anterior uveitis (Figure 2). The control population consisted of 152 healthy subjects, of 
whom 47 did not meet the inclusion criteria, resulting in 105 eligible subjects.
Demographic characteristics are depicted in Tables 1 and 2. The control group was 
significantly older than AS patients (68 (SD4) years, versus 60 (SD6) years, p<0.001, 
respectively). However, there were no significant differences in the presence of 
cardiovascular risk factors or previous CVD (Table 2).
Table 1. Disease characteristics Ankylosing Spondylitis patients (n=59)
Women, n (%) 30 (51)
Age in years, mean (SD) 60 (6)
AS disease duration since diagnosis, in years, mean (SD) 24 (11)
HLA-B27 positive, n (%) 43 (78)
Extra-articular manifestations, n (%)
Anterior uveitis 29 (49)
Inflammatory Bowel disease 3 (5)
Psoriasis 6 (10)
8
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Table 1. Continued.





CRP in mg/L, median (IQR) 3 (2-4)
ESR in mm/hr, median (IQR) 11 (2-15)
ASDAS-CRP/BSE, mean (SD) 2.1 (0.9)
BASDAI, mean (SD) 4 (2)
High disease activity (ASDAS≥2.1)*, n (%) 27 (46)
BASFI score, mean (SD) 4 (2)
Values are depicted as number of patients (%), mean (standard deviation) or median (Q1-Q3). 
AS, Ankylosing Spondylitis; ASDAS, AS disease activity score; BASDAI, Bath AS disease activity 
index; BASFI, Bath AS functional index; CRP, C-reactive protein; DMARDs, disease modifying 
antirheumatic drugs; ESR, erythrocyte sedimentation rate; NSAIDs, nonsteroidal anti-inflammatory 
drugs. Biologicals: mostly TNF inhibitors (n = 27; secukinumab n = 2). *If ASDAS was unavailable, 
a BASDAI _4 was defined as high disease activity.
In AS patients, the average disease duration was 36 (SD 12) years, the mean ASDAS-CRP/
ESR-score 2.1 (SD 0.9), 41% used NSAIDs, 10% a DMARD and 49% received biological 
treatment, mainly TNF inhibitors (Table 1). No subject used corticosteroids, as this was an 
exclusion criterion. Men and women with AS did not differ significantly in disease activity, 
medication use or disease duration (data not shown). Among the healthy controls, only 
6% used a NSAID, and no one used a conventional DMARD or biological agent.
Table 2. Demographics and cardiovascular profile AS and healthy control subjects.
AS
patients
Healthy controls a p-value
(n=59) (n=105)
Women, n (%) 30 (51) 52 (50) 0.87
Age in years, mean (SD) 60 (6) 68 (4) <0.001
Smoking currently, n (%) 11 (19) 8 (8) 0.06
Hypertension and/or dyslipidemia, n (%) 26 (44) 44 (42) 0.98
Hypertension 23 (39) 39 (37) 0.91
Dyslipidemia 9 (15) 18 (17) 0.78
History of cardiovascular disease, n (%) 9 (15) 15 (14) 0.89
Body mass index, mean (SD) 26 (4) 26 (3) 0.51
Waist-to-hip-ratio, mean (SD) 0.9 (0.1) 0.9 (0.1) 0.46
Systolic blood pressure, mean (SD) 143 (17) 143 (15) 0.98
Diastolic blood pressure, mean (SD) 83 (9) 81 (8) 0.30
Cholesterol-HDL ratio, mean (SD) 4 (1) 4 (1) 0.58
Values were depicted as mean (standard deviation) or number of patients (percentage of total). a. 
43 twin pairs and 19 singletons. AS, Ankylosing Spondylitis.
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Comparison of the retinal vasculature of AS patients with healthy controls
Retinal vessel morphology (fundus photography)
Fundus photos of at least one eye were available in 56 (95%) AS patients and 103 
(98%) healthy controls (Figure 2). On a group level, in crude analyses, only fractal 
dimension differed between AS and healthy controls (higher in AS: β 0.01, 95% CI [0.0; 
0.03], p = 0.04, Table 3), but this effect disappeared after correction for age (Table 4). 
Interestingly, crude analyses only showed a non-significant, lower arteriolar tortuosity 
in AS patients, but this association became stronger after correction for age and 
gender, and even more after correction for cardiovascular risk factors (Table 4; (Ln 
transformation of) arteriolar tortuosity: β -0.1, 95%CI [-0.2; -0.01], p = 0.02, Table 4; 
11% lower). A positive history of anterior uveitis was not a confounder in these analyses.
The comparison of gender specific differences between AS patients and healthy controls, 
revealed that gender was only a significant effect modifier for the association between 
AS and vascular diameter (retinal arteriovenous ratio, AVR; p<0.01; Table 4). Stratified 
analyses showed that men with AS had a significantly lower AVR (β-0.03, 95%CI 
[-0.05; -0.001], p = 0.04) than men without AS, whereas this parameter did not differ 
significantly between women with and without AS.








Vascular morphology (Fundus photography)
Number of patients 56 103
Diameter Arteriolar (µm) 125 (11) 124 (10) 0.37
Venular (µm) 197 (20) 191 (14) 0.08
Arteriovenous ratio (AVR) 0.64 (0.06) 0.65 (0.04) 0.43
Tortuosity Arteriolar, x10-5 a -9.8 (0.2) -9.7 (0.2) 0.19
Venular, x10-5 a -9.7 (0.2) -9.7 (0.2) 0.61
Complexity Fractal dimension 1.19 (0.04) 1.18 (0.03) 0.04
Vessel density (OCT-angiography)
Number of patients 44 77
Vessel density Inner ring macula, mm/mm2 18.4 (0.7) 17.6 (1.1) <0.001
Outer ring macula, mm/mm2 18.4 (0.6) 17.8 (1.1) <0.001
Values are depicted as mean (standard deviation, SD). a. analyses were performed on log-
transformed variable, because of a nonparametric distribution. b. 43 twin pairs and 19 
singletons. AS, Ankylosing Spondylitis.
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Retinal vessel density (OCT-Angiography)
OCT-A images were available for 75% of the AS patients (n = 44; both eyes in n = 21) 
and 73% of the healthy controls (n = 77; both eyes in n = 55; Figure 2). In this subgroup, 
AS patients were also significantly younger than healthy controls (59 (SD 6) versus 68 
years (SD 4) respectively, p<0.01). When comparing subjects with and without OCT-A: 
AS patients with OCT-A were significantly younger (58 (SD5) versus 66 (SD5) years, 
p<0.01), used more NSAIDs (66% versus 33%, p = 0.03) and had less often hypertension 
(30% versus 67%, p = 0.01), than AS patients without OCT-A. Healthy controls in whom 
OCT-A was performed did not differ significantly from controls without.
On a group level, univariable analyses suggested that AS patients had a significantly 
higher retinal vessel density in both the inner and outer region of the macula (Table 
3), compared to healthy controls. After correction for demographics, lifestyle-factors, 
hypertension and dyslipidemia, this difference persisted for the inner macula region 
(higher in AS: β 0.5, 95%CI [0.1; 0.9], p = 0.02, Table 4).
Gender was only a significant effect modifier for the association between AS and 
capillary density of the outer macula (p<0. 01; Table 4). Gender stratified analysis showed 
that male AS patients had a significantly higher vessel density in the outer macula (β 
0.6, 95%CI [0.1; 1.0], p = 0.03), compared to men without AS. Again, this parameter did 
not differ between women with and without AS.
Disease activity, cardiovascular history and retinal parameters in AS patients.
Disease activity and retinal characteristics
The mean ASDAS was 2.1 (SD 0.9), with 27 AS patients (49%) reporting a high 
disease activity (Table 1). Biologicals were used less often by patients showing 
a high disease compared to patients with low disease activity, respectively 44% 
versus 50% (not significant).
AS patients with high disease activity showed a significantly higher venular diameter 
(β 10, 95%CI [0; 21], p = 0.05; corrected for age and gender), compared to patients with 
low disease activity. Interestingly, in contrast, in AS patients who used biologicals, a 
significantly higher arteriole diameter was found compared to patients without this 
treatment, regardless of disease activity, age and gender (β 8, 95%CI [2; 14], p<0.01).
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Retinal parameters and cardiovascular history in AS patients
Cardiovascular risk factors were often present in AS patients: 39% had hypertension and 
15% dyslipidemia. In addition, 15% reported a history of CVD. Hypertension and CVD 
were both significantly associated with a higher venule diameter in AS patients, also 
after correction for age and gender: hypertension, β 11 (95%CI [4; 25], p<0.01) and CVD: 
β 16 (95%CI [1; 31], p = 0.03). Other retinal parameters did not show any associations 
with CVD, hypertension or dyslipidaemia. In contrast, in controls, CVD were associated 
with a higher arteriolar diameter and AVR (data not shown).
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Discussion
This study showed several retinal microvascular changes in AS patients, compared to 
healthy controls, of which some have been associated with cardiovascular risk. The 
most prominent changes in AS patients consisted of straighter arterioles and a higher 
vessel density. In addition, male AS patients showed a decreased arteriovenular ratio 
compared to male controls, whereas no specific changes were found in women with 
AS. In AS, high disease activity and previous CVD were associated with wider venules, 
whereas treatment with biologicals was related to wider arterioles.
This proof of concept study is the first to report on the microvasculature of the retina 
specifically in AS patients. The results are mostly in line with the expectations based 
on other populations. Large population studies demonstrated CVD to be associated 
with arterial narrowing, venular widening (or a decreased arteriovenular ratio), reduced 
arteriolar tortuosity and reduced complexity.(18, 20, 22, 32-34) The few studies in other 
rheumatic diseases, primarily including rheumatoid arthritis, psoriatic arthritis and 
systemic lupus erythematosus, found the same vascular diameter changes as reported 
for CVD (arteriolar narrowing, venular widening) in patients, compared to controls.
(24-28) Only one study included a small number of AS patients (n = 26) together with 
other rheumatic diseases, and reported no differences with controls. However, the AS 
patients included in that study were younger compared to our study, and the majority of 
controls suffered from hypertension which is known to influence the retinal vasculature.
(35) None of the studies in rheumatic patients evaluated the tortuosity or vessel density.
The current results are mostly in line with the expectations based on the abovementioned 
studies. Most prominently, the retinal arteriolar tortuosity was significantly decreased 
in AS patients, which is associated with an increased risk of CVD based on large 
population studies.(22, 32, 34) This decreased tortuosity appears to be due to AS itself 
as the association became stronger after correction for cardiovascular risk factors. In 
addition, there was a trend of an increased venular diameter and decreased arteriolar 
diameter and, consequently, decreased arteriovenular ratio (AVR), in AS patients. 
Although these diameter differences were not significant on a group level (only male 
AS patients had a significantly decreased AVR compared to controls), this combination 
of changes has been repeatedly reported to be associated with CVD.(20, 22) Also in the 
current study, within the AS population, venular widening was associated with CVD. In 
8
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contrast with other population studies, and the AS patients in this study, the controls 
in our study with CVD had wider arterioles.(20, 22, 23)
OCT-A imaging, which had not yet been described for rheumatic diseases, revealed an 
increased retinal vessel density in AS patients. In addition, in male AS patients, this 
was found for a more extensive area. This is a novel finding. Until now, only one study 
studied the vessel density, in patients with coronary heart disease, and found a decreased 
density, compared to controls.(21) However, this study focused on macrovascular 
CVD, whereas an early disease state with primarily microvascular damage might have 
different hemodynamic states. An alternative hypothesis is that the increased vessel 
density found in the AS patients, is related with systemic inflammation, causing an 
increased capillary flow (in AS patients, a higher CRP was associated with a higher vessel 
density, although not significant; β 0.01, 95%CI [-0.1; 0.13], p = 0.83). Nevertheless, the 
association between vessel density and microvasculopathy needs to be further explored.
Microvascular changes in women were of particular interest, as increasing evidence 
supports the importance of microvasculopathy, including retinal vascular diameter 
changes, in the risk of CVD.(10, 11, 23, 36) It was expected that, in particular in AS 
women, microvascular changes would be observed. However, in this study, differences 
between AS and controls were found only on a group level, and additionally in men, 
when stratified for gender. The fact that microvascular changes were not specifically 
detected in women, cannot be explained by more systemic inflammation in men, because 
disease activity parameters and treatment (ASDAS, biologicals, NSAIDs) did not differ 
between AS men and women.
A higher AS disease activity was associated with wider retinal venules, in accordance 
with studies in other rheumatic diseases.(14, 25, 28) Although the pathophysiological 
process is not fully understood, wider venules are associated with metabolic disturbances 
(diabetes mellitus, obesity, dyslipidemia), inflammation, smoking and CVD, and is 
therefore considered unfavourable.(16) In contrast, biologicals were associated with a 
more favourable arteriolar morphology (wider diameter, instead of narrowing, which 
is associated with CVD), and this was independent of disease activity. The main target 
of the biological, tumour necrosis factor alpha, hampers nitro oxide release. Studies in 
AS patients initiating a TNFi have shown to improve the vascular status, such as the 
endothelial function, intima media thickness and pulse wave velocity.(14, 15, 37) The 
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current findings are in accordance with the theory that TNFi have a beneficial effect 
on the vessel wall.
As this was a proof of concept study, there were a few limitations. Firstly, the healthy 
control group was significantly older than the AS patients. Therefore, analyses were 
adjusted for age, limiting this influence, but also for other cardiovascular risk factors that 
are considered to influence the microvasculature. Secondly, 43 of the control subjects 
were genetically related to another subject (twin). Alternatively, only one of the twin 
pairs could have been selected, but this would have resulted in a much smaller control 
group. Therefore, to increase statistical power, all available subjects were included, 
with adjustment for genetic relatedness. Thirdly, it was not possible to link the retinal 
vasculature directly to the current cardiac vessels conditions, as cardiac imaging data 
were not available. However, as this was a secondary aim, retinal parameters were 
compared with the presence of CVD, a clinically important endpoint. Fourthly, it is 
unclear how NSAIDs (and biologicals) could have had a confounding influence on the 
differences between AS and controls, but the use of NSAIDs is very common in AS, and 
an AS group without NSAIDs would not be representative. In addition, the potential 
influence of exercise should be considered in future studies. Fifthly, 49% of the AS 
patients had a history of anterior uveitis (AAU), which is comparable with the prevalence 
reported for patients with a long disease duration (43%).(38) Unfortunately, whether a 
previous history of AAU influences these retinal parameters is unknown. However, AAU 
in AS is typically a short-term inflammation of the anterior eye segment, that generally 
does not involve the posterior segment and is, therefore, unlikely to affect the retinal 
vessels. In addition, patients with active AAU at the time of the study were excluded and 
a positive history of AAU was not a confounder in the analyses. Lastly, because this is a 
proof of concept study, the study population size was limited, rendering it potentially 
underpowered to detect more microvascular changes. In this perspective, no additional 
correction for multiple testing was applied. However, this is the first study focusing on 
AS and, furthermore, the first that also evaluated the vascular tortuosity and density, 
which had not yet been described before for patients with rheumatic diseases in general.
In conclusion, this study was the first to report on the retinal microvasculature in a large 
group of AS patients, in comparison with healthy controls. It supports the hypothesis 
that AS causes microvascular changes, which were found more extensively in men. 
Importantly, the results might indicate a retinal vascular profile in AS patients that has 
also been demonstrated to be associated with CVD, whereas the value of a novel finding 
8
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(increased vessel density) needs to be explored further. By all means, this proof of 
concept study indicates that retinal imaging techniques might be useful for the detection 
of microvascular changes in AS patients. Importantly, these techniques are non-invasive 
and easily accessible in daily clinical practice, in contrast with other microvascular 
assessments. If longitudinal follow up further demonstrates its opportunities and 
predictive value, these techniques might provide a great future opportunity for the 
early recognition of CVD in AS.
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ABSTRACT
Introduction
Given the link between systemic inflammation, body composition and insulin resistance 
(IR), anti-inflammatory therapy may improve IR and body composition in inflammatory 
joint diseases. This study assesses the IR and beta cell function in rheumatoid 
arthritis (RA) patients with active disease compared to osteoarthritis (OA) patients 
and investigates the effect of anti-TNF treatment on IR, beta cell function and body 
composition in RA.
Methods
28 Consecutive RA patients starting anti-TNF treatment (adalimumab), and 28 age, and 
sex-matched patients with OA were followed for 6 months. Exclusion criteria were use 
of statins, corticosteroids, and cardiovascular or endocrine co-morbidity. Pancreatic 
beta cell function and IR, using the Homeostasis Model Assessment (HOMA2), and 
body composition, using Dual-energy X-ray Absorptiometry (DXA) were measured at 
baseline and 6 months.
Results
At baseline, IR [1.5 (1.1-1.8) vs. 0.7 (0.6-0.9), 100/%S] and beta cell function (133% vs. 
102%) were significantly (p<0.05) higher in RA patients with active disease as compared 
to OA patients. After 6 months of anti-TNF treatment IR [1.5 (1.1-1.8) to 1.4 (1.1-1.7), 
p=0.17] slightly improved and beta cell function [133% (115-151) to 118 (109–130), 
p<0.05] significantly improved. Improvement in IR and beta cell function was most 
pronounced in RA patients with highest decrease in CRP and ESR.
Conclusion
Our observations indicates IR and increased beta cell function are more common in 
RA patients with active disease. Anti-TNF reduced IR and beta cell function especially 
in RA patients with highest decrease in systemic inflammation and this effect was not 
explained by changes in body composition.
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Introduction
In healthy persons, normoglycaemia is maintained by a balanced interaction between 
insulin action (insulin sensitivity (IS) and insulin secretion (pancreatic beta cell 
function). Insulin resistance (IR) is more prevalent in rheumatoid arthritis (RA) and 
is associated with endothelial dysfunction and with increased CVD[1-3]. Already in 
1949, generalized muscle wasting and hyperglycaemia, both characteristics of IR, were 
identified in patients with RA[4]. Previous studies demonstrated that RA patients 
have peripheral IR that is correlated with inflammatory markers and normalizes after 
reduction of inflammation with glucocorticoid treatment[5-7]. Previous studies in non-
diabetic RA patients found pancreatic beta cell function to be impaired[8, 9].
Increasing evidence arises that body composition, particularly body fat distribution 
and the quantity and characteristics of (visceral) adipose tissue, is an important factor 
contributing to enhanced CV risk in inflammatory diseases[3]. Cachectic obesity, defined 
as a loss of body cell mass without weight loss, but with concomitant increased fat mass, 
is a prominent feature of RA, and associated with increased circulating tumor necrosis 
factor (TNF) levels[10].
A clear link between obesity and chronic (low grade) inflammation was established when 
TNF-α, a pro-inflammatory cytokine, was found to be overexpressed in the adipose 
tissue of obese mice [11]. TNF-α is also overexpressed in adipose and muscle tissues of 
obese humans[12] and exogenous TNF-α administration leads to IR[13].
Nowadays, TNF antagonists are widely used to treat several inflammatory diseases, including 
RA. A recent systematic review and meta-analysis suggests that anti-TNF treatment 
improved IR in RA patients[14]. However, the underlying inflammatory mechanisms 
affecting IR in relation with body composition have not yet been fully elucidated.
To investigate the role of systemic inflammation and body composition in the 
development of IR we compared RA patients, starting anti-TNF treatment, with matched 
osteoarthritis (OA) patients. We hypothesize that decrease in systemic inflammation 
and change in body composition (secondary to decrease in systemic inflammation) will 
positively affect IR in RA patients treated with anti-TNF. The objectives of the present 
investigation were 1) to investigate the body composition and IR in RA to sex and age 
matched OA patients 2) to investigate correlations between IR, inflammation and body 
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composition and 3) to study if and to what extent IR and body composition are influenced 
by anti-TNF treatment.
Methods
Study population and design
For this prospective study 69 consecutive subjects, 36 RA and 33 OA patients were 
recruited from the outpatient rheumatology clinic at Reade, Center for Rehabilitation 
and Rheumatology, Amsterdam, the Netherlands. RA patients fulfilled the American 
College of Rheumatology criteria of 1987 for RA[15]. The RA patients with active disease 
were biological naive and were included when they were eligible for Anti-TNF therapy 
according to the Dutch consensus statement on the initiation of Anti-TNF therapy [16]. 
All patients started with adalimumab 40 mg every two weeks. The OA patients, not 
treated with anti-TNF, were matched for sex and age to the RA patients and they all had 
OA of the hands according to the American College of Rheumatology criteria of 1990 
for osteoarthritis of the hand[17]. We chose OA patients as controls because they have 
substantially less systemic inflammation but many similarities to RA patients in terms 
of life style, physical inactivity, frequent use of non-steroidal anti-inflammatory drugs 
(NSAIDs) and obesity. Patients, with a medical history of CVD, diabetes mellitus or 
hypothyroidism and/or used glucose or cholesterol lowering medication, were excluded. 
Also, patients, who used systemic (oral or intramuscular) corticosteroids within a month 
before inclusion, were excluded from analyses. All patients were followed for 6 months 
and measurements were performed at t=0 (before start of Anti-TNF therapy and at 
t=6 months (after start of therapy). Non-steroidal anti-inflammatory drugs (NSAIDs) 
were allowed to be discontinued during follow up. When patients altered the use of 
Anti-TNF or disease modifying anti-inflammatory drugs (DMARDs) or started using 
corticosteroids, glucose or cholesterol-lowering medication during the follow up period, 
they were excluded from the follow up analyses. This study was approved by the Ethics 
committee of the Slotervaart Hospital/Reade (NL19944.048.07) and prior to inclusion 
written informed consent from all patients was obtained.
Patient characteristics
At baseline and after 6 months of treatment all patients were interviewed to record 
details about history of co-morbidity, medication use and disease characteristics. 
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Special attention was paid to history of cardiovascular risk factors like hypertension, 
hypercholesterolemia, overweight, diabetes mellitus (DM), and smoking.
A physical examination was performed by experienced research nurses to assess blood 
pressure, heart rate, waist and hip circumference, length, weight, and body mass 
index (BMI).
Blood pressure and heart rate were measured twice (left and right) in sitting position 
after 5 minutes of rest. Hypertension was defined as a mean systolic blood pressure (SBP) 
≥ 140 mmHg and/or a mean diastolic blood pressure (DBP) ≥ 90 mmHg and/or the use 
of antihypertensive drugs. Hypercholesterolemia was defined as total cholesterol (TC) 
level of ≥ 6.5 mmol/L.
Waist circumference was measured at the level of the navel, hip circumference was 
measured at the level of the trochanter major of the hip bone (widest circumference). 
The ratio of these two measurements was determined as waist-hip-ratio (WHR).
Height and weight were measured using the same portable weight scale and height 
meter, without shoes but with clothes on. Overweight was defined as a BMI ≥ 25 kg/m2 
and obesity as a BMI ≥ 30 kg/m2.
RA disease activity was assessed with the disease activity score of 28 joints (DAS28)[18] 
and the Health Assessment Questionnaire (HAQ)[19], a questionnaire measuring daily 
functioning in RA patients.
After the physical examination an Oral Glucose Tolerance Test (OGTT) was performed. 
Patients were asked to drink a solution of 250 ml of water with 75 grams of glucose 
within 5 minutes. Patients were not allowed to exercise or come out of the chair for the 
next 2 hours. Two hours (plus minus 15 minutes) after the glucose intake blood samples 
were drawn to measure the glucose level.
Blood tests
Fasting blood samples were collected to measure erythrocyte sedimentation rate (ESR), 
C-reactive protein (CRP), cholesterol levels (including apolipoprotein-A and B), and 
fasting glucose levels. All the above tests were performed the same day that blood was 
drawn in a single laboratory at Reade in Amsterdam. Furthermore, serum and plasma 
were stored at –20 degrees Celsius to measure C-peptide and insulin batch-wise after 
all the samples were collected.
Insulin resistance and beta cell function
The updated Homeostasis Model Assessment (HOMA2) computer model, available 
from www.OCDEM.ox.ac.uk, was used to estimate insulin resistance (HOMA2-IR), and 
9
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pancreatic beta cell function (HOMA2-%B)[20]. This model calculates IR and beta cell 
function from fasting plasma insulin and glucose concentrations and correlates well 
with insulin clamp method which is considered the gold standard in the assessment 
of insulin action in vivo[21]. This latest developed computer model has non-linear 
solutions as it accounts for variations in hepatic and peripheral glucose resistance 
and also other organs and tissues involved in glucose regulation. Pancreatic beta cell 
function is expressed as percentage of a normal reference population, where 100% is 
normal. However, HOMA2-%B measures first of all beta cell activity, not beta cell health 
or pathology. Therefore, the outcomes of HOMA2-%B have to be interpreted together 
with HOMA2-IR. Insulin resistance is expressed as 100/ %insulin sensitivity (100/%S) 
and a normal IR is 1. The HOMA2-IR is race and age dependent of which cut-off values 
for abnormal insulin resistance range from 1.6-3.8[22, 23]. For IR simultaneously drawn 
fasting plasma glucose and insulin values were used. For beta cell function instead of 
insulin, C-peptide values from the same blood sample were used[24].
Body composition
Next to the WHR and the BMI, specific body composition data, including total, gynoid 
(hip area) and android (abdominal area) fat percentage, lean body mass (LBM) and 
visceral adipose tissue (VAT) mass calculations were obtained using Dual-energy 
X-ray Absorptiometry (DXA) Whole Body Composition. (GE Healthcare Lunar iDXA 
and enCORE software version 13.6)[25].
Statistical analysis
 The sample size calculation was based on the results of the of HOMA-IR measurements 
by Dessein et al[26]. Based on a power analysis with alpha 0.05 and power >85% resulted 
in a sample size of 25 per group.
Results are expressed as mean ± standard deviation (SD) when normally distributed, 
as median (interquartile range) when not normally distributed or as number and 
percentage. When variables were not normally distributed, the (natural) logarithms 
of these variables were calculated and used for analyses. Unpaired sample t tests were 
used to observe differences in baseline variables between RA and OA. For comparisons 
of paired continuous variables between baseline and follow up with normal distribution 
paired t-test were used. In case of non-normal distribution we used the Wilcoxon signed-
ranks test or log transformation. Pearson or Spearman correlation coefficients were 
determined to look for correlations between IR, IS, beta cell function, body composition 
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measurements and inflammatory markers. To assess the effect of change in systemic 
inflammation on IR and beta cell function patients were stratified in tertiles for ΔCRP, 
ΔESR and ΔDAS28. Mann-Whitney U tests were used to determine changes of variables 
after 6 months between groups. Two sided p-values less than 0.05 were considered 
statistically significant. All analyses were performed by IBM SPSS Statistics version 18.0.
Results
Study population
From the 69 patients, who were initially screened for study inclusion, 13 patients were 
excluded at baseline, mostly due to the exclusion criteria and again 9 patients were 
excluded at follow up, because of discontinuation of adalimumab or loss to follow up 
(figure 1). Baseline patient characteristics are displayed in table 1.
9
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Figure 1. Flowchart of study inclusion
Table 1. Baseline characteristics
RA OA
Demographics n=28 n=28
 Females 20 (71) 19 (68)
 Age, years 53±10 55±11
Cardiovascular risk factors
 Impaired glucose tolerancea 3 (11) 4 (14)
 Diabetes mellitusa 0 1 (4)
 Metabolic syndrome (NCEP ATP III) 3 (11) 4 (14)
 Hypertension 4 (14) 4 (14)
 Antihypertensive drug use 3 (11) 4 (14)
 Hypercholesterolemia 3 (10) 8 (28)
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 Current smoker 5 (18) 10 (36)
 Past smoker 14 (50) 6 (21)
 Never smoker 9 (32) 12 (43)
Disease characteristics
 Disease duration, years 4 (1-14) 1 (1-2)
 Orthopedic surgery 5 (19) 8 (30)
Anti-inflammatory medication use
 NSAID use 14 (50) 10 (36)
 DMARD use 25 (89) 0
Rheumatoid arthritis specific characteristics
 Rheumafactor positive 22 (82) N/A
 Anti-CCP positive 24 (92) N/A
 Erosive disease 15 (56) N/A
 Disease activity score of 28 joints 4.34±1.35 N/A
 Health Assesment Questionnaire 1.0±0.6 N/A
RA= rheumatoid arthritis, OA= osteoarthritis, n= number, NSAID= non- steroidal anti-inflammatory 
drugs, DMARD= disease modifying anti- rheumatic drugs, DAS28= Disease activity score of 28 joints, 
HAQ= Health assessment questionnaire, N/A= not applicable. a according to the WHO criteria for 
OGTT [35]. Results are presented as mean and standard deviation (SD), median and interquartile 
range (IQR) or number and percentage (%).
Baseline measurements in patients with rheumatoid arthritis and osteoarthritis
Table 2 presents the results of the baseline measurements in RA and OA patients. 
There were no significant differences in the anthropometric characteristics or blood 
pressure between the groups. The prevalence of metabolic syndrome determined by the 
NCEP ATP III guidelines[27] was 11% in the RA group and 18% in the OA group. One 
matched OA patient with diabetes was included erroneously but was left in according 
to the intention-to-treat principle. Furthermore, leaving this patient out did not affect 
our results. Moreover, this did not hamper our analyses of the effect of anti-TNF on the 
insulin resistance as subjects did not receive any treatment and were only used as age and 
sex-matched controls. As expected, both ESR and CRP levels were significantly higher 
in the RA group. Baseline insulin levels, IR and beta cell function were all significantly 
higher in RA patients compared to OA patients (figure 2). Fasting glucose was significantly 
lower in RA patients compared to OA patients (p<0.05). The percentage of gynoid fat was 
significantly higher in RA patients compared to OA patients (p<0.05). LBM and VAT mass 
were not significantly different between the groups. Total cholesterol, LDL-cholesterol and 
apolipoprotein B were significantly lower in RA patients compared to OA patients (Fig. 3).
9
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Figure 2. Insulin resistance and pancreatic beta cell function at baseline and after 6 
months in patients with rheumatoid arthritis and osteoarthritis
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Figure 3. Associations between body mass index and insulin resistance and pancreatic 
beta cell function in rheumatoid arthritis patients (RA) and osteoarthritis patients (OA).
9
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Figure 4. Change in insulin resistance and pancreatic beta cell function in RA patients after 
6 months anti-TNF treatment categorized in tertiles for delta inflammatory parameters.
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Tertiles ΔCRP: 1=9 - 0, 2= 0 - -3, 3=-4 - -161; tertiles ΔESR: 1=3 - 0, 2=-7 - -2, 3= -10 -- -82; tertiles 
ΔDAS28: 1= 0.3 - -0.7, 2= -1.2 - -2.2, 3= -2.2 - -3.5.
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Inflammation, insulin resistance and beta cell function
To analyse the association between change in systemic inflammation and change in IR 
and beta cell function patients were stratified in equal tertiles of delta inflammatory 
parameters, i.e. ΔCRP, ΔESR and ΔDAS28. Results are displayed in figure 4.
Correlations between insulin resistance, beta cell function and body composition data per group
In the RA group, except for a correlation between BMI and IR (r=0.38, p<0.05) (see figure 
3) no significant correlations were found between IR or beta cell function and body 
composition (data not shown).
In the OA group IR and beta cell function were correlated (p<0.01) with BMI (r=0.73, 
r=0.65 respectively, figure 3), whole body fat percentage (r=0.65, r=0.60 respectively), 
android fat percentage (r=0.72, r=0.56 respectively) and (p<0.05) gynoid fat percentage 
(r=0.39, r=0.48 respectively). IR but not beta cell function was also significantly 
correlated with VAT mass (r=-0.66, p<0.01, r=0.31, p=0.14 respectively) and LBM (r=0.41, 
p=0.04, r=0.11, p=0.58 respectively).
The effect of anti-TNF treatment
The results of the comparisons between OA and RA patients after 6 months anti-
TNF treatment are displayed in figure 2 and table 2. Eventually, 5 RA patients and 
3 OA patients were excluded from follow up due to lost to follow up, change in anti-
inflammatory treatment and change in glucose/cholesterol lowering medication. Both 
inflammatory markers ESR and CRP decreased significantly in the RA group compared 
to the OA group. Also DAS28 and HAQ decreased significantly in RA. In contrast to the 
OA patients, in the RA group beta cell function and gynoid fat percentage decreased 
significantly (p<0.05 and p=0.01). Total cholesterol, LDL, apolipoprotein A and also HDL 
increased significantly after 6 months of treatment in the RA group compared to the 
OA group (p<0.01). However, total cholesterol/HDL ratio did not change at follow up.
Discussion
Insulin resistance (IR) is increased in rheumatoid arthritis (RA) and it is assumed that 
IR, systemic inflammation and body composition are interrelated. We hypothesized that 
a decrease of systemic inflammation and change in body composition would favourably 
affect IR in RA patients. The present study showed: 1) IR and beta cell function were 
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significantly higher in RA than in OA; 2) no significant correlations were found between 
IR or beta cell function and body composition in RA patients; 3) pancreatic beta cell 
function and IR improved after anti-TNF treatment in RA patients with highest decrease 
of CRP and ESR, albeit that this did not reach statistical significance.
This latter effect might be due to a decrease in hyper-metabolism and resting energy 
expenditure that comes along with inflammation and active disease[28, 29]. However, 
there was no clinical relevant alteration of the overall body composition.
Together with the inflammatory markers, IR and beta cell function were significantly 
higher in RA than in OA. Overall, in the OA group IR and beta cell function were in 
the normal range, whereas in the RA group IR and beta cell function were both raised. 
Inflammation is considered crucial in the pathogenesis of IR, Therefore, these observed 
differences were expected as RA is a high-grade inflammatory disease compared to 
OA which is a low-grade inflammatory disease [2]. When we investigated the effect of 
systemic inflammation in more detail by dividing the RA patients in tertiles according to 
change in CRP, ESR and DAS28 levels, we found that IR and especially beta cell function 
improved most after anti-TNF treatment in the RA patients with the highest decrease of 
CRP and ESR. This suggests that reducing inflammation also improves IR and beta cell 
function, whether or not this is anti-TNF specific or caused by inflammation reduction 
[30]. As we found beta cell function equally raised compared to IR and also found no 
differences between RA and OA in impaired glucose tolerance overall, it’s unlikely that 
beta cell function was significantly impaired in our group of RA patients as was found 
by Ferraz-Amaro et al. [8].
In OA patients there were clear correlations between IR, beta cell function and BMI and 
especially android fat percentages, as expected, while in RA only BMI was modestly 
correlated with IR. Total fat percentage and BMI were slightly higher in RA, but except 
for gynoid fat percentage, which was significantly higher in RA compared to OA, no 
significant differences were found in android fat percentage and VAT or LBM, which 
we had expected. This is to some extent in contrast to the existing literature where 
increases of BMI and body fat after anti-TNF have been described[31]. Generally, 
increases of BMI and body fat and BMI were observed after more than a year treatment. 
Therefore, the 6 months anti-TNF treatment in our study might have been be too short 
to detect changes in body composition particularly as in other studies also no changes 
of in BMI and/or body composition were observed after 6 months or shorter duration of 
9
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anti-TNF treatment[31]. Altogether, these data show that inflammation rather than an 
altered body composition explains the higher IR and beta cell function in RA, however 
further research to discover the exact pathophysiologic mechanism is still needed. 
Theoretically, a direct effect of anti-TNF on the insulin pathway and fat metabolism 
cannot be ruled out. However, as more studies demonstrated a correlation between 
systemic inflammation and insulin resistance, it is plausible to assume the impact of 
anti-TNF is based on the anti-inflammatory effect. This is underscored by several studies 
where the effect of other anti-inflammatory antirheumatic drugs therapy on the insulin 
resistance in RA patients was investigated[32, 33]. No significant differences in total 
fat percentage and VAT mass between RA and OA patients were found. This might be 
explained by the fact that OA is associated with obesity and physical inactivity leading to 
an altered body composition in comparison to the general population[34]. Furthermore, 
OA is a disease which has many similarities with RA, like for instance chronic pain and 
joint deformity that both could result in reduced physical activity. Our findings suggest 
that reduced physical activity and inflammation play an important role in the body 
composition of both groups, but presumably in different ways and gradations.
Strength of this study was that factors that could have influenced the results, i.e. use 
of corticosteroids, statin use, a history of CVD or metabolic diseases were excluded. 
Moreover, changes in medication use during the study period were prohibited. With 
OA patients as controls, the effect of anti-TNF treatment could be better evaluated, as 
time can also influence results. Our study has its limitations. It may be argued that the 
study duration was too short to capture the metabolic effects of anti-TNF on the insulin 
action and body composition. Nonetheless, as several studies did observe similar effects 
after comparable treatment period[14, 31], this did not hamper the assessment of the 
relation between systemic inflammation and insulin resistance
In conclusion, this study showed that IR and beta cell function are increased in RA 
patients compared to OA patients. Anti-TNF treatment improved IR and beta cell 
function in RA patients with highest decrease of CRP and ESR which was not explained 
by change in body composition. The data suggest that this is caused by lowering of 
inflammatory activity in general, however a direct effect by blocking TNF cannot be 
excluded in this study and needs further investigation. Nevertheless, our data indicate 
that reducing systemic inflammation and disease activity reduces IR and beta cell 
function which ultimately might lessen the CV disease burden.
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Summary and general discussion
This thesis describes the role of systemic inflammation resulting from inflammatory 
joint disease for the development of cardiovascular disease (CVD), particularly cardiac 
disease, and describes potential therapeutic and preventive strategies for cardiovascular 
disease risk management in inflammatory joint disease (IJD) patients.
Part I
In chapter 2 we describe the prevalence of CVD and the overlapping mechanisms of 
inflammation in the development of CVD in two forms of IJD, i.e. rheumatoid arthritis 
(RA) and gout. Rheumatoid arthritis and gout are associated with a 50–70% increased 
risk of cardiovascular disease compared with the general population. These patients do 
not only have inflammation of the joints but also experience systemic effects, including 
cardiovascular and thrombotic manifestations. Different underlying pathophysiological 
mechanisms, such as systemic inflammation, elevated oxidative stress, endothelial 
dysfunction, and changes in lipid profiles, might contribute to a substantially higher 
cardiovascular risk in these patients. The increased cardiovascular risk not only includes 
a higher rate of ischemic cardiovascular disease but also clinical heart failure (70%) 
and subclinical heart failure which in RA seems far more prevalent than previously 
thought. Therapeutic intervention with current antirheumatic treatment in rheumatoid 
arthritis resulted in favourable effects on CVD risk, reducing the risk for CVD with 
approximately 30%. Unfortunately, in gout, evidence that urate-lowering therapy has 
consistent beneficial effects on cardiovascular outcomes is still scarce.
In chapter 3 we investigated the effect of biologic disease modifying anti-rheumatic 
drugs (DMARD’s) on cardiac function and the incidence and prevalence of congestive 
heart failure in RA patients in a systematic review. Literature focusing on imaging 
studies mostly showed improvement of cardiac function assessed either with 
echocardiography or cardiac magnetic resonance imaging (cMRI) in RA patients 
treated with anti-tumor necrosis factor (TNF), anti-interleukin (IL)-6 and anti-IL-1 
drugs. However, most studies were of low (methodological) quality. Large prevalence 
and incidence studies demonstrated that RA patients treated with anti-TNF biological 
DMARD’s had a lower risk for congestive heart failure (CHF)compared to RA patients 
treated with non-biological DMARD’s (i.e. conventional synthetic (cs)DMARD’s). In 
addition, studies assessing the effect of anti-TNF on plasma NT-proBNP levels showed 
a significant and clinically relevant decrease of this cardiac wall stress biomarker 
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indicating improvement of Left ventricular (LV) filling pressures because of ameliorated 
cardiac function. Therefore, based on the literature, we concluded that biologic 
DMARD’s have an ameliorating effect on cardiac function. However, this research area 
was hampered by a lack of uniform study design, correct definition of CHF or cardiac 
dysfunction, improper use of cardiac function assessment tools and absence of well-
defined study populations.
Against the background of the previous chapter, chapter 4 consists of an observational 
study on the effect of anti-TNF therapy on diastolic and systolic function in RA patient 
using comprehensive echocardiography and biomarker assessments. We observed a 23% 
decrease in NT-proBNP after anti-TNF treatment, suggesting some improvement of 
cardiac function. However, echocardiography showed no improvement nor deterioration 
of the cardiac function in RA patients as a result of anti-TNF treatment. These unexpected 
results can be explained by the following causes. First, this could have been due to the 
low prevalence of cardiac dysfunction at baseline as only three (7%) patients had diastolic 
dysfunction. Therefore, the study may have been underpowered to detect improvement of 
the cardiac function after anti-TNF therapy. Second, this population had a relatively short 
disease duration and a relatively low disease activity compared to other studies where an 
increased prevalence of cardiac dysfunction in RA patients compared to healthy subjects 
were found. Third, in addition, our population was relatively cardiac healthy as patients 
were relatively young and had low prevalence of cardiovascular comorbidities, and were 
thus less prone to the development of cardiac dysfunction.
In chapter 5, a case report of a female systemic lupus erythematosus (SLE) patient 
with heart failure with preserved ejection fraction (HFpEF) is discussed. We assumed 
that HFpEF was mediated by systemic inflammation secondary to SLE. Therefore, anti-
inflammatory therapy with belimumab was added (a biological agent against soluble 
B-lymphocyte stimulator protein). After 16-weeks of treatment, the patient reported 
an improved condition. Also, cardiopulmonary exercise test and echocardiography 
results improved, indicating normalization of the left ventricular (LV) diastolic function. 
Altogether, this case suggests that targeting inflammation might have therapeutic 
potential in a subset of HFpEF-patients.
Part II
The prevalence of cardiac diseases associated with ankylosing spondylitis (AS) was 
investigated in elderly AS patients aged 50-75 years, compared to matched osteoarthritis 
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(OA) controls as reported in Chapter 6. This study revealed that AS-patients had a five 
times increased risk of aortic valve regurgitation (AVR) compared to OA controls. Disease 
activity, disease duration and use of anti-TNF were not associated with AVR. Although 
AVR was mostly mild, it is important to realize that any stage of AVR is considered 
to be pathological as trace/mild regurgitation may progress to severe regurgitation 
which compromises LV function. However, if timely recognized it can be monitored 
adequately and in severe cases treated with aortic valve or aortic root replacement 
thereby preventing the development of CHF. Therefore, our findings indicate that 
echocardiographic screening of elderly AS patients (50-75 years) should be considered. 
Furthermore, unexpectedly, conduction disorders and diastolic LV dysfunction, based 
on the 2016 criteria of the ASE/EACVI, were rare in both AS-patients and controls, and 
the prevalence was comparable for both groups.
In chapter 7 the association between human leukocyte antigen (HLA)-B27 genotype 
and aortic root diameter in AS patients was investigated. HLA-B27+ AS patients had 
a significantly increased aortic root index compared to HLA-B27- AS patients. This 
association was not explained by difference in age, sex nor cardiovascular risk factors. 
The prevalence of AVR was, however, similar in both groups. Furthermore, aortic 
dilatation was more often seen in HLA-B27+ AS patients, although it failed to reach 
statistical significance. Finally, our data suggest a sex and HLA-B27 genotype linked 
difference in aortic root index as male HLA-B27+ patients had an increased aortic root 
index compared to the HLA-B27- male patients and the overall female AS patients.
Part III
In chapter 8 we performed a cross-sectional study in AS patients and healthy controls to 
assess the difference in retinal vasculature and to assess the value of retinal screening 
for cardiovascular disease. This study showed several retinal microvascular changes in 
AS patients, compared to healthy controls, of which some have been associated with 
cardiovascular risk. The most prominent changes in AS patients consisted of straighter 
arterioles and a higher vessel density. In addition, male AS patients showed a decreased 
arteriovenular ratio compared to male controls, whereas no specific changes were found 
in women with AS. In AS, high disease activity and previous CVD were associated with 
wider venules, whereas treatment with biologicals was related to wider arterioles. This 
proof of concept study indicates that retinal imaging techniques might be useful for the 
detection of microvascular changes in AS patients. If confirmed in further longitudinal 
follow up, these techniques might be useful for the early recognition of CVD in AS.
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In chapter 9 we performed a prospective observational cohort study to assess the 
effect of anti-inflammatory treatment with anti-TNF on the insulin resistance (IR) 
and body composition in RA patients. This study showed that IR and beta cell function 
are increased in RA patients compared to OA patients. Anti-TNF treatment improved 
beta cell function with 19% and IR and beta cell function particularly improved in RA 
patients with highest decrease of CRP and ESR which was both not explained by change 
in body composition. The data suggest that this is caused by lowering of inflammatory 
activity in general. Altogether, our data indicate that reducing systemic inflammation 
and disease activity reduces IR and beta cell function. This could ultimately lead to a 
reduction in CVD burden.
Table 1. Answers to the research questions
Chapter 1 General introduction
Part I
Chapter 2 Different underlying pathophysiological mechanisms, such as systemic 
inflammation, elevated oxidative stress, endothelial dysfunction, and changes 
in lipid profiles, might contribute to a substantially higher cardiovascular risk 
in inflammatory joint disease patients.
Chapter 3 Literature shows an ameliorating effect of bDMARD’s on the cardiac function 
and the prevalence and incidence of CHF in RA patients.
Chapter 4 NT-pro-BNP decreased with 23% after anti-TNF treatment suggesting an 
(moderate) improvement of cardiac function. However, we found no effect of 
anti-TNF on the diastolic and systolic function assessed with echocardiography.
Chapter 5 Anti-inflammatory treatment with belimumab showed improvement of SLE 
induced HFpEF.
Part II
Chapter 6 Elderly (50-75 years) AS patients have an up to five-time increased risk for aortic 
valve regurgitation compared to OA controls. Therefore, our findings indicate 
that echocardiographic screening of elderly AS patients (50-75 years) should be 
considered. Conduction disorders and diastolic dysfunction were rare in both 
populations.
Chapter 7 HLA-B27+ AS patients had a significantly increased aortic root index compared to 
HLA-B27- AS patients. The prevalence of AVR was however similar in both groups.
Part III
Chapter 8 AS patients have several retinal microvascular changes of which some have been 
associated with cardiovascular risk.
Chapter 9 Anti-TNF treatment improved IR and beta cell function in RA patients with high 
CRP and ESR. This improvement was not explained by change in body composition.
Chapter 10 Summary, general discussion and future perspectives
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Future research
Multiple studies showed a direct relation between systemic inflammation and CVD 
in the past decennia. In RA, the increased risk for CVD has led to the development 
of CV risk management guidelines, e.g. the European Alliance of Associations for 
Rheumatology (EULAR). However, CVD risk management guidelines are still lacking 
for other systemic inflammatory disease and therefore need to be developed. In 
addition, there are still mechanisms and clinical manifestations in these patients 
which need to be further investigated.
Aortic valve regurgitation in AS
More specific guidelines for CVD risk management in AS patients should be developed. 
Follow up studies in AS patients with AVR are required to assess the clinical course of 
AVR. This is necessary to assess the cost-effectiveness of echocardiographic screening 
in AS patients. If aortic valve regurgitation, in a significant amount of AS patients, 
evolves to severe and symptomatic AVR requiring aortic valve/root replacement, the 
need for mandatory and repetitive echocardiographic screening of the AS population 
will be established. Perhaps, a specific age limit can be determined from which onwards 
echocardiographic screening should be done. Prospective cohort studies such as the 
CARDAS study offer a great opportunity to perform such a follow up. Obviously, cost-
effectiveness of echocardiographic screening in AS patients should also be considered. 
Furthermore, future studies should aim to assess the possible sex differences in respect 
to the development of cardiac disease including AVR.
Anti-inflammatory therapy and cardiac dysfunction in IJD
The effect of anti-inflammatory therapy on cardiac dysfunction should be further 
assessed. There is accumulating evidence that systemic inflammation may lead 
to cardiac dysfunction, particularly diastolic dysfunction in patients with chronic 
inflammatory diseases. This process starts with inflammation-induced microvascular 
dysfunction, leading to deposition of collagen with subsequent stiffness and hypertrophy 
of cardiomyocytes and a decreased ability of the myocardium to contract and relax, 
which might evolve into heart failure with preserved ejection fraction. Until now no 
large cohort studies could give a concluding answer to this research question. This is 
mainly due to the fact that in most studies the subjects did not have baseline LV diastolic 
dysfunction at rest. They probably required exercise echocardiography to unveil baseline 
diastolic LV dysfunction which could then be demonstrated to be potentially amenable 
to treatment with anti-TNF.
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Our case report in chapter 5 describes the favorable effect of anti-inflammatory therapy 
in a SLE associated HFpEF and this could be indicative for a larger future study. We found 
a possible causal relation between systemic inflammation and HFpEF. However, this 
relation has not been studied in adequately powered studies. We further investigated 
this (potential) effect in the CHARM study (chapter 4). However, unexpectedly we 
found a (very) low prevalence of diastolic dysfunction in the RA population and could 
therefore only demonstrate indirectly (decline of NT-proBNP levels) favorable effects 
on cardiac (dys)function. Future studies therefore should investigate the effect of anti-
inflammatory therapy in IJD patients with evidence of diastolic dysfunction at rest 
or during exercise. If diastolic dysfunction shows improvement at follow up in a large 
cohort this can further elucidate the link between systemic inflammation and cardiac 
dysfunction paving the road for preventive therapeutic strategies. To recruit a sufficient 
amount of IJD patients with diastolic dysfunction, future studies could aim to screen 
HFpEF patients for a medical history of IJD in which the effect of more strong/effective 
anti-inflammatory therapy can then be assessed.
Inflammatory pathways and CVD
The role of specific inflammatory pathways in the development of CVD, i.e. oxidative 
stress and cytokines, in IJD has not yet been fully elucidated.
As new anti-inflammatory therapies with e.g. bDMARDs or tsDMARDs (i.e. anti-
IL-17, anti-IL-12 and JAK-inhibitors) target more specific inflammatory pathways, the 
underlying mechanisms for CVD could also be revealed. It will then also become clear if 
and to what extent anti-inflammatory therapies differ between each other with respect 
to CVD risk reducing effects. Future studies should therefore assess these specific 
pathways and also the effect of specific bDMARDs on the risk of CVD. In reverse, these 
studies should also assess if the CVD risk increases when drugs are tapered. The latter 
treatment strategy is used more often in clinical practice.
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Nederlandse samenvatting
Samenvatting en discussie
Dit proefschrift beschrijft de rol van systemische ontsteking als gevolg van inflammatoire 
gewrichtsziekten bij de ontwikkeling van hart- en vaatziekten (HVZ), in het bijzonder 
hartziekten, en beschrijft mogelijke therapeutische en preventieve strategieën 
voor risicomanagement van hart- en vaatziekten bij patiënten met inflammatoire 
gewrichtsziekten.
Deel I
In hoofdstuk 2 beschrijven we de prevalentie van HVZ en de overlappende 
ontstekingsmechanismen bij de ontwikkeling van HVZ bij reumatoïde artritis (RA) en 
jicht. RA en jicht zijn geassocieerd met een 50-70% verhoogd risico op HVZ in vergelijking 
met de algemene bevolking. Deze patiënten hebben niet alleen ontsteking van de 
gewrichten, maar ondervinden ook systemische effecten, waaronder manifestaties in 
het hart en de vaten. Verschillende onderliggende pathofysiologische mechanismen, 
zoals systemische ontsteking, verhoogde oxidatieve stress, endotheeldysfunctie en 
veranderingen in het lipidenprofiel, kunnen bijdragen aan een verhoogd risico op HVZ 
bij deze groep patiënten. Het verhoogde risico op HVZ omvat niet alleen een hoger 
percentage ischemische HVZ, maar ook subklinisch hartfalen, wat vaker lijkt voor te 
komen dan eerder werd gedacht. Vroegtijdige behandeling met ontstekingsverlagende 
medicijnen bij reumatoïde artritis resulteerde in een verminderd risico op HVZ.
Bij jicht is het bewijs dat uraatverlagende medicijnen een gunstig effect hebben op HVZ 
helaas nog schaars.
In hoofdstuk 3 onderzochten we in een systematische review het effect van biologic 
disease modifying anti-rheumatic drugs (bDMARD’s) op de hartfunctie en het effect van 
bDMARD’s op de incidentie en prevalentie van hartfalen bij RA patiënten. Literatuur die 
zich richtte op beeldvormend onderzoek toonde meestal verbetering van de hartfunctie 
aan bij RA patiënten die werden behandeld met anti-tumor necrose factor (anti-TNF), 
anti-interleukine (anti-IL)-6 en anti-IL-1 geneesmiddelen. Deze beeldvormende 
onderzoeken werden verricht met echocardiografie of cardiale magnetische resonantie 
(cMRI) beeldvorming. De meeste studies waren echter van lage (methodologische) 
kwaliteit. Grote prevalentie- en incidentiestudies toonden aan dat RA-patiënten 
behandeld met anti-TNF een lager risico op hartfalen (HF) hadden in vergelijking 
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met RA-patiënten die werden behandeld met niet-bDMARD’s (d.w.z. conventionele 
synthetische (cs)DMARD’s). Bovendien toonden studies naar het effect van anti-
TNF op de plasma NT-proBNP een daling van deze biomarker aan. Dit wijst op een 
verbetering van de linker ventriculaire (LV) vullingsdruk als gevolg van een verbeterde 
hartfunctie. Daarom concludeerden wij dat bDMARD therapie bij RA patiënten een 
gunstig effect heeft op de hartfunctie. Een eenduidig antwoord op de onderzoeksvraag 
was echter moeilijk te geven vanwege het gebruik van verschillende onderzoeksopzetten, 
het gebruik van verschillende beeldvormende onderzoeksmethoden en niet goed 
gedefinieerde studiepopulaties.
Tegen de achtergrond van het vorige hoofdstuk, beschrijft hoofdstuk 4 een observationele 
studie naar het effect van anti-TNF therapie op de diastolische en systolische hartfunctie 
in RA patiënten onderzocht middels echocardiografie en biomarker onderzoek. We zagen 
een daling van 23% in het NT-proBNP plasmaspiegel na anti-TNF therapie, wat wijst op 
een enige verbetering van de hartfunctie. Echocardiografisch onderzoek toonde echter 
geen effect van anti-TNF therapie op de hartfunctie bij RA patiënten. Een beperking 
van deze studie was dat hartfunctiestoornissen weinig voorkwamen in de geobserveerde 
patiëntenpopulatie, waardoor bij slechts een beperkt aantal patiënten het effect van 
anti-TNF therapie op de hartfunctie onderzocht kon worden.
In hoofdstuk 5 wordt een casus besproken van een patiënte met systemisch lupus 
erythematosus (SLE) en hartfalen met behouden ejectiefractie (heart failure with 
preserved ejection fraction (HFpEF)). Onze hypothese was dat HFpEF werd gemedieerd 
door systemische ontsteking secundair aan SLE. Derhalve werd ontstekingsremmende 
therapie middels belimumab (een biologisch middel tegen B-lymfocyten stimulator 
eiwit) aanvullend gestart. Na 16 weken behandeling meldde de patiënte een verbetering 
van de conditie. Ook de resultaten van de cardiopulmonale inspanningstest en het 
echocardiografisch onderzoek toonden verbetering van de hartfunctie, wat wijst op 
normalisering van de LV diastolische functie. Al met al. suggereert deze casus dat 
ontstekingsremmende therapie de hartfunctie kan verbeteren in een specifieke subgroep 
HFpEF patiënten.
Deel II
In hoofdstuk 6 wordt de prevalentie van hartziekten die zijn geassocieerd met 
ankyloserende spondylitis (AS) onderzocht bij oudere AS patiënten in de leeftijd van 
50-75 jaar, en vergeleken met gematchte osteoartritis (OA) controle patiënten. Deze 
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studie toonde aan dat AS patiënten een vijf maal verhoogd risico hebben op aortaklep 
insufficiëntie (AoI) in vergelijking met OA controles. Ziekteactiviteit, ziekteduur en 
gebruik van anti-TNF waren niet geassocieerd met AoI. Hoewel de AoI meestal mild 
was, is het belangrijk in acht te nemen dat elk stadium van AoI als pathologisch wordt 
beschouwd, aangezien een milde AoI zich kan ontwikkelen tot een ernstige AoI. 
Indien tijdig herkend, kan dit echter adequaat worden behandeld met een aortaklep- of 
aortawortelvervanging. Daarom geven onze bevindingen aan dat echocardiografische 
screening van oudere AS patiënten (50-75 jaar) moet worden overwogen.
Tegen de verwachting in kwamen geleidingstoornissen en LV diastolische dysfunctie 
(o.b.v. de 2016 ASE/EACVI criteria) weinig en vergelijkbaar voor in beide groepen.
In hoofdstuk 7 wordt de associatie tussen humaan leukocyten antigen (HLA)-B27 
genotype en de aortaworteldiameter bij AS patiënten onderzocht. HLA-B27+ AS 
patiënten hadden een significant verhoogde aortawortel index vergeleken met HLA-B27- 
AS patiënten. Deze associatie werd niet verklaard door verschil in leeftijd, geslacht of 
cardiovasculaire risicofactoren. De prevalentie van AoI was echter vergelijkbaar in beide 
groepen. Bovendien werd aortadilatatie vaker gezien bij HLA-B27+ AS patiënten, hoewel 
dit geen statistische significantie bereikte. Tenslotte suggereren onze gegevens een 
geslachts- en HLA-B27 genotype-gerelateerd verschil in de aortawortelindex, aangezien 
mannelijke HLA-B27+ patiënten een verhoogde aortawortelindex hebben in vergelijking 
met de HLA-B27- mannelijke patiënten en de vrouwelijke AS patiënten in het algemeen.
Deel III
In hoofdstuk 8 hebben we een cross-sectionele studie uitgevoerd bij AS patiënten 
en gezonde controles om het verschil in retinale vasculatuur te beoordelen en om de 
waarde van retinale screening op hart- en vaatziekten te evalueren. Deze studie toonde 
verschillende retinale microvasculaire veranderingen bij AS patiënten vergeleken met 
gezonde controles, waarvan sommige geassocieerd zijn met cardiovasculaire risico’s. 
De meest opvallende veranderingen bij AS patiënten bestonden uit rechtere arteriolen 
en een hogere vaatdichtheid. Bovendien vertoonden mannelijke AS-patiënten een 
verminderde arteriovenulaire ratio in vergelijking met mannelijke controles, terwijl 
er geen specifieke veranderingen werden gevonden bij vrouwen met AS. Bij AS waren 
een hoge ziekteactiviteit en een voorgeschiedenis met HVZ geassocieerd met wijdere 
venulen, terwijl behandeling met bDMARD’s gerelateerd was aan wijdere arteriolen. 
Deze proof of concept studie geeft aan dat beeldvormende onderzoek van het netvlies 
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nuttig kan zijn voor de detectie van microvasculaire veranderingen bij AS patiënten. 
Indien bevestigd in longitudinale follow-up studies, zouden deze technieken nuttig 
kunnen zijn voor de vroegtijdige herkenning van HVZ in AS.
In hoofdstuk 9 hebben we een prospectieve observationele cohort studie uitgevoerd 
om het effect van ontstekingsremmende therapie met anti-TNF te onderzoeken op 
de insuline resistentie (IR) en lichaamssamenstelling in RA patiënten. Deze studie 
toonde aan dat IR en bètacel functie verhoogd zijn bij RA patiënten in vergelijking 
met OA controle patiënten. Anti-TNF therapie verbeterde de IR en bètacel functie 
bij RA patiënten met de hoogste daling van C-reactief proteïne (CRP) en bezinking 
(BSE). Dit effect werd niet verklaard door verandering in de lichaamssamenstelling. 
De gegevens suggereren dat dit wordt veroorzaakt door verlaging van de algehele 
ontstekingsactiviteit. Al met al. wijzen onze gegevens erop dat het verminderen van 
systemische ontsteking en ziekteactiviteit de IR en bètacelfunctie vermindert. Dit zou 
uiteindelijk kunnen leiden tot een verminderd risico op HVZ.
Toekomstig onderzoek
Meerdere studies hebben in de afgelopen decennia een direct verband aangetoond tussen 
systemische ontsteking en HVZ. Bij RA heeft het verhoogde risico op HVZ geleid tot 
de ontwikkeling van risicomanagement richtlijnen voor HVZ (EULAR). Richtlijnen 
voor risicomanagement voor HVZ ontbreken echter nog voor andere systemische 
ontstekingsziekten en moeten daarom nog worden ontwikkeld. Bovendien zijn er nog 
steeds mechanismen en klinische verschijnselen bij deze patiënten die verder moeten 
worden onderzocht.
Aortaklepinsufficiëntie in AS
Het is aanbevolen dat een specifiek risicomanagement richtlijn voor HVZ bij AS-
patiënten wordt ontwikkeld. Follow-up studies bij AS-patiënten met AoI zijn nodig om 
het klinische beloop van AoI te beoordelen. Dit is nodig om de kosteneffectiviteit van 
echocardiografische screening bij AS-patiënten te beoordelen. Als AoI bij een aanzienlijk 
aantal AS-patiënten evolueert tot ernstige en symptomatische AoI waarvoor aortaklep-/
wortelvervanging nodig is, impliceert dit dat verplichte en herhaalde echocardiografische 
screening van de AS-populatie nodig is. Door aanvullend onderzoek moet aangetoond 
worden of een leeftijdsgrens zinvol is vanaf welke echocardiografische screening moet 
worden uitgevoerd. Prospectieve cohortstudies zoals de CARDAS-studie bieden een 
uitgelezen kans om daarop volgend een dergelijk follow-up onderzoek uit te voeren. 
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Uiteraard moet hierbij ook rekening worden gehouden met de kosteneffectiviteit van 
echocardiografische screening bij AS-patiënten. Daarnaast moeten toekomstige studies 
zich richten op het beoordelen van de mogelijke geslachtsverschillen met betrekking 
tot de ontwikkeling van hartziekten, waaronder AoI.
Ontstekingsremmende therapie en hartfunctiestoornissen bij IGZ
Het effect van ontstekingsremmende therapie op de hartfunctie moet verder worden 
onderzocht. Er zijn steeds meer aanwijzingen dat systemische ontsteking kan leiden tot 
hartfunctiestoornissen, vooral diastolische dysfunctie bij patiënten met inflammatoire 
gewrichtsziekten. Dit proces begint met ontstekingsgemedieerde microvasculaire 
dysfunctie, die leidt tot afzetting van collageen met daaropvolgende stijfheid en 
hypertrofie van cardiomyocyten en een verminderd vermogen van het myocard om 
samen te trekken en te ontspannen, wat kan uitmonden in HFpEF. Tot dusver konden 
grote cohortstudies echter geen sluitend antwoord geven op deze onderzoeksvraag. Dit is 
vooral te wijten aan het feit dat in de meeste studies de proefpersonen op baseline geen 
diastolische dysfunctie hadden in rust. Waarschijnlijk had inspannings-echocardiografie 
uitgevoerd moeten worden om de aanwezige LV diastolische dysfunctie aan het licht 
te brengen. Vervolgens kan onderzocht worden of anti-TNF therapie de hartfunctie in 
deze patiënten verbeterd.
De casus in hoofdstuk 5 beschrijft het gunstige effect van ontstekingesremmende 
therapie op de hartfunctie in een patiënte met SLE geassocieerde HFpEF. Wij vonden 
een mogelijk causaal verband tussen systemische ontsteking en HFpEF. Dit verband 
is echter nog niet onderzocht in studieverband. We hebben dit (potentiële) effect 
verder onderzocht in de CHARM studie (hoofdstuk 4). Echter, tegen onze verwachting 
in vonden we een (zeer) lage prevalentie van diastolische dysfunctie in de RA 
populatie en konden derhalve alleen een indirect (daling van NT-proBNP niveaus) 
gunstig effect op de hartfunctie aantonen. Toekomstige studies zouden daarom het 
effect van ontstekingsremmende therapie moeten onderzoeken bij inflammatoire 
gewrichtsziekten-patiënten met aanwijzingen voor diastolische dysfunctie in rust of 
tijdens inspanning. Indien de diastolische dysfunctie verbetert bij follow up in een grote 
cohort studie kan dit het verband tussen systemische ontsteking en cardiale dysfunctie 
verder ontrafelen en de weg vrijmaken voor preventieve therapeutische strategieën. Om 
voldoende inflammatoire gewrichtsziekten patiënten met diastolische dysfunctie te 
rekruteren, is het aanbevolen dat toekomstige studies zich richten op het screenen van 
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HFpEF-patiënten met inflammatoire gewrichtsziekten waarbij het effect van sterkere/
effectievere ontstekingsremmende therapie op de hartfunctie kan worden beoordeeld.
Ontstekingsmechanismen en HVZ
De rol van specifieke ontstekingsmechanismen in de ontwikkeling van HVZ, o.a. 
oxidatieve stress en cytokines, bij inflammatoire gewrichtsziekte is nog niet volledig 
opgehelderd.
Echter bieden nieuw ontwikkelde anti-inflammatoire therapieën (o.a. bDMARD’s) 
die aangrijpen op specifieke ontstekingsmechanismen (bv. anti-IL-17, anti-IL12 en 
JAK-remmers) de mogelijkheid onderzoeken op te zetten om de onderliggende rol 
van specifieke ontstekingsmechanismen in de ontwikkeling van HVZ te ontrafelen. 
Middels deze onderzoeken kan duidelijk worden of het onderdrukken van specifieke 
ontstekingsmechanismen het risico op HVZ kan verminderen en in welke mate het 
kan worden verminderd. Daarnaast zou in deze toekomstige onderzoeken ook gekeken 
moeten worden wat het effect is van het afbouwen van deze anti-inflammatoire 
therapieën op het risico op HVZ. Aangezien deze behandelstrategie steeds vaker in de 
praktijk toegepast wordt.
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chocolaatje. Zonder jouw inbreng was het ons niet gelukt om deze studies tot een 
succesvol einde te brengen, veel dank hiervoor!
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met name Nivin, Simone, Wendy, Gino bedankt! Toni, Corrie en Ingrid dank voor jullie 
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Jim, wat was ik blij toen jij ook bij Reade kwam werken. Ik heb ontzettend met (en om) je 
gelachen en je maakte mijn tijd bij Reade een stuk leuker. Bart, jij was de eerste mannelijk 
collega sinds lange tijd. Met jullie kon ik eindelijk weer ongegeneerd slechte mannengrappen 
maken die werden gewaardeerd, dank hiervoor! 
Daisy jij ook erg bedankt voor alle gezelligheid die je in de groep bracht met o.a. 
sinterkerstvieringen en andere ideetjes, jij was altijd de bindende factor binnen de groep 
voor gezelligheid!
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Tot slot wil ik al mijn vrienden en familie bedanken voor al hun support. Mijn moeder 
in het bijzonder. Lieve maman, jij hebt een ongelofelijk offer gemaakt om je familie en 
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welzijn van je kinderen. Jaren later realiseerde ik mij pas hoe zwaar deze periode voor 
jou geweest moet zijn. Als alleenstaande moeder van vier kinderen wist jij ondanks alles 
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altijd stand te houden. Ik heb die periode als turbulent ervaren maar het is jouw liefde 
en geborgenheid geweest en door de normen en waarden die je mij hebt geleerd dat ik 
mij heb kunnen focussen op mijn toekomst en idealen. Mijn eeuwige dank en liefde 
hiervoor mijn liefste moeder. 
Mashad, grote broer en voorbeeld. Ik kan altijd op je vertrouwen en op je rekenen als ik je 
nodig heb. Ik ben blij dat je mij tijdens mijn verdediging wilt bijstaan als mijn paranimf. 
Hopelijk kunnen we nog veel mooie momenten samen delen.
Liefste Mariëlle, mijn vrouw, mijn maatje, wat was jij een ongelofelijke steun tijdens mijn 
promotietraject zoals met zoveel dingen in mijn leven. Toen ik aan mijn promotietraject 
begon was jij al aan het einde van jouw promotietraject waardoor jij mij op sleeptouw 
nam en tips gaf. Waarschijnlijk werd je soms gek van me als ik weer eens over mijn 
onderzoeken met je wilde sparren of mijn frustraties met je wilde delen, desondanks 
was je er altijd voor mij. De gezegde luidt “Achter elke sterke man staat een sterkere 
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kleine wondertjes Florence en Parsa. Dank je wel voor alles mijn liefste!!
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ongekend hoeveel je van je kinderen kan houden! Daarom mijn liefsten, dank jullie wel 
dat jullie er zijn en dank jullie wel dat jullie mij zo een ongelofelijk trotse papa maken x.
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